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Abstract
Every year millions of people die worldwide due to infectious diseases, the like human
immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS),
tuberculosis (TB) and hepatitis C virus (HCV). Although there are many distinguish-
ing factors associated with each disease, mathematical models can provide reliable
predictions for disease progression, and help decision makers devising public health
policies. This thesis begins by reviewing the existing models in the literature, concerning
the dynamics of HIV/AIDS transmission and relevant coinfections. Five models for
the transmission dynamics of HIV/AIDS, HIV and HCV, HIV and TB, are detailed and
analyzed mathematically and epidemiologically.
Two deterministic models for HIV virus are proposed. First in model I, it is considered
a model for the dynamics of HIV epidemics under distinct highly active antiretroviral
therapy (HAART) regimes. Model I predicts HIV patterns of untreated HIV patients
for all stages of HIV infection. The local and the global stability of the disease-free
equilibrium of the model are calculated. Simulations of the model are done for two
distinct HIV patients, the rapid progressors (RP) and the long-term non-progressors
(LTNP). The effects of equal reverse transcriptase inhibitors (RTIs) and protease in-
hibitors (PIs) efficacies, as well as distinct drug efficacies, namely RTI-based and PI-
based therapeutics, are studied. Treatment is initiated when the CD4+ T cells count
is less than 350 cells mm−3. PI-based drugs seem to produce better outcomes, with
respect to disease progression, than RTI-based regimes. Model II is a simple delay
mathematical model for the dynamics of AIDS-related cancers, where treatment for HIV
and chemotherapy is included. The main goal of this model are the study of the effects
of the delay and of treatment (HAART and chemotherapy) in cancer cells growth. The
model is simulated for several biologically reasonable values of the delay, of HAART
efficacies and of chemotherapeutic drugs decay rates. Results show that HAART may
benefit HIV-infected patients not only by reducing HIV viral load but also by controlling
cancer cell growth. Important inferences are drawn for designing treatment protocols.
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Next, two deterministic coinfection models for HIV and HCV are presented. Model III
describes HIV and HCV coinfection. The model predicts four distinct equilibria, the
disease free, the HIV endemic, the HCV endemic, and the full endemic equilibria. The
local and global stability of the disease free equilibria are calculated for the full model
and for the HIV and HCV submodels. Simulations of the qualitative changes of the
dynamical behavior of the full model are done for variation of relevant parameters. From
the results of the model, are inferred measures which could be implemented to reduce
the burden of the coinfection, by the policy makers. In model IV, a new coinfection
model for HCV and HIV is developed. The model considers treatment for both diseases,
screening, unawareness and awareness of HIV infection, and condom use. The local
stability of the disease-free equilibria for the full model and for the two submodels (HCV
only and HIV only submodels) are studied. Bifurcation diagrams for different parameters,
such as the probabilities that a contact will result in a HIV or an HCV infection, are
sketched. Numerical simulations of the full model show HIV, HCV and double endemic
equilibria. Moreover, plots of dynamics of the model for variation of relevant parameters
are also depicted. The model results are extrapolated to actual measures that could be
implemented in order to reduce the number of HIV/HCV infected individuals, such as
distributing more condoms to individuals; develop campaign in order to warn individuals
about the consequences of having many sexual partners; continuing treatment for AIDS
and pursuing the investigation of new and better drugs to combat the virus and regular
screening.
Finally, it is presented a non-integer order model for coinfection of HIV and TB, in the
presence of multi-drug resistant TB strains (MDR-TB) and treatment for both diseases.
The reproduction number of the HIV and TB submodels and of the full model, and
the local and global stabilities of the disease-free equilibria are calculated. Numerical
simulations show the different dynamics of the model for variation of epidemiologically
relevant parameters, and for the order of the fractional derivative α ∈]0, 1]. The results
obtained highlight the importance of treatment for HIV and TB and the role of the
MDR-TB strains in the severity of the coinfection. Moreover, the order of the fractional
derivative is a significant player in the epidemics theatre.
In conclusion, the models presented in this thesis are mathematically and epidemiolog-
ically well posed.
Resumo
Todos os anos milhões de pessoas morrem em todo o mundo devido a doenças infec-
ciosas, como a infeção do vírus da imunodeficiência humana e o síndrome da imunod-
eficiência adquirida (VIH/SIDA), a tuberculose (TB) e o vírus da hepatite C (VHC). Emb-
ora existam muitos fatores distintivos associados a cada doença, os modelos matemáti-
cos podem fornecer previsões confiáveis da progressão da doença e ajudar a tomar
decisões sobre a política de saúde pública. Nesta tese começa-se por analisar os mod-
elos existentes na literatura, sobre a dinâmica da transmissão do VIH/SIDA e coinfeções
relevantes. São detalhados e analisados matematicamente e epidemiologicamente,
cinco modelos para a dinâmica da transmissão do VIH/SIDA, do VIH e do VHC, do VIH
e da TB.
São propostos dois modelos determinísticos para a dinâmica da propagação do vírus
VIH. Primeiro no modelo I, é considerado um modelo para a dinâmica da epidemia do
VIH sob diferentes regimes de terapia antirretroviral altamente ativa (TARV). O modelo
I prevê padrões do VIH de pacientes infetados não tratados para todas as etapas da
infeção. As estabilidades local e global do equilíbrio livre de doença do modelo são
calculadas. O modelo é simulado para dois pacientes distintos infetados com o VIH,
os progressores rápidos (RP) e os não-progressores de longo prazo (LTNP). Os efeitos
dos inibidores da transcriptase reversa (RTIs) iguais aos inibidores de protease (PIs)
são estudados, assim como distintas eficiências das drogas, ou seja, terapias baseadas
em RTI e em PI. O tratamento é iniciado quando as células CD4+ T são inferiores a 350
células mm−3. Os fármacos baseados em PI parecem produzir melhores resultados,
em relação à progressão da doença, do que os regimes baseados em RTI. O modelo
II é um modelo matemático com atraso para a dinâmica dos cancros relacionados com
a SIDA, onde o tratamento para o VIH e a quimioterapia estão incluídos. O objetivo
principal deste modelo é o estudo dos efeitos do atraso e do tratamento (TARV e
quimioterapia) no crescimento das células cancerígenas. O modelo é simulado para
vários valores biologicamente razoáveis do atraso, das eficiências da TARV e das taxas
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de decomposição dos fármacos quimioterapêuticos. Os resultados mostram que a
TARV pode beneficiar os pacientes infetados pelo VIH, não só por reduzir a carga
viral do VIH, mas também por controlar o crescimento de células cancerígenas. As
principais conclusões são elaboradas para a conceção de protocolos de tratamento.
Em seguida, são apresentados dois modelos determinísticos para a coinfeção do VIH
e do VHC. O modelo III descreve a coinfeção por VIH e VHC. O modelo prevê quatro
equilíbrios distintos, o livre de doença, o endémico do VIH, o endémico do VHC e
o equilíbrio endémico completo. As estabilidades local e global dos equilíbrios livres
de doença são calculadas para o modelo completo e para os submodelos do VIH e
do VHC. As mudanças qualitativas do comportamento dinâmico do modelo completo
são simuladas para a variação de parâmetros relevantes. A partir dos resultados do
modelo, são inferidas medidas que podem ser implementadas para reduzir a coinfeção
pelos decisores políticos. No modelo IV é desenvolvido um novo modelo para a coin-
feção por VIH e VHC. O modelo considera o tratamento das doenças, o rastreio, a
inconsciência e a consciencialização sobre a infeção pelo VIH e o uso de preserva-
tivo. São estudadas as estabilidades locais dos equilíbrios livres de doença para o
modelo completo e para os dois submodelos (somente para VHC e para o VIH). Os
diagramas de bifurcação para diferentes parâmetros, como as probabilidades de que
um contacto resulte numa infeção por VIH ou VHC, são esboçados. As simulações
numéricas do modelo completo mostram o equilíbrio endémico do VIH, o equilíbrio
endémico do VHC e o equilíbrio endémico duplo. Também se mostram os gráficos da
dinâmica do modelo para variação dos parâmetros relevantes. Os resultados do modelo
são extrapolados para medidas reais que poderiam ser implementadas para reduzir o
número de indivíduos infetados pelo VIH/VHC como distribuir mais preservativos pelos
indivíduos; desenvolver campanhas para alertar os indivíduos sobre as consequências
de ter muitos parceiros sexuais; tratamento contínuo da SIDA e a investigação de novos
e melhores medicamentos para combater o vírus e a triagem regular.
Finalmente, é apresentado um modelo de ordem fracionária (FO) para a coinfeção por
VIH e TB, na presença de estirpes resistentes da TB a vários medicamentos (MDR-TB)
e o tratamento para ambas as doenças. São calculados, os números de reprodução
dos submodelos de VIH e da TB e do modelo completo, as estabilidades local e global
dos equilíbrios livres de doença. As simulações numéricas mostram as diferentes
dinâmicas do modelo para a variação de parâmetros epidemiologicamente relevantes
e para a ordem da derivada fracionária α ∈]0, 1]. Os resultados obtidos destacam a
importância do tratamento do VIH e da TB e o papel das estirpes MDR-TB na gravidade
da coinfeção. A ordem da derivada fracionária é uma componente importante no
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cenário das epidemias.
Em conclusão, os modelos apresentados nesta tese são matematicamente e epidemi-
ologicamente bem definidos.
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Chapter 1
Introduction
HIV is classified as a member of the Retroviridae family, subfamily Orthoretrovirinae,
genus Lentivirus (ICTV, 2009). This virus has a cone-shaped capsid that holds its
genome consisting of two single-stranded ribonucleic acid (RNA) molecules. Retro-
viruses are characterized by the ability of transcribing their RNA genome into a double-
stranded deoxyribonucleic acid (DNA) prior to the integration of the virus genome into
the host cell chromosome. This process is mediated by an RNA-dependent DNA poly-
merase called reverse transcriptase [147].
Figure 1.1: HIV [88]
HIV has three structural genes: gag, responsible for viral capsid synthesis; pol (poly-
merase), which encodes the PR (protease), RT (reverse transcriptase), IN (integrase)
proteins and env (envelope), responsible for the production of the viral surface glyco-
proteins. In addition, HIV has two regulatory genes (tat and rev ) and four accessory
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genes (vpr, vpu, nef and vif ) (see Figure 1.2).
Figure 1.2: Structure of an HIV virion particle [89, 121]
As shown in the Figure 1.2, HIV has a lipoprotein envelope derived from the membrane
of the target cell, which exposes to its surface glycoproteins (gp120), that are anchored
in the virus through interactions with transmembrane glycoproteins (gp41) [147]. In
addition to these proteins, there are others that are also derived from the host cell mem-
brane during the virus entry process in the cell, which are Principal Histocompatibility
Complex antigens, actin and ubiquitin [9]. HIV has a structural matrix consisting of
matrix proteins (p17), viral capsid (p24), nucleocapsid (p7), which involves both copies
of the viral genome and p6 [44]. PR, RT and IN are present inside the capsid. The
HIV genome is also responsible for encoding the regulatory proteins Tat (transcriptional
transcriptivator) and Rev (transcriptional regulator of the viral gene), as well as the
accessory proteins Vpr, Vpu, Nef and Vif. These proteins are important for the viral
3transcription process and, consequently, for host pathogenesis [44].
Figure 1.3: Schematic overview of the HIV-1 replication cycle [39]
As shown in Figure 1.3, viral replication begins with the specific binding of HIV virus
particles to cells which have, on their surface, CD4 type receptors, a protein that has
immune function. This binding occurs through specific interactions between the viral
envelope glycoproteins (gp120) and the amino-terminal immunoglobulin domain of CD4,
which is essential for the binding, but not sufficient for the infection. The HIV virus
requires an additional surface protein present in the host cell for fusion between the viral
envelope and the host cell membrane. These proteins are the co-receptors CCR5 (β-
chemokine receptor) and CXCR4 (α-chemokine receptor), which direct fusion between
membranes [82]. Initially, the gp120 molecule binds to the CD4 molecule, present in
the membrane of the target cell. This molecular interaction generates conformational
changes in the gp120 molecule, exposing new binding sites, thus allowing the molecular
interaction between gp120 and co-receptors CCR5 or CXCR4. Such interactions lead
to modifications in the conformation now in the gp41 molecule, exposing a hydrophobic
region called fusion peptide. The later is inserted into the cell membrane allowing its
fusion with the viral envelope [44]. After this fusion, the viral capsid is introduced into
the cell cytoplasm, being digested and thus releasing the viral genome associated with
the viral enzymes PR, RT and IN. These enzymes become active, thus initiating the viral
replication cycle [44]. Viral RNA is transcribed by the RT enzyme, firstly by forming a
hybrid RNA/DNA molecule, which will then give rise to a double-stranded linear DNA
molecule [143]. RT is a multifunctional enzyme that exhibits both DNA and RNA-
dependent DNA polymerase as well as ribonuclease H (RNase H) activities. RNase
H acts on the formation of the hybrid RNA/DNA molecule, through the specific cleavage
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of viral RNA tape. This proviral DNA will be associated with the IN, MA, RT and Vpr
viral proteins, forming a preintegration complex (PIC). This complex will be transported
to the cell nucleus where it can be integrated into the genome of the infected cell [126].
Integration is an essential step in replication and hence persistence of infection [111].
HIV is associated with impairment and destruction of the immune system’s response,
mostly by depletion of CD4+ T cells. HIV infects several types of these cells, but its
primary targets are the CD4+ T helper cells. The depletion of CD4+ T cells may have
destructive effects in immune regulation [96]. These include reduced antibody devel-
opment capacity for new attackers, abnormal function of macrophages and decrease
in production of chemical messengers [90]. Macrophages play a major role in adaptive
and innate immune response [65]. However, their relevance for HIV transmission, prop-
agation and pathogenesis is not yet completely understood [62]. This is mainly due to
the variation of macrophages susceptibility to infection and capacity to actively replicate
the virus, with the tissue localization and cytokine activity. Nevertheless, macrophages
live longer and become good HIV reservoirs [112], preventing its eradication from the
body.
Cytotoxic T cells (CTLs) are important players in the control of viral infections. Some
results show that the level of viral load is determined by the efficacy of CTLs and that
the degree of the response to viruses may influence the outcome of the disease. Nev-
ertheless, there are viruses able to escape the host immune responses and establish
persistent infections. HIV is one of those virus. In the acute (first) phase of HIV infection,
the CTL response to HIV is mostly linked with the viral set-point, influencing the rate
of HIV disease progression. In the chronic phase of the infection, CTL response is
associated with the partial containment of HIV replication [13].
As shown in Figure 1.4, a typical HIV infection is, in the absence of treatment, char-
acterized by three stages [107]. The first is the acute phase, where there is a spike
in HIV load and a sharp decrease in the CD4+ T cells count. Patients in this stage
suffer commonly from fever, headaches, rash, pharyngitis. The second stage is the
chronic phase, characterized by a dramatic drop in the viral load, approaching a quasi-
steady state, and an increase in the CD4 cells count. This behavior is explained by the
balance between virus production and clearance rates [158]. After the chronic phase,
the acquired immunodeficiency syndrome (AIDS) takes place. In the later, the number
of CD4+ T cells declines steadily and the viral load increases rapidly. AIDS leaves the
human body vulnerable to life-threatening opportunistic infections and cancers, such
that is a deadly disease in untreated patients. In these cases, time since initial infection
till death is approximately 9-10 years.
5Figure 1.4: Time course of HIV infection [7]
Treatment for HIV/AIDS relies in antiretroviral therapy (ART) that suppress HIV viral load
below the limit of detection (50 copies mL−1), particularly if initiated in early stages of
the infection. The major five drug classes to fight HIV/AIDS are the reverse transcriptase
inhibitors (RTIs), the protease inhibitors (PIs), the fusion/entry inhibitors (FEIs), the inte-
grase inhibitors (IIs), and the multidrug combinations. RTIs prevent the transcription of
RNA virus into a complementary DNA sequence, blocking the viral genome to become
incorporated into the host DNA. PIs hamper the ability of the viral protease to cleave viral
polypeptide into functional enzymes, thus interfering with continued infection. FEI inter-
fere with the ability of the virus to bound to the cell membrane. II block the introduction
of virus genetic material in the host DNA. Finally, MI combine distinct drugs of the above
classes in order to avoid resistance from virus strains to specific antiretroviral drugs.
The later is known as highly active antiretroviral therapy (HAART). Drug-resistance is
associated with high virus replication and mutation rates, poor adherence to therapy, or
poor absorption and pharmacokinetics [154].
HAART may not be effective for certain patients. There are evidence of virus persistence
during treatment, or of viral load rebounds shortly after ART interruption [50, 79]. The
existent virus reservoirs, in the form of latently infected CD4+ T cells, and infected
macrophages and dendritic cells, are responsible for this phenomenon and make the
eradication of HIV extremely complex. These cells are infected during the primary phase
of infection and remain at a resting state. In the second phase of infection, several cells
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contribute to plasma virus, namely the long-lived HIV infected cells (e.g., macrophages),
the latent cells, and the release of virus from tissue sources (e.g. lymphoid tissue).
Latently infected cells take 6 to 48 months to be activated [110, 129]. Never thought, the
significant advances in the development of ART that effectively fight HIV, currently HIV
infection is considered a chronic disease. This means that it has no cure, but is treatable.
In addition, ART prevents onward HIV transmission. Other forms of HIV transmission
prevention are the treatment as prevention (TasP), the pre-exposure prophylaxis (PrEP),
the post-exposure prophylaxis (PEP) and HIV counselling and testing (HCT).
TasP uses antiretroviral treatment in HIV prevention programs to reduce the risk of
HIV transmission. The treatment reduces the HIV viral load in the body to such low
levels that it remains undetectable. This viral suppression leads to these individuals not
transmitting HIV. Thus the effectiveness of ART as a prevention tool can be used as a
strategy for intervention in public health
PrEP consists on the intake of HIV medicines daily, by people that are at very high risk of
being infected with HIV. PrEP acts by halting HIV spread in the body. The risk of getting
HIV in sexual intercourse is reduced by 90%. In injecting drug users, it decreases
to 70%. PrEP is effective only when following treatment guidelines thoroughly [87].
In 2015, the World Health Organization (WHO) recommended that at-risk populations
should be given PrEP as an additional prevention choice [93].
PEP is an ART drug treatment, started immediately after exposure to HIV. One study
showed that PEP has little or no effect on the prevention of HIV infection if it is initiated
later than 72 hours after exposure to it. PEP is effective in HIV prevention when admin-
istered correctly, but not at 100%. Therefore, it does not replace the regular use of other
HIV preventionmethods, such as PrEP. This treatment is intended to prevent the survival
and multiplication of HIV in a person’s body, protecting against being exposed to HIV
again and reducing the chances of HIV transmission [87]. WHO recommends the use
of PEPs for occupational and non-occupational exposures for adults and children [93]
HCT is an important part of an integrated framework for HIV prevention. Knowing one’s
HIV status is critical to prevent the spread of HIV and access counselling and medical
care [87]. Nevertheless, nowadays HCT is limited since 40% of the people living with
HIV worldwide are unaware of their status [93].
People infected with HIV are at a higher risk of developing cancer. It is expected that
30% to 40% of HIV-infected people will develop some type of malignancy. Moreover,
clinical courses of cancers in HIV-positive individuals are much more aggressive than
in HIV-negative ones. The malignancies are of two types: AIDS-related ones and non-
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AIDS related ones. In the first type are included the Hodgkin’s lymphoma, Kaposi’s
sarcoma and invasive cervical cancer. These are the majority of cancers affecting
HIV/AIDS infected individuals. The second type, aka opportunistic cancers, also affect
the HIV-infected people but are not directly associated with AIDS. Examples of the later
are: Hodgkin’s disease, anal cancer, lung cancer, testicular tumours.
Though some controversy still exists on attributing an oncogenic role to HIV, it is con-
sensual that it fuels tumour growth. Distinct factors may contribute to the development
of these AIDS-related and non-related cancers, namely impaired immune surveillance,
inability to fight genomic instability, dysregulation of cytokine pathways, cellular prolifer-
ation and differentiation imbalance [83].
1.1 Mathematical models in epidemiology
Epidemiology studies, among others, the incidence of transmissible diseases in large
populations. Over the years, the epidemiologists applied statistics to describe their
data and formulate their hypothesis. The classic epidemiology is highly associated
with the description of the number of disease cases per thousands of inhabitants, per
geographical area, and/or per unit of time. This description can consist of simple bar
charts, mapping techniques or even in sophisticated multivariate analysis methods. In
the last decades, there were also significant developments in the understanding of
the transmission of epidemic diseases in large populations, based in the application
of mathematical models. The conclusions drawn from these models are extremely
important in the conception of control programs and strategic interventions in developed
and developing countries.
The infection, pathology and symptomatology of most human infectious diseases is
reasonably understood. This knowledge, however, is not enough to predict how the
diseases will propagate in a large population. For that, it is necessary to consider factors
that considerably complicate the investigation. These factors are related to the biology of
the infectious agent (lifecycle, vulnerability to climate factors), the demographic features
of the population to be infected (infected mortality of infected and non-infected, age,
spatial distribution), behavioural aspects (contact rates among individuals, hygiene)
and, of course, possible control measures (vaccination, isolation of infected, distribution
of condoms and syringes, amongst others). The complexity of the problem makes it
impossible to make predictions for the course of an epidemic, based only on intuition.
On the contrary, it is necessary to integrate all the relevant information effectively and
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this can be done using mathematical models.
Mathematics offers appropriate tools to express complex relations, in a way that makes
it relatively easy to evaluate their consequences. Thus, mathematics offers a concise
and powerful way to expose exactly the factors that determine the epidemiology of the
diseases.
The mathematical models often used to describe the dynamics of a disease are of
compartmental type. Namely, the population is divided into categories or compartments.
These compartments translate the way an individual gets infected and show how the
infection spreads. In a very large population, the movement of individuals between
compartments may be considered a continuous phenomenon. Therefore, it is possi-
ble to represent mathematically the variation of the number of individuals within each
compartment, ‘as time goes by’, by systems of differential equations. These systems
of equations may have useful analytical solutions, but, when the model has a minimum
of realism, this rarely happens and it becomes necessary to implement computationally
tools.
The first compartmental model was introduced in 1864 by Guldberg and Waage [127].
It is the SIR (Susceptible - Infected - Recovered) model. In 1911, Ross [119] analysed
the dynamics of malaria through the mosquito-borne pathogen transmission. Ross,
Kermach and McKendrick continued to work and founded the field of deterministic
compartmental epidemic modeling in 1927 [58].
Chapter 2
Literature review
This chapter, contains the state-of-the-art in modeling of HIV/AIDS dynamics and rele-
vant coinfections (HIV and HCV, HIV and TB). There are many more modeling papers
than could be reviewed here. Nevertheless, are highlighted only a few which were
considered to be more relevant for the theme/development of the thesis.
2.1 HIV
Throughout the years, mathematical models have contributed to a better understanding
of the mechanisms behind the immune response against HIV [98].
2.1.1 Within-host models
In 1996, Perelson et al. [97] studied a model for viral load data, collected from infected
patients, after administration of a PI. They calculated the lifespan of productively infected
cells and of plasma virions, the virions production rate, and the HIV-1 generation time
(namely, the intracellular delay from the time virions are released until they infect another
cell, and cause the release of new viruses). Spouge et al. [134] described two models
for HIV dynamics, considering virus-to-cell transmission in one model and cell-to-cell
transmission in the other. The authors concluded that both models show similar asymp-
totic behaviors, using realistic parameter regimes. In 1998, Wein et al. [159] presented
a mathematical model to predict the role of drug regimens, based on combinations of
PIs and RTIs, in the eradication of HIV-1 or in the maintenance of low viral loads. The
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model included the CD4+ T cells, macrophages (as long-lived cells) and sensitive and
resistant virus. From the model the authors infer that the behaviour of the cells and virus,
and the eradication of the virus, are dependent on the strength of the combined therapy
against the mutant strain and the maximum achievable increase in the uninfected CD4+
T cell concentration. Under certain conditions, the model suggests that a successful
formula to control HIV infection would be to start with a strong inductive therapy to
reduce viral load, and proceed with a weaker maintenance regime. In 2000, Arnout et
al. [8] concluded that during the administration of antiretroviral drugs, priming the CTL
response can lead to better immune responses from the patients. Viral load decreases
rapidly when CTLs are abundant and less quickly otherwise. In 2005, Jones et al. [56]
used mathematical models to show that the amplitude and duration of the viral blips,
in well-suppressed chronically infected HIV patients, under HAART, can be generated
by opportunistic infections. In 2006, Asquith et al. [10] analysed multiple sets of HIV
data and estimated that only 2% of infected CD4+ T cells is due to CTLs, recognising
only one epitope. The authors suggested that CTLs are responsible for the killing of a
considerable number of infected T helper cells, but nonetheless the majority of infected
cells are killed by other cells of the immune system. Kim and Perelson [59] studied the
persistence of the latently infected cells and low levels of plasma virus in HIV-infected
patients. Simulations of the model revealed that the intrinsic stability of latently infected
resting memory CD4+ T cells is the key factor to their long-term persistence. The role
of ongoing viral replication to the stability of the latent reservoir is meaningless. The
presented model is also used to assess the contribution of long-lived infected cells to
plasma virus. It is found that these cells have a significant contribution to plasma virus
only in the first few months of therapy, when the viral load is above 50 copies/ml. In
2007, Wodarz et al. [162] showed that HIV virus ability to infect CD4+ T cells induces
the dynamics of HIV infection. Moreover, infected CD4+ T cells spread fueled the
virus spread at higher virus loads, and it supplied a protection of infected cells during
drug therapy. In what concerns vaccination, a larger number of CD4+ T cells might
be beneficial to the virus, if CD8+ T cells were not boosted at the same time. As
a consequence, vaccination might precipitate disease progression rather than prevent
it [135]. In 2009, Weng et al. [161] studied a model that includes virus-to-cell and cell-
to-cell transmissions. They demonstrated that cell-to-cell transmission is crucial for the
dynamics of HIV infection and it is much more important than virus-to-cell transmission.
Hadjandreou et al. [48], proposed a model for long term HIV dynamics, subjected to
continuous and structured treatment interruptions (STI). Their results showed that an
optimized scheduling, where the interplay between the two virus strains (drug-resistant
and drug-susceptible) is facilitated, favors better responses from the patients. Opti-
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mized STI is thus promising in patients that have developed strong drug-resistance,
and for whom continuous therapy fails. In 2011, Sigal et al. [128] verified that cell-to-
cell transmission can adversely affect the immune system, leading to treatment failure
in individuals with risk factors and potentially contribute to viral persistence. In 2012,
Roy et al. [120] proposed a model for the patterns of HIV and CD4+ T cells, assuming
the existence of two helper cell clones, directed against epitopes of the virus. The
model predicted that a stronger helper cell clone could exclude a weaker one, since
the two clones were infected by the same pathogen. On the other hand, if one of the
helper cell clones was too weak to become established in isolation, the presence of
a stronger one provided enhanced antigenic stimulation, allowing the weaker clone to
persist. Chan et al. [25] studied a model for primary and secondary CTL response cells.
The model exhibits rich dynamics and the authors observed oscillatory patterns for a
wide parameter range. In 2013, Titanji et al. [145] determined that protease inhibitors
are more efficient in blocking cell-to-cell spread of virus than transcriptase inhibitors.
They also found that the efficacy of ART is dependent on the multiplicity of infection.
Komarova et al. [61] showed that virus-to-cell and cell-to-cell transmission contribute
approximately equally to the growth of the virus population. Hernandez-Vargas and
Middleton [52] developed a model for the three stages of HIV infection. They concluded
that macrophage population plays a key role in the progression to AIDS. In 2014, Li
et al. [66] studied a mathematical model which describes the dynamics of HIV under
treatment. The model exhibits a backward bifurcation and the bistability accompanying
it may explain the sudden recovery of the viral load, when treatment is interrupted, and
the occurrence of viral blips. In 2015, Agosto et al. [3] suggested, based on experimental
data, that most ART regimens are effective in blocking cell-to-cell virus transmission and
preventing CD4+ T cells depletion. They argued that efforts are to be applied in better
understanding HIV pathogenesis in vivo, in order to develop smarter ART regimens. The
later would alleviate the treatment burden of people living with HIV. In 2016, Carvalho et
al. [22] proposed a model for the dynamics of HIV under distinct HAART regimes, and
study the emergence of drug-resistance. The model is simulated for two distinct HIV
patients, the RP and the LTNP. The effects of equal RTIs and PIs efficacies, as well as
distinct drug efficacies, namely RTI-based and PI-based therapeutics are studied. The
PI-based drugs seem to produce better outcomes, with respect to disease progression,
than RTI-based regimes. Wang et al. [155] compared the effect of different categories of
drugs on the dynamics of the viral load. The authors concluded that when treatment is
100% effective, drugs acting later in the viral replication cycle lead to a rapid decline in
the viral load. On the other hand, for a non-100% effective treatment, the drugs acting at
intermediate stages of the viral load cycle, induce multiple viral load declines, lowering
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also its slope. Lorenzo-Redondo et al. [68], proposed a spatial and dynamic model to
explain the mechanism behind viral rebound in suppressive HIV patients. The model
simulates the dynamics of viral replication subjected to drug-concentration and HIV
spread among two spatially distinct compartments of the body. The larger compartment
has a high effective drug concentration, the smaller has a lower drug concentration
and may be seen as a sanctuary inside the lymphoid tissue. The authors concluded
that spatial and dynamic processes contribute to the persistence of HIV-1 within in-
fected cells and prevent drug-resistance even under ART. Thus, the viral reservoir is
maintained by the sanctuaries inside lymphoid tissues, where drug concentration is
low. These sanctuaries also promote HIV traffic to blood or lymphoid tissue. In 2017,
Carvalho et al. [23] studied the contributions of within-host (virus-to-cell) and synaptic
(cell-to-cell) transmissions in a mathematical model for human immunodeficiency virus
dynamics. The cell-to-cell transmission rate has a considerable impact in the value of
the reproduction number. This is consistent with biological findings of HIV dynamics in
vivo, where at the level of the lymph nodes, cell-to-cell transmission is crucial for the
development of the disease.
Time-dependent drug regimens have also been considered in the literature. In 2010,
Yang et al. [163] analysed a HIV time-dependent model, where drug efficacy changes
periodically. They proved that the disease-free equilibrium is stable for a threshold
parameter less than unity and unstable for values greater than one. In this case, the
model depicts a globally asymptotically stable periodic solution. In 2012, Browne et
al. [18] considered the effects of the periodic forcing of threshold drug efficacies on
the disease-free equilibrium of an HIV infection model. The authors considered two
time scales, a larger one for the STIs, and the small one for the daily drug dosages.
It was shown that in the first, varying the phase difference between the RTI on-days
relative to PI on-days, significantly impacts the treatment results. For small time scales,
optimization of the timing between daily dosages of RTI and PI may induce greater
treatment effectiveness.
Some of these models include time delays, namely the time needed for infected cells to
produce new virus, and the delay in the stimulation of the immune response. In 2006,
Ciupe et al. [28] modeled the dynamics of the primary HIV infection and the beginning
of the latency phase, considering a delay in the CTL response. This delay leads to
the appearance of periodic solutions, through a Hopf bifurcation. These oscillations
describe the rapid rotation between viral strains and the CTL response, needed to
control the infection. In 2009, Ouifki et al. [95] proposed a model for HIV-1 infection
that included reverse transcriptase inhibitors and three intracellular delays. Authors
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observed that introducing delays promoted the appearance of Hopf bifurcations, trans-
lated in the model as periodic orbits around the endemic equilibrium. These solutions
were consistent with the viral blips seen in HIV patients data. In 2013, Pitchaimani et
al. [107] studied a model for HIV-1 infection that includes protease inhibitor therapy and
three intracellular delays. They showed that the delays reduce the number of infected
cells and viruses at the HIV endemic equilibrium, thus lowering the critical efficacy of
the PI regimen needed to eliminate the virus. In 2014, Wang et al. [156], proposed
a model for drug-resistance, that includes intracellular delay and a general form of
target cell density, during ART. Authors obtained sustained oscillations, promoted by
variation of the T cells growth rate, in a biologically reasonable parameter space. This
finding suggested the viral strains rapidly turn over and any successful ART regimen
should take this into consideration. Pinto et al. [99] studied a model for HIV dynamics
in HIV-specific CD4+ T cells, including intracellular delays. The authors argued that a
good strategy to control HIV should focus on drugs to prolong the latent period and/or
slow down the virus production. In 2016, Huanga et al. [55] presented a model for
HIV infection with treatment and delayed immune response. They concluded that the
higher the delay, the higher the amount of virus and infected T cells in the body and the
frequency of oscillations. Prakast et al. [109] studied a model for macrophages infection
by HIV that includes CTL. The authors concluded that the inclusion of the delay may
destabilize the solutions of the model. This could help devise new treatment options.
In the last few years, several mathematical models have been developed to study tumour
growth in the presence of HIV [73, 71, 69, 70, 136]. In 2006, Pillis et al. [35] pro-
posed a mathematical model to describe cancer growth, on a cell population level, with
combination immune, vaccine and chemotherapy treatments. Simulations of the model
suggest that neither chemotherapy nor immunotherapy alone are sufficient to control
tumour growth, and a combination of the two therapies is able to eliminate the entire
tumour. In 2013, Rihan et al. [113] developed a delay mathematical model to describe
the interactions between a tumour and the immune system in the presence of HIV. The
time delay plays an important role in the dynamics of the model, affecting the stability of
the disease-free steady state. The delay model is consistent with biological findings. In
2014, Louzoun et al. [72] studied a mathematical model of pancreatic cancer. The model
shows that tumour growth depends on complex feedback loops between the tumour
cells, endothelial cells and the immune response. These loops set the cancer growth
rate and its response to immunotherapy. If the immune system is weakened, as in the
case of HIV-infected patients, then cancer treatment is not effective.
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2.1.2 Epidemic models
In the last decades, researchers have tried to understand the long-term dynamics of
HIV epidemics, in order to help devise better HIV prevention programmes nationwide
and worldwide. In 2011, Nyabadza et al. [85] developed a deterministic model, that
incorporated the use of condoms, screening (HCT) and treatment, to infer the impact
of HCT in the long-term dynamics of HIV infection. HCT reduced the prevalence of
HIV only when the screening campaign efficacy exceeded a given threshold. In 2013,
Abbas et al. [1] studied ART and PrEP impacts, with overlapping and non-overlapping
antiretroviral drugs, on HIV transmission and drug resistance. They concluded that the
combination of ART and PrEP prevents more HIV infections than any strategy alone. On
the other hand, it may increase drug resistance. In 2017, Simpson et al. [132] proposed
a deterministic model to assess the impact in an MSM-population of the use of PrEP on
the dynamics of HIV disease transmission. Simulations of the model revealed that, at the
current rate of administration of ART to HIV patients, the HIV viral load decreases with
increasing use of PrEP. Pinto et al. [104] assess the impact of HIV prevention strategies,
namely PrEP and HCT, in a model for the dynamics of HIV. It is observed that the
reproduction number is extremely impacted by the efficacy of the screening and not by
the screening rate. This means that future measures to prevent HIV/AIDS transmission
should also focus on explicit campaigns highlighting the importance of the screening
efficacy. The model without PrEP was fitted to data on the cumulative HIV and AIDS
cases in Portugal. This could help policy makers to devise strategies to reduce heavy
economical and social burden of HIV infection in Portugal.
2.2 HIV and HCV
HIV and HCV share the same transmission routes, namely by injection drug use, sex-
ual contact, mother to child transmission during pregnancy or birth, blood and blood
products transfusion, organs transplantation from infected donors, exposure to blood by
health care professionals [6, 138].
Typically, the coinfection of HIV and other diseases is associated with more serious risks
and severe consequences for patients. In the coinfection with HCV, HIV accelerates the
progression of HCV, moreover, the risk of severe liver disease is higher if the CD4 count
falls below 200 cells/mm3 [47]. In addition, there is a higher risk of cirrhosis, end-
stage liver disease, hepatocellular carcinoma and liver-related death [144]. In Portugal,
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end-stage liver disease is, after tuberculosis, the second leading cause of death among
HIV-positive people [47].
The current international consensus, to control the HIV epidemic, focuses on the need
for clear leadership on policies and programs for prevention, early diagnosis, treatment
that respects human rights, and quality of health care, effective and accessible to ev-
eryone. In what concerns coinfection, some successful treatments for HCV using drug
combination in individuals coinfected with HIV have been reported. Furthermore, most
people with HCV can be treated successfully for HIV [43]. However, more studies are
needed to show the efficacy of new antiviral drugs for HCV in people coinfected with
HIV.
HIV and HCV infections are major global public health issues. There are 37 million
people infected with HIV worldwide, and about 115 million people HCV antibody pos-
itive [93]. One-third of HIV-infected patients are infected with HCV [51]. People coin-
fected with HIV and HCV are more prone to a faster development of HCV infection [51],
presenting higher HCV viral loads, and are more efficient in transmitting HCV [108].
Moreover, the spontaneous elimination of HCV is also decreased in untreated HIV
coinfected patients [108]. One of the leading causes of death in HIV treated coinfected
patients is chronic HCV infection [142], due to drug related hepatoxicity. Chronic in-
fection results in a large number of deaths annualy due to cirrhosis and hepatocellular
carcinoma. Moreover, liver transplants, for HCV induced liver disease patients, are a
major part of health care costs [137]. On the other hand, there is evidence that treatment
for HIV can slow the natural progression of HCV infection and reduce HCV mortality
related to liver diseases [51].
In Portugal, it is estimated that about 25% to 40% of the 41.086 people infected with
HIV are coinfected with HCV [47]. Portugal is the third country, of Western Europe, with
higher prevalence and more new diagnosed cases of HIV/AIDS, per year.
In the last few decades, mathematical models have been applied in the literature to
the modeling of infectious diseases. HIV and known coinfections epidemiologies are
the research topic of some of those models. In 2008, Vickerman et al. [153] pro-
posed a transmission model for HCV/HIV coinfection, aimed at evaluating the cost-
effectiveness of needle and syringe programs for injecting drug users (IDUs). They
concluded that although the needle/syringe sharing events were defined as low risk in
Rawalpindi, the prevalence of HIV/HCV in IDUs would increase. They emphasized the
importance of intervention measures in that low prevalence setting, in order to prevent
the HIV/HCV prevalence. Recently, in 2011 [152], the authors used a mathematical
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model to understand the trends in the prevalence of HIV and HCV. They determined the
different epidemiological profiles and how these profiles affect intervention impact. They
concluded that there were threshold levels of HCV prevalence below which HIV risk was
negligible. Nevertheless, these thresholds varied by setting. The authors infered that
HIV and HCV prevalence settings could provide new insights into IDU risk behaviour
and intervention impact. In 2012 [36], the authors proved that HCV prevalence could be
used as an indicator of risk for successful HIV infection, in an IDU population. In [157],
the authors formulated a mathematical model for HIV/AIDS treatment, where vertical
transmission from mother to child was included. It is shown that HAART and control
of vertical transmission rate were associated with a reduction of the HIV transmission.
Alexander et al. [5] proposed a model for drug resistance in patients with a chronic
viral disease, such as HIV or HCV. They derived dependencies between the parameters
of the system that are important factors in driving drug resistance. Rong et al. [117]
presented a mathematical model of two virus strains, one sensitive and one resistant,
to HCV drugs. They provided a theoretical framework to explore the prevalence of pre-
existing mutant variants and the evolution of drug resistance during HCV treatment. In
2013, Bhunu et al. [16] studied a mathematical model for HIV and HCV coinfection, that
includes treatment for both diseases. The model predicted that HCV had an ongoing
prolonged negative effect on the population health, irrespective of their HIV status. The
authors infered that specific measures to control HCV should be taken/reinforced in
resource limited settings. Corson et al. [32], proposed a mathematical model to explore
the risk of HCV infection through the sharing of injecting paraphernalia (including filters,
cookers and water). Namely, the sharing of injecting paraphernalia among IDUs is
common, thus, HCV transmission through this route could contribute to the growing
burden in healthcare systems associated with it. The authors infered that more work
was needed to detail the contribution of the paraphernalia sharing to the spread of HCV,
and that health care providers should distribute sterile paraphernalia to prevent HCV
infection. In 2014, Carvalho et al. [21] studyed a mathematical model for HIV and HCV
coinfection, that includes treatment for both diseases, and vertical transmission in the
case of HIV. The outcomes suggest that specific measures should be considered, by
the policy makers, in order to reduce HIV infection, such as: distributing more condoms
to individuals; develop campaigns in order to warn individuals about the consequences
of having many sexual partners; continuing treatment for AIDS and pursuing the inves-
tigation of new and better drugs to combat HIV, treat new borns infected with HIV and
advise pregnant women for the benefits of HIV treatment. Considering HCV infection,
treatment is highly recommended as well as other measures (e.g., more informational
campaigns about the disease, its transmission routes, amongst others) in order to
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decrease the number of infectious and of chronic carriers. Pinto et al. [101] developed
a new a coinfection model for HCV and HIV, in which it was considered treatment for
both diseases, screening, unawareness and awareness of HIV infection, and the use of
condoms. The results obtained suggest that specific measures should be considered in
order to reduce HIV infection, such as: distributing more condoms to individuals and try
to forward the message that condoms should be used during anal intercourse (though
this might not be well accepted in MSM population due to unprotected sex negotiation);
develop campaign in order to warn individuals about the consequences of having many
sexual partners; continuing treatment for AIDS and pursuing the investigation of new
and better drugs to combat the virus and regular screening. MSM population is at risk
of HCV reinfection following successful treatment and documented clearance of HCV,
they should be warned about this important risk. In 2015, Birger et al. [17] improved an
existing model for HCV infection to include the dynamics of the HIV and HCV coinfection,
where an immune system component for infection clearance is incorporated. They
found that the progression of HCV infection is more rapid when the immune response
is compromised by HIV. A better understanding of the mechanisms behind this immune
impairment in coinfection may help to devise better therapeutic regimens and to identify
patients more compliant to certain drugs.
2.3 HIV and TB
TB is an infectious disease caused by the bacteriaMycobacterium tuberculosis (MTB). It
is transmitted through droplets, when people suffering from pulmonary TB expel bacte-
ria, for example, by coughing. In general, a relatively small proportion of people infected
with MTB develops active TB, but this proportion is much higher in people with impaired
immunity.
The incidence (number of new cases in the population per year) of TB found in various
regions of the globe ranges from almost zero to more than 600 cases per 100 000
persons per year. A significant contributing factor to these rates is the phenomenon of
exogeneous reinfection. Exogeneous reinfection has, thus, a determinant role in the
dynamics and the epidemiology of TB [26, 80, 41, 60]. The transmission of TB differs
from other infectious diseases. Approximately only 10% of the infected individuals de-
velop active TB. Most people’s immune response to the initial infection limits proliferation
of the bacilli and leads to partial immunity. Apparently, the longer the bacilli is in the
organism, the less likely people are to develop active TB (unless the immune system
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becomes seriously compromised by other diseases, such as HIV/AIDS). Nevertheless,
re-exposure to the bacilli through repeated contacts with infectious TB individuals may
accelerate the progression to active TB. The phenomenon of exogeneous reinfection is
driven by the condition that the risk of a second disease causing infection for a person,
who has recovered from a TB episode, is about 7(±4) times greater than the risk of a
first-time infection that leads to disease [148]. This estimate is in close agreement with
actual minimum estimates based on data from a high TB incidence community [151],
where the risk of developing a second episode of TB after infection was estimated to be
4− 7 times higher than a first episode.
In 2010, there were an estimated 8.8 million new cases of tuberculosis, approximately
13% of which occurred in people living with HIV. In 2010, an estimated 1.1 million HIV-
negative people died from tuberculosis, while an additional 0.35 million died from HIV-
associated tuberculosis. Since 1990, mortality due to tuberculosis has fallen by just
over one third. Treatment of TB is achieved through antibiotics. Treatment takes at least
six months and is increasingly hampered by multidrug-resistance. There are 6 types
of multidrug-resistant TB [94]. The treatment for TB has had a success rate of 87%
worldwide. In EU/EEA this sucess rate drops to 74.3% [42]. Treatment success had
been achieved in 76.8% of new pulmonary TB cases, 53.7% of previously treated cases,
and 31.6% of multidrug-resistant TB cases. Some first-line drugs used to treat TB are
rifampcin, isoniazid, pyrazinamide, ethambtol. The second line drugs includes amikacin,
capreomycin, cycloserine, azithromycin, clarithromycin, moxifloxacin, levofloxacin. The
exposed individuals are treated with isoniazid.
Resurgence of TB in the 1980’s is attributed jointly to the emergence of multi-drug resis-
tant strains (MDR-TB) and the AIDS pandemic, which led the WHO to declare TB as a
global emergency in 1983. MDR-TB and, more recently, extensively resistant TB (XDR-
TB), jeopardize TB control, and rise concerns of a future of non-effective drugs [46]. In
1993, the WHO declared TB a global emergency by its overall size and consequences,
namelly its association with HIV/AIDS, and the emergence of multidrug-resistance. The
Global Plan to Stop TB [94] indicates the goals to be achieved in the ‘war’ against TB.
Some of these goals are to determine strategies and costs associated with multidrug-
resistant TB, reduce consequences of coinfection with HIV, to aid laboratories to develop
research on TB in a consistent and coordinated way, amongst others.
TB and HIV exhibit a kind of synergistic relationship, where each accelerates the pro-
gression of the other. In coinfected individuals, TB causes cell activation and excessive
cytokine and chemokine productions. The later stimulates HIV replication and accel-
erates the progression to AIDS. On the other hand, HIV increases twenty times the
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odds of TB reactivation and increases the risk of infection by MDR-TB of MTB, since it
expands the number of individuals with active TB [75, 93]. Moreover, it may contribute
to selection for spontaneous mutations. Factors worsening this scenario are the lack of
treatment adherence due to excessive pill burden, the treatment toxic effects, and/or the
communication gaps in HIV and TB treatment programs [46].
TB is nowadays one of the 10 top causes of death worldwide. Moreover, in 2015, 35%
of HIV infected individuals deaths were due to coinfection with TB, making TB a leading
killer of HIV-positive people [93]. Dual infection with HIV and TB contributes heavily
to the morbidity and mortality associated with TB. In comparison, there is a 20-fold
higher risk of individuals infected with HIV to develop tuberculosis, when compared
to those without the HIV virus, in countries where HIV prevalence is at least 1% [94].
The HIV/AIDS pandemic plays an important role in the resurgence of TB, increasing
morbidity and mortality worldwide. It decreases the TB latency period, accelerating
active disease in people infected with MTB. Namely, an HIV-positive person infected
with MTB has a 50% chance of developing active TB, whereas an HIV-negative person
has only a 10% chance of developing it [81]. These high figures may be justified by the
late diagnosis of TB in HIV infected individuals, or of HIV in individuals infected with TB.
Even when diagnosed, this occurs in a very late stage of the disease [49].
Several mathematical models have been derived with the purpose of understanding
the dynamics of HIV, and TB, and of the coinfection [130]. In 1997, Castillo-Chavez
et al. [24], formulated a model for TB where it is possible to determine the survival
and spread of naturally resistant strains of TB and resistant strains of TB generated
by antibiotics. They concluded that the coexistence of the two strains only occurs in
treated individuals and results from the lack of adherence to treatment. In 2006, Cohen
et al. [29] proposed a mathematical model for TB and HIV co-infection and examine
the impact of community-wide implementation of IPT for dually infected individuals.
They found that diagnostic and specific treatment policies together with community-
wide IPT should be implemented to identify and properly treat the increasing number of
individuals drug-resistant to TB. In 2007, Rodrigues et al. [115], proposed a model for
TB infection, where the dynamics of the drug-resistant and sensitive strains are studied.
The long-term behavior of the model reflects how reinfection modifies the conditions for
the coexistence of the strains. In 2009, Roeger et al. [116], introduced a highly simplified
deterministic model that incorporates the joint dynamics of TB and HIV. They observed
that increasing the progression rate from latent to active TB in co-infected individuals
might play a significant role in the rising prevalence of TB, and the increased HIV to
AIDS progression rates translated in an increase of the prevalence level of HIV, while
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decreasing TB prevalence, and generated damped oscillations in the system. In 2011,
Bhunu [14] studied a mathematical model to evaluate the impact of active treatment of
TB (multi-drug sensitive and resistant) in controlling the spread of TB. The results of
the analytical and numerical simulations suggest that the quarantine of extensively drug
resistant cases will help reduce the spread of tuberculosis. In 2012, Sergeev et al. [124]
explored the effect of HIV on the dynamics of MDR-TB. An increase in the HIV viral
load in coinfected individuals increases the prevalence of MDR-TB within populations.
This occurs even as it lowers the average fitness of circulating MDR-TB strains, when
compared to similar HIV uninfected populations. Gakkhar and Chavda [45], developed a
mathematical model for HIV and TB co-infection. They computed the reproduction num-
bers of the two diseases. They computed the stability of the disease free equilibrium and
of the endemic equilibrium. Authors suggested, as the endemic equilibrium is unstable,
that co-infection is not long lasting. In 2014, Trauer et al. [146] developed a mathematical
model for TB that includes the partial and temporary efficacy of the vaccine, reduction of
the risk of active disease after infection, the possibility of reinfection, during the latency
period of the infection or after treatment, multidrug-resistant tuberculosis and resistance
during treatment. They concluded that improving the treatment of susceptible individuals
increases multidrug-resistant tuberculosis. In 2016, Mallela et al. [76], studied the effect
of early and late HIV treatment in coinfected individuals receiving treatment for TB.
The model suggests that the coinfection burden depends highly on the timing of the
initiation of ART. Ronoh et al. [118] included resistance to tuberculosis in a standard
SEIRS model. They found that in the case of patients with active tuberculosis and multi-
resistant tuberculosis with both strains, the disease will persist due to lack of permanent
immunity. In 2017, McBryde et al. [77] studied a mathematical model for tuberculosis
and considered multi-drug resistance. In their analysis, they determined that without a
renewed focus on prevention, early diagnosis and treatment of multi-resistance cases,
TB transmission will be dominated by MDR-TB, which could divert progress towards
global control of TB and final elimination.
2.4 Fractional calculus
Fractional calculus (FC) is a generalization of the integer order calculus. Lagrange and
Leibniz were the first mathematicians exchanging letters about the possible meaning of
a 1/2-order derivative. They were the predecessors of non-integer-order differentiation
and integration, also known as fractional calculus. Since then, the meaning andmethods
to compute 1/2-order derivatives or, in general, α-order derivatives, with α non-integer,
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has been a major research in mathematics. Some well-known mathematicians that have
devoted their work to fractional differentiation and integration are Euler, Abel, Liouville,
Riemann, Grünwald, Letnikov, Caputo, amongst others [91, 122].
There are several definitions for a fractional order (FO) derivative. For simplification,
consider the interval [0, t] as an index in the differential operator. Suppose that the
function f(t) satisfies some smoothness conditions in every finite interval (0, t) with
t ≤ T . The Riemann–Liouville definition is given by:
Dα⋆ f(t) =


1
Γ(m−α)
dm
dtm
∫ t
a
f(τ)
(t−τ)α+1−m
dτ, m− 1 < α < m
dmf(t)
dtm
, α = m
The Caputo’s fractional derivative is defined as follows.
Definition 2.4.1 [20] Let α > 0, t > a, α, a, t ∈ R. The fractional operator
Dα⋆ f(t) =


1
Γ(n−α)
∫ t
a
f(n)(τ)
(t−τ)α+1−n
dτ, n− 1 < α < n ∈ N
dn
dtn
f(t), α = n ∈ N
The main advantage using Caputo’s fractional derivative is that classical initial condi-
tions can be used without encountering any problem during solvability. Now the main
properties of the Caputo operator are revealed. It begins with interpolation.
Lema 2.4.2 Let n − 1 < α < n, n ∈ N, α ∈ R and f(t) be such that Dα⋆ f(t) exists.
Then:
Dα⋆ f(t) = I
n−αDnf(t)
Lema 2.4.3 Let n − 1 < α < n, n ∈ N, α ∈ R and f(t) be such that Dα⋆ f(t) exists.
Then the following properties hold:
lim
α→n
Dα⋆ f(t) = f
(n)(t)
lim
α→n−1
Dα⋆ f(t) = f
(n−1)(t)− f (n−1)(0)
The Caputo operator is a linear operator.
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Lema 2.4.4 Let n−1 < α < n, n ∈ N, α, λ ∈ C and the functions f(t) and g(t) be such
that both Dα⋆ f(t) and D
α
⋆ g(t) exist. The Caputo fractional derivative is a linear operator,
i.e.:
Dα⋆ (λf(t) + g(t)) = λD
α
⋆ f(t) +D
α
⋆ g(t)
Generally, the Caputo operator is non-commutative.
Lema 2.4.5 Let n − 1 < α < n, n,m ∈ N, α ∈ R and the function f(t) is such that
Dα⋆ f(t) exists. Then in general
Dα⋆D
mf(t) = Dα+m⋆ f(t) 6= D
mDα⋆ f(t)
Lema 2.4.6 Let n− 1 < α < n, β = α− (n− 1), n ∈ N, α, β ∈ R and the function f(t)
is such that Dα⋆ f(t) exists. Then
Dα⋆ f(t) = D
β
⋆D
n−1f(t)
The algorithm used for the numerical solution of non-linear differential equations of
fractional order is presented in [38]. This algorithm allows an efficient analysis of a
mathematical model. The algorithm for the numerical solution of these equations is
based on a PECE (Predict, Evaluate, Correct, Evaluate) method. This method combines
a fractional-order algorithm with a classical method. Thus, the authors choose an
Adams-Bashforth-Moulton approach for both integrators. Given that this approach is
well known for first-order equations, in the case of the fractional variant, the key to
deriving the method is simply to use the trapezoidal quadrature formula of the product.
The main properties of the algorithm are: the behavior of the method is independent
of the parameter α and behaves very much like the classical method of an Adams-
Bashforth-Moulton stage (ie α = 1). As for the stability of the method, these properties
remain unchanged in the fractional version against the classical algorithm, and therefore
it is also clear that the behavior does not depend on the order of the differential operators
involved [38].
Fractional models have been used in the literature to understand the behavior of epi-
demiological models, where the integer-ordermodels fail to give a complete explanation.
In 2013, Diethelm [37] proposed a fractional order model for the dynamics of dengue
fever. It was shown that the numerical simulations of the model provide better agreement
with real data, from the 2009 outbreak of dengue in Cape Verde, than the integer order
2.4. FRACTIONAL CALCULUS 23
model. In 2014, Pinto et al. [100] studied a model for HIV and TB co-infection and
concluded that the dynamics of the integer and the fractional order versions of the model
are very rich and that together these versions may provide a better understanding of the
dynamics of the co-infection. In 2015, Pinto et al. [102] proposed a fractional complex-
order model for HIV dynamics in the three-stages of infection. The fractional model
unravels interesting dynamics that may help to understand the differences in individuals’
disease progression. In 2016, Pinto et al. [103] studied a fractional complex-order model
for drug resistance during HIV therapy, that includes three distinct growth rates for the
CD4+ T cells. The numerical results suggest that the variation of the complex-order
fractional derivative may be compared to the variation of the delay in integer-order
systems, in biologically meaning intervals. This happens for all growth rates. It is
also observed the appearance of sustained oscillations (blips) as the proliferation rate
increases. Sweilan et al. [139] proposed a fractional order model for multi-strain TB,
which incorporates drug-sensitive, emerging MDR-TB and XDR-TB. They approximated
the solutions of the FO model by distinct numerical methods and discussed the results
obtained. In [140], the authors formulated an optimal control problem for a FO TB model
and studied it using the Pontryagin maximum principle. They considered four controls
variables to minimize the cost interventions and two numerical methods to approximate
the solutions of the FO optimal control problem. They found that the iterative optimal
control method provides better results. In 2017, it was analysed a FO model for HIV
infection where latent T helper cells are included [105]. The order of the fractional
derivative is associated to a decrease in the severity of the disease. Moreover, the
results of the simulations of relevant parameters, such as the fraction of uninfected
CD4+ T cells that become latently infected, and the CTLs proliferation rate due to
infected CD4+ T cells, are biologically acceptable, for all values of the order of the
fractional derivative. Pinto et al. [106] proposed a mathematical model with memory for
the dynamics of HIV, where two transmission modes, cell-to-cell and virus-to-cell, and
drug resistance are considered. The results showed that the cell-to-cell transmission is
crucial for the development of the disease. The later highlights the extremely important
role of the cell-cell pathway in the progression to AIDS in HIV infected patients. The
order of the fractional derivative may be used, in this sense, to explain differences in the
progression routes of HIV infected patients, associated with patients’ immune system
status, specific features in donor and target cell types, genetic profile, age.
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Chapter 3
Mathematical models for HIV
3.1 Model I
A.R.M. Carvalho and C.M.A. Pinto, Emergence of drug-resistance in HIV dynamics
under distinct HAART regimes, Communications in Nonlinear Science and Numerical
Simulation 30, 207–226, 2016.
It is proposed a mathematical model for HIV infection, which includes helper cells,
macrophages, CTLs and two viral strains. The main goals are to study the dynamics
of the rapid progressors (RP) and of the long-term non-progressors (LTNP), and the
effects of RTI and PI efficacies. Initially, the model is described, then the reproduction
number and the local and global stability of the disease-free equilibrium are calculated.
Finally, several model simulations are analyzed for different treatment regimens and the
implications of the results are discussed.
3.1.1 Description of the model
The proposed compartmental model includes nine compartments. It yields the dynam-
ics of uninfected (T , M ), and of drug-sensitive (Ts, Ms) and drug-resistant (Tr, Mr)
sub-populations of CD4+ T cells and macrophages, respectively. Moreover it includes
the dynamics of CTLs (Z) and of two viral strains (Vs, Vr).
The source of new T and M cells is represented by the first two terms of the corre-
sponding equations. The logistic term of the T cells prevents its number to exceed the
maximum concentration Tmax. T cells are infected by HIV and infected macrophages at
25
26 CHAPTER 3. MATHEMATICAL MODELS FOR HIV
rates k1 and k2, respectively. Macrophages are infected by HIV at rate k4. The death
rates of uninfected T cells and infected Ts, Tr cells are given by δ1 and δ2, respectively.
Macrophages populations are eliminated at rate δ3.
CTLs, Z, are generated by the first three terms of the corresponding equation. Rates k3
and k5 refer to the elimination of infected Ts, Tr cells and infectedMs, Mr macrophages
by CTLs, respectively. The natural death rate of CTLs is δ4.
The sensitive (Vs) and resistant (Vr) virions are produced by the corresponding infected
CD4+ T cells and macrophages populations, with bursting sizes of drug-sensitive strain,
Ns, and of drug-resistant strain, Nr. Virions are cleared at a rate c.
Parameters t1, t2 ∈ [0, 1] in the equations represent the efficacy of RTIs and PIs, re-
spectively. A value of 0 is associated with non-treatment and a value of 1 with full efficacy
in the treatment. Drug-resistance is a result of genetic mutations. Viral mutations are
accounted in the model via the parameter u, which represents the probability of mutation
per replication cycle. Genetic mutations confer resistance to drugs. On the contrary,
they reduce the infection rate of mutated virus. I.e., the virus’s ability to transcribe its
genome and integrate it into the host’s genome is diminished, as well as its replicating
capacity. As a result, infection rates by mutated viruses are considered to be smaller.
As such, it is assumed that mutated virus is less fit than the wild-type. In the model,
this is accounted by the parameter ψ. Moreover, drug efficacy in macrophages is lower
than in CD4+ T cells. Therefore, efficacy of the drugs on macrophages is fiti, where
fi ∈ [0, 1] and subindex i refers to each drug.
The schematic diagram of the model can be found in Figure 3.1.
The model is described by the following system of equations:
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Figure 3.1: Schematic diagram of the model (3.1).
T˙ (t) = λ1 +
p1(Vs(t)+Vr(t))
Vs(t)+Vr(t)+C1
T (t)− (1− t1)(k1Vs(t) + k2Ms(t))T (t)− ψ(k1Vr(t) + k2Mr(t))T (t)+
+rT (t)(1− (T (t) + Ts(t) + Tr(t))/Tmax)− δ1T (t);
T˙s(t) = (1− t1)(k1Vs(t) + k2Ms(t))T (t)− δ2Ts(t)− k3Ts(t)Z(t)
T˙r(t) = ψ(k1Vr(t) + k2Mr(t))T (t)− δ2Tr(t)− k3Tr(t)Z(t)
M˙(t) = λ2 +
p2(Vs(t)+Vr(t))
C2+Vs(t)+Vr(t)
M(t)− k4(1− f1t1)Vs(t)M(t)− k4ψVr(t)M(t)− δ3M(t)
M˙s(t) = k4(1− f1t1)Vs(t)M(t) − δ3Ms(t)− k5Ms(t)Z(t)
M˙r(t) = k4ψVr(t)M(t)− δ3Mr(t)− k5Mr(t)Z(t)
V˙s(t) = Ns(1− u)((1− t2)δ2Ts(t) + (1− f2t2)δ3Ms(t))− cVs(t)
V˙r(t) = Nr(ψ(1− u)(δ2Tr(t) + δ3Mr(t)) + u((1− t2)δ2Ts(t) + (1− f2t2)δ3Ms(t))− cVr(t)
Z˙(t) = λ3 + k6(Ts(t) + Tr(t))Z(t) + k7(Ms(t) +Mr(t))Z(t)− δ4Z(t)
(3.1)
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with non-negative initial conditions T (0) = T 0, Ts(0) = T
0
s , Tr(0) = T
0
r , M(0) = M
0,
Ms(0) = M
0
s ,Mr(0) = M
0
r , Vs(0) = V
0
s , Vr(0) = V
0
r , and Z(0) = Z
0.
3.1.2 Reproduction numbers and stability of the disease-free equi-
librium
In this subsection, the reproduction number, R0, of the model (3.1) is calculated. The
basic reproduction number is defined as the number of secondary infections due to a
single infection in a completely susceptible population [150].
Two sub-models of model (3.1) are considered. Model (3.2) is obtained from model (3.1)
by setting the variables concerning resistance dynamics (Tr,Mr and Vr) to zero. On the
other hand, model (3.5) follows from model (3.1) by setting the variables with respect to
the sensitive dynamics (Ts,Ms and Vs) to zero.
The reproduction number of system (3.2),Rs, is calculated. The next generationmethod [150]
is used.
T˙ (t) = λ1 +
p1Vs(t)
Vs(t)+C1
T (t)− (1− t1)(k1Vs(t) + k2Ms(t))T (t)
+rT (t)(1− (T (t) + Ts(t))/Tmax)− δ1T (t);
T˙s(t) = (1− t1)(k1Vs(t) + k2Ms(t))T (t)− δ2Ts(t)− k3Ts(t)Z(t)
M˙(t) = λ2 +
p2Vs(t)
C2+Vs(t)
M(t)− k4(1− f1t1)Vs(t)M(t)− δ3M(t)
M˙s(t) = k4(1− f1t1)Vs(t)M(t)− δ3Ms(t)− k5Ms(t)Z(t)
V˙s(t) = Ns(1− u)((1− t2)δ2Ts(t) + (1− f2t2)δ3Ms(t))− cVs(t)
Z˙(t) = λ3 + k6Ts(t)Z(t) + k7Ms(t)Z(t)− δ4Z(t)
(3.2)
The disease-free equilibrium of model (3.2) is given by:
P 10 = (T
0, T 0s ,M
0,M0s , V
0
s , Z
0) =
=


Tmax
[
(r−δ1)+
√
(r−δ1)2+
4rλ1
Tmax
]
2r
, 0, λ2
δ3
, 0, 0, λ3
δ4

 (3.3)
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Using the notation of [150] in system (3.2), the matrices for the new infection terms, F1,
and the other terms, V1, are computed as follows:
F1 =


0 (1− t1)k2T
0 (1− t1)k1T
0
0 0 k4(1− f1t1)M
0
0 0 0


V1 =

 δ2 + k3Z0 0 00 δ3 + k5Z0 0
−Ns(1− u)(1− t2)δ2 −Ns(1− u)(1− f2t2)δ3 c

 =

 A 0 00 B 0
−Ns(1− u)D −Ns(1− u)E c


The associative basic reproduction number is calculated to be:
Rs = ρ(F1V
−1
1 ) =
GD
A
+ HE
B
+
√(
GD
A
+ HE
B
)2
+ 4HD
AB
k2(1− t1)T 0
2
(3.4)
where G = (1−t1)k1T
0Ns(1−u)
c
, H = (1−f1t1)k4M
0Ns(1−u)
c
and ρ indicates the spectral radius
of F1V
−1
1 . By Theorem 2 [150], one obtains the Lemma 3.1.1.
Lema 3.1.1 The disease-free equilibrium P 10 is locally asymptotically stable if Rs < 1
and unstable if Rs > 1.
Proof The matrix of the linearization of model (3.2) around the disease-free equilibrium,
P 10 , is:
M1 =


r
(
1− 2T
0
Tmax
)
− δ1 −
rT 0
Tmax
0 −(1− t1)k2T
0 p1T 0
C1
− (1− t1)k1T
0 0
0 −δ2 − k3Z
0 0 (1− t1)k2T
0 (1− t1)k1T
0 0
0 0 −δ3 0
p2M0
C2
− k4(1− f1t1)M
0 0
0 0 0 −δ3 − k5Z
0 k4(1− f1t1)M
0 0
0 Ns(1− u)(1− t2)δ2 0 Ns(1− u)(1− f2t2)δ3 −c 0
0 k6Z
0 0 k7Z
0 0 −δ4


The following eigenvalues are easily obtained:
(
1−
2T 0
Tmax
)
− δ1, −δ3, −δ4,
The remaining eigenvalues are the roots of the characteristic equation of a 3× 3 matrix,
M2, given by:
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M2 =

 −δ2 − k3Z0 (1− t1)k2T 0 (1− t1)k1T 00 −δ3 − k5Z0 k4(1− f1t1)M0
Ns(1− u)(1− t2)δ2 Ns(1− u)(1− f2t2)δ3 −c

 =

 −A (1− t1)k2T 0 (1− t1)k1T 00 −B k4(1− f1t1)M0
Ns(1− u)D Ns(1− u)E −c


The determinant |M2 − λI3| = 0 is equivalent to:
(−A− λ)(−B − λ)(−c− λ) + (1− t1)k2T
0k4(1− f1t1)M
0Ns(1− u)D−
−Ns(1− u)D(−B − λ)(1− t1)k1T
0 −Ns(1− u)Ek4(1− f1t1)M
0(−A− λ) = 0
(−A− λ)(−B − λ)(−c− λ) + (1− t1)k2T
0HcD −GcD(−B − λ)−HcE(−A− λ) = 0
λ3 + (A+B + c)λ2 + (AB + Ac+Bc−GcD −HcE)λ+
+ABc− (1− t1)k2T
0HcD − BGcD −HcEA = 0
where I3 is the identity matrix of order 3. By the Routh-Hurwitz criteria, the three roots
of the characteristic equation λ3 + a1λ
2 + a2λ + a3 = 0 have negative real parts if
and only if a1, a3 > 0 and a1a2 − a3 > 0. It is proved below for a1 = A + B + c,
a2 = AB+Ac+Bc−GcD−HcE, and a3 = ABc−(1−t1)k2T
0HcD−BGcD−HcEA.
It is easy to show that a1 = A+B+ c = δ2+k3Z
0+ δ3+k5Z
0+ c > 0. Next, it is shown
the proof of a3 > 0.
ABc > c((1− t1)k2T
0HD +BGD +HEA)⇔ AB > (1− t1)k2T
0HD +BGD +HEA⇔
⇔ (1− t1)k2T
0HD
AB
+ GD
A
+ HE
B
< 1
This last inequality (1− t1)k2T
0HD
AB
+ GD
A
+ HE
B
< 1 is equivalent to Rs < 1 (see below).
Rs < 1 ⇔
GD
A
+HE
B
+
√
(GDA +
HE
B )
2
+4HD
AB
k2(1−t1)T 0
2
< 1
⇔
√(
GD
A
+ HE
B
)2
+ 4HD
AB
k2(1− t1)T 0 < 2−
GD
A
− HE
B
⇔
⇔
(
GD
A
+ HE
B
)2
+ 4HD
AB
k2(1− t1)T
0 < 4
(
1− GD
A
− HE
B
)
+
(
GD
A
+ HE
B
)2
⇔
⇔ HD
AB
k2(1− t1)T
0 + GD
A
+ HE
B
< 1
Thus, a3 > 0 if Rs < 1. Some algebraic manipulations are now performed to prove that
a1a2 − a3 > 0.
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(A +B + c)(AB + Ac+Bc−GcD −HcE)− ABc+ (1− t1)k2T
0HcD +BGcD +HcEA > 0
A2B + A2c+ ABc− AGcD − AHcE + AB2 + ABc +B2c− BGcD −BHcE + ABc + Ac2+
+Bc2 −Gc2D −Hc2E −ABc + (1− t1)k2T
0HcD +BGcD +HcEA > 0
A2B + A2c+ ABc− AGcD + AB2 +B2c− BHcE + ABc+ Ac2 +Bc2 −Gc2D −Hc2E+
+(1− t1)k2T
0HcD > 0
A2B + 2ABc+ AB2 + Ac(A−GD) +Bc(B −HE) + c2(A−GD) + c2(B −HE)+
+(1− t1)k2T
0HcD > 0
It follows that, for Rs < 1, all eigenvalues of the linearization matrix M1 have negative
real parts, then the disease-free equilibrium P 10 is locally asymptotically stable.

It follows the computation of the reproduction number of model (3.5), Rr.
T˙ (t) = λ1 +
p1Vr(t)
Vr(t)+C1
T (t)− ψ(k1Vr(t) + k2Mr(t))T (t)+
+rT (t)(1− (T (t) + Tr(t))/Tmax)− δ1T (t);
T˙r(t) = ψ(k1Vr(t) + k2Mr(t))T (t)− δ2Tr(t)− k3Tr(t)Z(t)
M˙(t) = λ2 +
p2Vr(t)
C2+Vr(t)
M(t)− k4ψVr(t)M(t) − δ3M(t)
M˙r(t) = k4ψVr(t)M(t) − δ3Mr(t)− k5Mr(t)Z(t)
V˙r(t) = Nr(ψ(1− u)(δ2Tr(t) + δ3Mr(t)))− cVr(r)
Z˙(t) = λ3 + k6Tr(t)Z(t) + k7Mr(t)Z(t)− δ4Z(t)
(3.5)
The disease-free equilibrium state P 20 of model (3.5) is given by:
P 20 = (T
0, T 0r ,M
0,M0r , V
0
r , Z
0)
=


Tmax
[
(r−δ1)+
√
(r−δ1)2+
4rλ1
Tmax
]
2r
, 0, λ2
δ3
, 0, 0, λ3
δ4

 (3.6)
Using the notation of [150] in system (3.5), the matrices for the new infection terms, F2,
and the other terms, V2, are calculated as:
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F2 =


0 ψk2T
0 ψk1T
0
0 0 k4(1− f1t1)M
0
0 0 0


V2 =


δ2 + k3Z
0 0 0
0 δ3 + k5Z
0 0
−Nrψ(1− u)δ2 −Nrψ(1− u)δ3 c

 =


A 0 0
0 B 0
−Nr(1− u)D1 −Nr(1− u)E1 c


The associative basic reproduction number is given by:
Rr = ρ(F2V
−1
2 ) =
ID1
A
+ JE1
B
+
√(
ID1
A
+ JE1
B
)2
+ 4JD1
AB
ψk2T 0
2
(3.7)
where I = ψk1T
0Nr(1−u)
c
, J = ψk4M
0Nr(1−u)
c
and ρ indicates the spectral radius of F2V
−1
2 .
By Theorem 2 [150], the following lemma is obtained.
Lema 3.1.2 [150] The disease-free equilibrium P 20 is locally asymptotically stable if
Rr < 1 and unstable if Rr > 1.
Proof The linearization of model (3.5) around the disease-free equilibrium, P 20 is given
by:
M3 =


r
(
1− 2T
0
Tmax
)
− δ1 −
rT 0
Tmax
0 −ψk2T
0 p1T 0
C1
− ψk1T
0 0
0 −δ2 − k3Z
0 0 ψk2T
0 ψk1T
0 0
0 0 −δ3 0
p2M0
C2
− k4ψM
0 0
0 0 0 −δ3 − k5Z
0 k4ψM
0 0
0 Nrψ(1− u)δ2 0 Nrψ(1− u)δ3 −c 0
0 k6Z
0 0 k7Z
0 0 −δ4


The following eigenvalues are easily obtained:
(
1−
2T 0
Tmax
)
− δ1, −δ3, −δ4,
The remaining eigenvalues are the roots of the characteristic equation of a 3× 3 matrix,
M4, given by:
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M4 =

 −δ2 − k3Z
0 ψk2T
0 ψk1T
0
0 −δ3 − k5Z
0 k4ψM
0
Nrψ(1− u)δ2 Nrψ(1− u)δ3 −c

 =

 −A ψk2T 0 ψk1T 00 −B k4ψM0
Nr(1− u)D1 Nr(1− u)E1 −c


The determinant |M4 − λI3| = 0 is equivalent to:
(−A− λ)(−B − λ)(−c− λ) + ψk2T
0k4ψM
0Nr(1− u)D1 −Nr(1− u)D1(−B − λ)ψk1T
0−
−Nr(1− u)E1k4ψM
0(−A− λ) = 0
(−A− λ)(−B − λ)(−c− λ) + ψk2T
0JcD1 − IcD1(−B − λ)− JcE1(−A− λ) = 0
λ3 + (A +B + c)λ2 + (AB + Ac+Bc− IcD1 − JcE1)λ+ ABc− ψk2T
0JcD1 − IcD1B − JcE1A = 0
where I3 is the identity matrix of order 3. By the Routh-Hurwitz criteria, the three roots
of the characteristic equation λ3 + a1λ
2 + a2λ + a3 = 0 have negative real parts if
and only if a1, a3 > 0 and a1a2 − a3 > 0. This is shown for a1 = A + B + c, a2 =
AB + Ac +Bc− IcD1 − JcE1, and a3 = ABc− ψk2T
0JcD1 − IcD1B − JcE1A.
It is trivial to show that a1 = A+B+ c = δ2 + k3Z
0+ δ3+ k5Z
0+ c > 0. Now it’s proven
that a3 = ABc− ψk2T
0JcD1 − IcD1B − JcE1A > 0 if Rr < 1.
ABc > c(ψk2T
0JD1 + ID1B + JE1A)⇔ AB > ψk2T
0JD1 + ID1B + JE1A⇔
⇔ ψk2T
0 JD1
AB
+ ID1
A
+ JE1
B
< 1
Last inequality is equivalent to Rr < 1.
Rr < 1 ⇔
ID1
A
+
JE1
B
+
√
( ID1A +
JE1
B )
2
+4
JD1
AB
k2ψT 0
2
< 1⇔
⇔
√(
ID1
A
+ JE1
B
)2
+ 4JD1
AB
k2ψT 0 < 2−
ID1
A
− JE1
B
⇔
⇔
(
ID1
A
+ JE1
B
)2
+ 4JD1
AB
k2ψT
0 < 4
(
1− ID1
A
− JE1
B
)
+
(
ID1
A
+ JE1
B
)2
⇔
⇔ JD1
AB
k2ψT
0 + ID1
A
+ JE1
B
< 1
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It is shown that a1a2 − a3 > 0.
(A+B + c)(AB + Ac+Bc− IcD1 − JcE1)−ABc + ψk2T
0JcD1 + IcD1B + JcE1A > 0
A2B + A2c + ABc− AIcD1 − AJcE1 + AB
2 + ABc+B2c−BIcD1 − BJcE1 + ABc+
+Ac2 +Bc2 − Ic2D1 − Jc
2E1 −ABc + ψk2T
0JcD1 + IcD1B + JcE1A > 0
A2B + A2c + ABc− AIcD1 + AB
2 +B2c−BJcE1 + ABc + Ac
2 +Bc2−
−Ic2D1 − Jc
2E1 + ψk2T
0JcD1 > 0
A2B + 2ABc+ AB2 + Ac(A− ID1) +Bc(B − JE1) + c
2(A− ID1) + c
2(B − JE1)+
+ψk2T
0JcD1 > 0
Last inequality is true since A > ID1 and B > JE1. It follows that all eigenvalues of
the linearization matrix of model (3.5) have negative real parts. Thus, the disease-free
equilibrium P 20 is locally asymptotically stable if Rr < 1.

The calculation of the reproduction number of the full model (3.1), R0 proceeds. The
disease-free equilibrium state, P0, of the full model (3.1) is given by:
P0 = (T
0, T 0s , T
0
r ,M
0,M0s ,M
0
r , V
0
s , V
0
r , Z
0)
=


Tmax
[
(r−δ1)+
√
(r−δ1)2+
4rλ1
Tmax
]
2r
, 0, 0, λ2
δ3
, 0, 0, 0, 0, λ3
δ4

 (3.8)
Using the notation in [150] on system (3.1), the matrices for the new infection terms, F ,
and the other terms, V , are calculated as:
F =


0 0 (1− t1)k2T
0 0 (1− t1)k1T
0 0
0 0 0 ψk2T
0 0 ψk1T
0
0 0 0 0 k4(1− f1t1)M
0 0
0 0 0 0 0 k4ψM
0
0 0 0 0 0 0
0 0 0 0 0 0


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V =


δ2 + k3Z
0 0 0 0 0 0
0 δ2 + k3Z
0 0 0 0 0
0 0 δ3 + k5Z
0 0 0 0
0 0 0 δ3 + k5Z
0 0 0
−Ns(1− u)(1− t2)δ2 0 −Ns(1− u)(1− f2t2)δ3 0 c 0
−Nru(1− t2)δ2 −Nrψ(1− u)δ2 −Nru(1− f2t2)δ3 −Nrψ(1− u)δ3 0 c


=


A 0 0 0 0 0
0 A 0 0 0 0
0 0 B 0 0 0
0 0 0 B 0 0
−Ns(1− u)D 0 −Ns(1− u)E 0 c 0
−NruD −Nr(1− u)D1 −NruE −Nr(1− u)E1 0 c


The associative basic reproduction number, R0, is computed to be:
R0 = ρ(FV
−1) = max{Rs, Rr} (3.9)
where ρ indicates the spectral radius of FV −1. By Theorem 2 [150], get the following
lemma.
Lema 3.1.3 The disease-free equilibrium P0 is locally asymptotically stable if R0 < 1
and unstable if R0 > 1.
Proof The linearization matrix of model (3.1) around the disease-free equilibrium, P0,
is:
3
6
C
H
A
P
T
E
R
3
.
M
A
T
H
E
M
A
T
IC
A
L
M
O
D
E
L
S
F
O
R
H
IV
M5 =


r
(
1− 2T
0
Tmax
)
− δ1 −
rT 0
Tmax
− rT
0
Tmax
0 −(1− t1)k2T
0 −ψk2T
0 p1
C1
T 0 − (1− t1)k1T
0 p1
C1
T 0 − ψk1T
0 0
0 −δ2 − k3Z
0 0 0 (1− t1)k2T
0 0 (1− t1)k1T
0 0 0
0 0 −δ2 − k3Z
0 0 0 ψk2T
0 0 ψk1T
0 0
0 0 0 −δ3 0 0
p2
C2
M0 − k4(1− f1t1)M
0 p2
C2
M0 − k4ψM
0 0
0 0 0 0 −δ3 − k5Z
0 0 k4(1− f1t1)M
0 0 0
0 0 0 0 0 −δ3 − k5Z
0 0 k4ψM
0 0
0 Ns(1− u)(1− t2)δ2 0 0 Ns(1− u)(1− f2t2)δ3 0 −c 0 0
0 Nru(1− t2)δ2 Nrψ(1− u)δ2 0 Nru(1− f2t2)δ3 Nrψ(1− u)δ3 0 −c 0
0 k6Z
0 k6Z
0 0 k7Z
0 k7Z
0 0 0 −δ4


The following eigenvalues are easily obtained:
(
1−
2T 0
Tmax
)
− δ1, −δ3, −δ4,
The remaining eigenvalues are the roots of the characteristic equation of a 6× 6 matrix,M6, given by:
M6 =


−δ2 − k3Z
0 0 (1− t1)k2T
0 0 (1− t1)k1T
0 0
0 −δ2 − k3Z
0 0 ψk2T
0 0 ψk1T
0
0 0 −δ3 − k5Z
0 0 k4(1− f1t1)M
0 0
0 0 0 −δ3 − k5Z
0 0 k4ψM
0
Ns(1− u)(1− t2)δ2 0 Ns(1− u)(1− f2t2)δ3 0 −c 0
Nru(1− t2)δ2 Nrψ(1− u)δ2 Nru(1− f2t2)δ3 Nrψ(1− u)δ3 0 −c


=


−A 0 (1− t1)k2T
0 0 (1− t1)k1T
0 0
0 −A 0 ψk2T
0 0 ψk1T
0
0 0 −B 0 k4(1− f1t1)M
0 0
0 0 0 −B 0 k4ψM
0
Ns(1− u)D 0 Ns(1− u)E 0 −c 0
NruD Nr(1− u)D1 NruE Nr(1− u)E1 0 −c


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The determinant |M6 − λI6| = 0 is equivalent to:
[(−A− λ)(−B − λ)(−c− λ)− (−A− λ)Nr(1− u)E1k4ψM
0+
+Nr(1− u)D1k4ψM
0ψk2T
0 −Nr(1− u)D1ψk1T
0(−B − λ)]×
× [(−A− λ)(−B − λ)(−c− λ) +Ns(1− u)D(1− t1)k2T
0k4(1− f1t1)M
0−
−Ns(1− u)D(−B − λ)(1− t1)k1T
0 − (−A− λ)Ns(1− u)Ek4(1− f1t1)M
0] = 0
The first factor of the characteristic equation of matrix M6 is the characteristic equation
of matrixM4, and the second factor is the characteristic equation of the matrixM2. Thus,
as it has already been shown that the disease-free equilibria of subsystems (3.2)-(3.5)
are stable for Rs < 1 and Rr < 1, respectively, one concludes that the disease-free
equilibrium P0 is locally asymptotically stable if R0 = max{Rs, Rr} < 1.

3.1.3 Global stability of disease-free equilibria
In this subsection, the global stability of the disease-free equilibrium of the full model (3.1)
is calculated. Again, one begins by the stability of the disease-free equilibria of the two
submodels.
Lema 3.1.4 The disease-free equilibrium P 10 is globally asymptotically stable if Rs < 1.
Proof The rate of change of the variables (Ts,Ms, Vs) of system (3.2) can be rewritten
as follows.


T˙s
M˙s
V˙s

 = (F1 − V1)


Ts
Ms
Vs

−


(1− t1)(k1Vs + k2Ms)(T
0 − T ) + k3TsZ
k4(1− f1t1)Vs(M
0 −M) + k5MsZ
0

 (3.10)
where F1 and V1 are as defined above. Now let’s prove that system (3.10) satisfies:


T˙s
M˙s
V˙s

 ≤ (F − V )


Ts
Ms
Vs

 (3.11)
38 CHAPTER 3. MATHEMATICAL MODELS FOR HIV
The proof starts by showing that T (t) ≤ T 0. Consider the helper T cells’ growth function
f1(T ) = λ1 + rT
(
1− T
Tmax
)
− δ1T . This function satisfies assumptions (A1) and (A2)
below.
(A1) ∃T0 such that f1(T0) = 0 and f
′
1(T0) < 0.
f1(T0) = 0 ⇔ λ1 + rT0
(
1− T0
Tmax
)
− δ1T0 = 0
⇔ − r
Tmax
(T 0)2 + (r − δ1)T0 + λ1 = 0
⇔ T0 = T
0 =
Tmax
[
(r−δ1)±
√
(r−δ1)2+
4rλ1
Tmax
]
2r
Proof continues with the calculation of the first derivative of function f1(t).
f ′1(T0) = r −
2rT0
Tmax
− δ1
This derivative has negative sign at T0 = T
0:
f ′1(T
0) = −
√
(r − δ1)2 +
4rλ1
Tmax
< 0
(A2) f1(T ) > 0, T ∈ (0, T0) and f1(T ) < 0, T > T0.
At T0 = T
0, it is obtained:
f1(T ) > 0⇔
r
Tmax
(T 0)2 + (r − δ1)T
0 + λ1 > 0 (3.12)
As this function has the shape of a parable with concavity facing down, then it is
positive between 0 and T 0 and negative for T > T 0.
The equation T˙ (t) and assumptions (A1) and (A2) imply that lim supT (t) ≤ T 0, t→∞.
Now, it is proven that M(t) ≤ M0. Consider the macrophages growth rate f2(M) =
λ2 − δ3M . This function satisfies assumptions (A3) and (A4) below - analogous to
assumptions (A1) and (A2).
(A3) ∃M0 such that f2(M0) = 0 and f
′
2(M0) < 0.
f2(M) = 0⇔ λ2 − δ3M0 = 0⇔M0 =
λ2
δ3
= M0
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The first derivative of f2(t), f
′
2(M) = −δ3, is negative ∀M , in particular for M0 =
M0.
(A4) f2(M) > 0,M ∈ (0,M0) and f2(M) < 0,M > M0.
f2(M) > 0⇔ λ2 − δ3M > 0⇔M <
λ2
δ3
= M0 = M
0
f2(M) < 0⇔ λ2 − δ3M < 0⇔M >
λ2
δ3
= M0 = M
0
Assumptions (A3) and (A4) and the form of equation M˙(t) of (3.2) imply that
lim supM(t) ≤M0, t→∞.
Thus, the inequality (3.11) is proven. If Rs < 1, then ρ(F1V
−1
1 ) < 1, which is equivalent
to the matrix F1 − V1 having all its eigenvalues in the left-half plane [150]. It follows
that the linear system given by equality (3.11) is stable whenever Rs < 1, and hence
(Ts(t),Ms(t), Vs(t)) → (0, 0, 0) as t → ∞. Consequently, after using a standard
comparison theorem [63, 133], it is obtained (Ts(t),Ms(t), Vs(t)) → (0, 0, 0), for the
nonlinear system given by the equations of submodel (3.2). Returning now to the
equations of this submodel and substituting Ts = Ms = Vs = 0, one obtains a linear
system, where T (t) = T 0,M(t) = M0 and Z(t) = Z0. Thus,
(T (t), Ts(t),M(t),Ms(T ), Vs(t), Z)→ (T
0, 0,M0, 0, 0, Z0)
as t→∞. It is concluded that, if Rs < 1 then P
1
0 is globally asymptotically stable.

Now, the same procedure for the computation of the global stability of the disease-free
equilibrium of submodel (3.5) is repeated.
Lema 3.1.5 The disease-free equilibrium P 20 is globally asymptotically stable if Rr < 1.
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Proof The rate of change of the variables (Tr,Mr, Vr) of system (3.5) can be rewritten
as:


T˙r
M˙r
V˙r

 = (F2 − V2)


Tr
Mr
Vr

−


ψ(k1Vr + k2Mr)(T
0 − T ) + k3TrZ
k4ψVr(M
0 −M) + k5MrZ
0

 (3.13)
where F2 and V2 are as defined previously. Since T (t) ≤ T
0,M(t) ≤ M0 and Z(t) ≥ 0
for all t ≥ 0, then:


T˙r
M˙r
V˙r

 ≤ (F − V )


Tr
Mr
Vr

 (3.14)
In [150] it is proven that if the reproduction number is less than 1, the matrix F2 −
V2 has all its eigenvalues in the left-half plane. Thus, if Rr < 1, the linear system
given by the equality (3.14) is stable, and hence (Tr(t),Mr(t), Vr(t))→ (0, 0, 0) as t→
∞. Consequently, after using a standard comparison theorem [63, 133], it is obtained
(Tr(t),Mr(t), Vr(t))→ (0, 0, 0) for the nonlinear system, given by the equations of (3.5).
Returning now to the equations of this submodel and substituting Tr = Mr = Vr = 0,
one obtains a linear system with T (t) = T 0, M(t) = M0 and Z(t) = Z0. Thus, if
Rr < 1, (T (t), Tr(t),M(t),Mr(t), Vr(t), Z(t)) → (T
0, 0,M0, 0, 0, Z0) as t → ∞, which
proves that P 20 is globally asymptotically stable.

A similar procedure for the computation of the global stability of the disease-free equi-
librium of the full model (3.1) follows.
Lema 3.1.6 The disease-free equilibrium P0 is globally asymptotically stable if
R0 = max{Rs, Rr} < 1.
Proof The rate of change of the variables (Ts, Tr,Ms,Mr, Vs, Vr) of system (3.1) can
be rewritten as:
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

T˙s
T˙r
M˙s
M˙r
V˙s
V˙r


= (F − V )


Ts
Tr
Ms
Mr
Vs
Vr


−


(1− t1)(k1Vs + k2Ms)(T
0 − T ) + k3TsZ
ψ(k1Vr + k2Mr)(T
0 − T ) + k3TrZ
k4(1− f1t1)Vs(M
0 −M) + k5MsZ
k4ψVr(M
0 −M) + k5MrZ
0
0


(3.15)
where F and V are as defined above for system (3.1). Since T (t) ≤ T 0, M(t) ≤ M0
and Z(t) ≥ 0 for all t ≥ 0, then:


T˙s
T˙r
M˙s
M˙r
V˙s
V˙r


≤ (F − V )


Ts
Tr
Ms
Mr
Vs
Vr


(3.16)
If max{Rs, Rr} < 1, then ρ(FV
−1) < 1, which is equivalent to the matrix F − V
having all its eigenvalues in the left-half plane [150]. It follows that the linear sys-
tem given by the equality (3.16) is stable whenever max{Rs, Rr} < 1, and hence
(Ts(t), Tr(t),Ms(t),Mr(t), Vs(t), Vr(t)) → (0, 0, 0, 0, 0, 0) as t → ∞ for this linear ODE
system. Consequently, applying a standard comparison theorem [63, 133], results in
(Ts(t), Tr(t),Ms(t),Mr(t), Vs(t), Vr(t))→ (0, 0, 0, 0, 0, 0) for the nonlinear system, given
by the equations of (3.1). Returning now to the equations of this model and substituting
Ts = Tr = Ms = Mr = Vs = Vr = 0, one gets a linear system with T (t) = T
0,
M(t) = M0 and Z(t) = Z0. Thus, if max{Rs, Rr} < 1,
(T (t), Ts(t), Tr(t),M(t),Ms(t),Mr(t), Vs(t), Vr(t), Z(t))→ (T
0, 0, 0,M0, 0, 0, 0, 0, Z0),
as t→∞, and P0 is globally asymptotically stable.

3.1.4 Numerical results
The model (3.1) is simulated. The parameters used in the simulations are given in
Table 3.1 and the initial conditions are set to T (0) = 1000,M(0) = 30, Z(0) = 333, and
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all other variables are set to 0.001.
Parameter DF RP LTNP Units Reference
λ1 10 11 35 mm
−3 day−1 [48]
λ2 0.15 0.15 0.15 mm
−3 day−1 [48]
λ3 5 5 4 mm
−3 day−1 [48]
δ1 0.02 0.02 0.01 day
−1 [48]
δ2 0.28 0.33 0.28 day
−1 [48]
δ3 0.005 0.004 0.005 day
−1 [48]
δ4 0.015 0.015 0.028 day
−1 [48]
r 0.03 0.072 0.072 day−1 [48]
c 23 23 10 day−1 [156, 48]
Tmax 1500 1500 1500 mm
−3 [156]
C1 300 188 300 mm
−3 [52, 48]
C2 200 220 200 mm
−3 [52]
t1 0 0 0 [48]
t2 0 0 0 [48]
u 0.001 0.005 0.001 [48]
ψ 0.9 0.6 0.9 [48]
p1 0.01 0.01 0.065 day
−1 [48]
p2 0.02 0.0089 0.0068 day
−1 [48]
k1 2.4× 10
−5 4.0× 10−5 2.5× 10−5 mm3 day−1 [74]
k2 1× 10
−6 1× 10−8 9.8× 10−9 mm3 day−1 [74]
k3 9.9× 10
−4 9.9× 10−4 9.9× 10−4 mm3 day−1 [74]
k4 4.22× 10
−8 4.22× 10−8 4.22× 10−8 mm3 day−1 [74]
k5 6.6× 10
−6 6.6× 10−6 9.6× 10−6 mm3 day−1 [74]
k6 2.3× 10
−4 2.3× 10−4 3.93× 10−4 mm3 day−1 [74]
k7 5.28× 10
−9 5.28× 10−9 6.6× 10−9 mm3 day−1 [74]
Ns 200 3000 3000 [156]
Nr 50 2000 2000 [156]
f1 0.34 0.34 0.34 [48]
f2 0.34 0.34 0.34 [48]
Table 3.1: Parameters used in the numerical simulations of model (3.1). DF - disease-
free equilibrium; RP - rapid progressor; LTNP - long-term non progressor.
In Figure 3.2 it is depicted the disease-free equilibrium of model (3.1).
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Figure 3.2: Disease-free equilibrium of the model (3.1).
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In Figs 3.3-3.4, the patterns of the rapid progressors (RP) and long-term non progres-
sors (LTNP) of model (3.1) are shown. RP are a 10% of untreated HIV patients, whose
CD4+ T cells decrease below the AIDS threshold after, approximately, 3-5 years after
infection [11]. LTNP are a special class of HIV patients, who without therapy, manage
to escape the common route to AIDS for 15-20 years. LTNP account for 10-17%, of
HIV infected patients [64]. The generality of untreated HIV infected patients progress
to AIDS, after initial infection, within 8-10 years. The distinct routes of progression to
AIDS have been associated with patients’ immune system status, genetic profile, and
age [11].
Figure 3.3: Rapid progressors (RP) of the model (3.1).
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Figure 3.4: Long-term non progressors (LTNP) of the model (3.1).
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Figure 3.5 depicts the dynamics of CD4+ T cells, sensitive and drug-resistant virus for
distinct treatment regimes, but equal efficacies of RTIs and PIs. Namely, it is considered
t1 = t2 = 0.1, t1 = t2 = 0.4, and t1 = t2 = 0.7. It is observed that at very low
drug efficacy (t1 = t2 = 0.1), the drug-sensitive virus are not supressed which leads
to faster progression to AIDS. At higher drug efficacies (t1 = t2 = 0.7) it is observed
an expressive depletion of drug-sensitive virus and an increase of drug-resistant virus.
The later may be explained by the high level of CD4+ T cells at higher drug efficacies. A
larger number of helper cells are infected by the virus, promoting the earlier appearance
of drug-resistant virus. The results from low and higher drug efficacies seem to allude to
an optimal treatment regime that can reduce drug-sensitive virus and at the same time
delay the appearance of drug-resistance.
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Figure 3.5: Effect of three distinct values of RTI and PI drug efficacy in the patterns of
uninfected T cells, drug-sensitive virus and drug-resistant virus, for a typical untreated HIV
patient. Presumed t1 = t2 = 0.1, t1 = t2 = 0.4, and t1 = t2 = 0.7.
Bearing this in mind, in Figure 3.6, distinct efficacies are assumed for RTIs and PIs. The
RTI-based treatment is characterized by a significantly greater efficacy of RTIs when
compared to PIs (t1 = 0.7, t2 = 0.1). On the contrary, the PI-based drug regime
assumes a greater efficacy for PIs (t1 = 0.1, t2 = 0.7). From observation of the figure,
it seems that PI-based therapeutics produce better results, in terms of delaying disease
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progression. In fact, PI-based regime promotes an increase in the T cells, reduces
the drug-sensitive virus and delays the appearance of drug-resistant virus. In what
concerns the RTI-based treatment, it is observed a faster emergence of drug-resistant
virus, associated to a sharper increase in the T cells. Moreover, RTI-based drugs do
not reduce drug-sensitive virus to the same extent as PI drugs do [12, 48].
Figure 3.6: RTI-based (t1 = 0.7, t2 = 0.1) and PI-based (t1 = 0.1, t2 = 0.7) treatment,
initiated at a CD4+ T cell count lower than 350 cells mm−3 of the model (3.1).
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3.1.5 Conclusions
Model I presents the emergence of drug-resistance in a model for HIV epidemics,
under distinct HAART regimes. Numerical simulations of the model for different therapy
regimes, namely equal RTI and PI efficacies, as opposed to distinct RTI and PI effica-
cies, are performed. The results of applying equal drug efficacy therapies points to an
optimal treatment, able to reduce drug-sensitive virus and prolonging the emergence of
resistance. In this sense, RTI-based and PI-based regimes are simulated. The RTI-
based drugs identify higher efficacy RTI drugs, and the later define higher efficacy PI
drugs. It is observed that PI-based treatments seem to produce better results in terms
of disease progression, than RTI-based ones. This agrees with previous results in the
literature.
3.2 Model II
Ana R.M. Carvalho and Carla M.A. Pinto, New developments on AIDS-related cancers:
the role of the delay and treatment options, Mathematical Methods in the Applied Sci-
ences, 1–14, DOI: 10.1002/mma.4657, 2017.
A simple delay mathematical model for the dynamics of AIDS-related cancers is pro-
posed, in which HAART and chemotherapy are considered. The model is simple with
only 4 cells’ populations; nevertheless, it provides biologically reasonable results and
important inferences are drawn. The main goals are to determine how the intracellular
delay affects the overall cancer growth and how HAART and chemotherapy influence
cancer development. Initially, the model is defined and the properties of the model are
studied, namely, equilibria and positiveness of solutions. The outcomes of the numerical
simulations are discussed.
3.2.1 Description of the model
The model is composed by four populations of cells: cancer cells, C, healthy CD4+ T
cells, T , infected CD4+ T cells, I , and HIV, V .
The cancer cells growth follows a ‘universal law’, i.e., the total number of cancer cells’,
C, grows with a rate r1
(
1−
(
C
C0
)1−q)
Cq, where r1 is the growth rate and C0 is the
maximum size of the cancer cell population. Previous studies show that cancer tissue
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growth can be described with an exponent q ranging from 2/3 to 1, depending on
the growth conditions and the fractal topology of the neoplastic vascular system. It
is considered q = 3/4 [72]. Cancer cells are killed by the immune system at rate k1.
Healthy cells are produced at a rate s2 and die by apoptosis at a rate µ1. They also
die due to the effect of the cancer cells at rate p, and are infected by HIV at rate k2.
Following infection of HIV, there is a period of 1 day, known as the eclipse phase, before
viral RNA is produced. This ‘incubation period’ is modeled by τ . RTI-based treatment
efficacy is included in the CD4+ T cells equations using the parameter 0 ≤ ǫRT ≤ 1. A
value of 1 means 100% treatment efficacy. The infected cells die at a rate µI . The virus
are produced by the infected CD4+ T cells, with bursting size N . However, this number
will be decreased by a factor (1 − ǫP ), where (0 ≤ ǫP ≤ 1) is the PI drug efficacy. The
virus die at a rate c.
The nonlinear system of delay differential equations describing the dynamics of the
model is:
C˙(t) = r1
(
1−
(
C(t)
C0
)1/4)
C(t)3/4 − k1T (t)C(t)
T˙ (t) = s2 + T (t)
[
r2
(
1− C(t)+T (t)+I(t)
m
)
− µ1 − pk1C(t)− (1− ǫRT )k2V (t)
]
I˙(t) = (1− ǫRT )k2T (t− τ)V (t− τ)− µII(t)
V˙ (t) = (1− ǫP )NµII(t)− cV (t)
(3.17)
The proposed model is extended to include the effects of the chemotherapy, D(t), in
cancer cell growth. It is assumed that the drugs are effective only at certain phases of
the cell cycle and that their effectiveness is bounded. As such, the saturation term (1−
e−D), represents the fraction of the cells killed by a dose D of chemotherapy. Cell dose
response terms are included in the equations of the cancer, healthy and infected cells,
in particular, PC(1− e
−D) and PT (1− e
−D). Function u(t) describes the amount of drug
influx into the system and the injection time, assuming intravenous administration [53].
Constant dD represents the drug elimination rate. It is assumed an instantaneous drug
distribution in all body parts. The extended system is thus:
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C˙(t) = r1
(
1−
(
C(t)
C0
)1/4)
C(t)3/4 − k1T (t)C(t)− PC
(
1− e−D(t)
)
C(t)
T˙ (t) = s2 + T (t)
[
r2
(
1− C(t)+T (t)+I(t)
m
)
− µ1 − pk1C(t)− (1− ǫRT )k2V (t)−
−PT
(
1− e−D(t)
)]
I˙(t) = (1− ǫRT )k2T (t− τ)V (t− τ)− µII(t)− PT
(
1− e−D(t)
)
I(t)
V˙ (t) = (1− ǫP )NµII(t)− cV (t)
D˙(t) = u(t)− dDD(t)
(3.18)
where
u(t) =


2.3869, t = 21n, n = 1, 2, ...
0, otherwise
3.2.2 Model properties
Let X = C([−τ, 0],R) be the Banach space of continuous mapping from [−τ, 0] to R
equipped with the sup-norm. The initial conditions for system (3.17) are given as follows:
C(θ) ≥ 0, T (θ) ≥ 0, I(θ) ≥ 0, V (θ) ≥ 0, θ ∈ [−τ, 0] (3.19)
Lema 3.2.1 Given the initial conditions (3.19), the solutions of C(t), T (t), I(t), and V (t)
remain positive for all t ≥ 0.
Proof Considering the CD4+ T cells, one derives:
T (t) ≥ T (0)e−
∫ t
0
(Θ(ǫ))dǫ +
∫ t
0
s2e
−
∫ t
ν
(Θ(ǫ))dǫdν ≥ 0 (3.20)
Θ(t) = µ1 + pk1C(t) + (1− ǫRT )k2V (t).
Similarly, for the infected cells:
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I(t) = I(0)e−
∫ t
0
µIdǫ+
+
∫ t
0(1− ǫRT )k2T (ν − τ)V (ν − τ)e
−
∫ t
ν
µIdǫdν
I(t) ≥ I(0)e−
∫ t
0
µIdǫ ≥ 0
(3.21)
For the virus population, it is obtained:
V (t) = V (0)e−ct +
∫ t
0(1− ǫP )NµII(ν)e
−c(t−ν)dν
V (t) ≥ V (0)e−ct ≥ 0
(3.22)
For the cancer cell population:
C(t) ≥ C(0)e−
∫ t
0
k1T (ǫ)dǫ ≥ 0 (3.23)
this implies that all state variables are non-negative and the solutions of model (3.17)
remain positive for all t ≥ 0.

Lema 3.2.2 The solutions of model (3.17) with initial conditions C ≥ 0, T ≥ 0, I ≥ 0,
and V ≥ 0 are bounded for all t ≥ 0 in the biologically feasible region defined by the set
Ω =

(C, T, I, V ) ∈ R4+ : T, I ≤ T 0, V ≤
(1− ǫP )NµIT
0
c
, C ≤

 r1C1/40
r1 + k1T 0C
1/4
0


4


Proof It is now shown that all feasible solutions are uniformly bounded in Ω. From the
CD4+ T cells equation of system (3.17), it is known T (t) ≤ T 0, where
T 0 =
m
2r2

r2 − µ1 +
√
(r2 − µ1)2 +
4r2s2
m

 .
Moreover, adding the equation of the infected cells, gives:
dTtotal
dt
= s2 + T
[
r2
(
1− C+T+I
m
)
− µ1 − pk1C
]
− µIITtotal
≤ s2 + T
0r2 −
(
T0
m
+ µ1
)
Ttotal
(3.24)
Through integration, it is obtained:
Ttotal ≤
K
A
+
(
TTotal(0)−
K
A
)
e−At (3.25)
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where K = s2 + T
0r2 and A =
T0
m
+ µ1 therefore:
lim sup
t→∞
Ttotal(t) ≤
K
A
(3.26)
and Ttotal is bounded. Considering the virus population:
dV
dt
≤ (1− ǫP )NµIT
0 − cV (3.27)
Integration gives:
V (t) ≤
(1− ǫP )NµIT
0
c
+
(
V (0)−
(1− ǫP )NµIT
0
c
)
e−ct (3.28)
and:
lim sup
t→∞
V (t) ≤
(1− ǫP )NµIT
0
c
(3.29)
hence V (t) is bounded. From the equation of the cancer cells of system (3.17), one
gets:
dC
dt
≤ C
[
r1C
−1/4
(
1−
(
C
C0
)1/4)
− k1T
0
]
=
C
[
r1C
1/4
0 − r1C
1/4 − k1T
0C
1/4
0 C
1/4
]
C
1/4
0 C
1/4
(3.30)
Integration gives:
C(t) ≤


r1C
1/4
0 − exp
((
−
r1+k1T 0C
1/4
0
4C
1/4
0
)
t
)
r1 + k1T 0C
1/4
0


4
(3.31)
thus,
lim sup
t→∞
C(t) ≤

 r1C1/40
r1 + k1T 0C
1/4
0


4
(3.32)
therefore C(t) is also bounded.
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Our invariant region is therefore defined by Ω. Hence, any solution of system (3.17) that
starts in the positive orthant R4+ at t ≥ 0 will approach it asymptomatically. Hence, Ω is
positively invariant and attracting with respect to model (3.17).

Next, the equilibria of model (3.17) are calculated. It is assumed a quasi-steady state
for the viral population, obtaining:
V ⋆ =
(1− ǫP )NµII
⋆
c
(3.33)
Substituting V ⋆ in the equation of the I cells in model (3.17), one gets:
I⋆
[
(1− ǫRT )k2(1− ǫP )NµIT
⋆
c
− µI
]
= 0 (3.34)
which implies:
I⋆ = 0 or T ⋆ =
cµI
(1− ǫRT )k2(1− ǫP )NµI
(3.35)
For I⋆ = 0, the system (3.17) is at an HIV-free cancer equilibrium state. The full endemic
state is of the form P = (C⋆, T ⋆, I⋆, V ⋆), in which HIV and cancer are simultaneously
present in the organism.
First, the solution T ⋆ was replaced in the equation of the T cells in model (3.17). From
this equation can derive the value of V at equilibrium, obtaining:
V ⋆ =
s2 + T
⋆
[
r2
(
1− C
⋆+T ⋆+I⋆
m
)
− µ1 − pk1C
⋆
]
(1− ǫRT )k2T ⋆
(3.36)
Now, from equation (3.33):
I⋆ = cm

s2 + T ⋆
[
r2
(
1− C
⋆+T ⋆
m
)
− µ1 − pk1C
⋆
]
m(1− ǫRT )k2T ⋆(1− ǫP )NµI + cr2T ⋆

 (3.37)
Now, it turns to the cancer cells’ equation in model (3.17).
g(C) = C
[
r1C
−1/4
(
1−
(
C
C0
)1/4)
− k1T
⋆
]
= 0 (3.38)
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whose solutions are:
C⋆ = 0 or r1C
−1/4
(
1−
(
C
C0
)1/4)
− k1T
⋆ = 0 (3.39)
Now, g(C) is defined at equilibrium, getting:
g(C⋆) = r1C
−1/4
(
1−
(
C
C0
)1/4)
− k1T
⋆ (3.40)
It should be noted that only the cancer-free equilibrium point is explicitly obtained. Thus,
the disease-free equilibrium is given by P0 = (C0, T0, I0, V0) = (0, T0, 0, 0), where T0 =
m
2r2
(
B +
√
B2 + 2r2s2
m
)
and B = r2 − µ1.
The cancer-free equilibrium is written as: P1 = (0, T1, I1, V1), where
T1 =
cµI
(1−ǫRT )k2(1−ǫP )NµI
, I1 = cm
(
s2+T1[r2(1−T1m )−µ1]
m(1−ǫRT )k2T1(1−ǫP )NµI+cr2T1
)
and
V1 =
s2+T1[r1(1−T1+I1m )−µ1]
(1−ǫRT )k2T1
.
3.2.3 Numerical results
In this section, models (3.17) and (3.18) are simulated. The parameters used in the
simulations are given in Table 3.2 and the initial conditions are set to C(0) = 100 mL−1,
T (0) = 5× 105 mL−1, I(0) = 100 mL−1 and V (0) = 1000 mL−1.
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Parameter Value Units Reference
r1 0.18 day
−1 [69]
m 1500× 103 mL−1 [69]
k1 10
−8 mL−1 day−1 [69]
r2 0.03 day
−1 [69]
p 0.1 [69]
k2 2.4× 10
−7 mL−1 day−1 [31]
µI 0.3 day
−1 [69]
N 1000 mL−1 [33]
c 3 day−1 [30]
τ varied
PC 0.9 day
−1 [35]
PT 0.6 day
−1 [35]
dD 0.9 day
−1 [35]
ǫRT [0, 1]
ǫP [0, 1]
C0 10
6 day−1 [72]
s2 10000 mL
−1 day−1 [30]
µ1 0.02 day
−1 [30]
Table 3.2: Parameters used in the numerical simulations of models (3.17) and (3.18).
Results with no chemotherapeutic drug
The numerical results of model (3.17) are presented. Figures 3.7-3.8 depict the density
of the cancer cells and of HIV at days 350, 1000 and 2000, for several combinations of
HAART efficacies, ǫRT and ǫP , and τ = 1. One can observe that the number of cancer
cells decreases for a combination of RTI and PI with efficacies above 0.85. HIV has
a slight different pattern, in which more severity is seen for smaller values of ǫRT and
ǫP < 0.92. As ǫRT increases and for ǫP > 0.9, HAART is more effective. Moreover, the
number of CD4+ T cells increases for higher values of ǫRT and ǫP , whereas the infected
T cells decrease. These results are epidemiologically valid.
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Figure 3.7: Contour plot showing cancer cells after 350, 1000 and 2000 days, for various
combinations of RTI and PI treatments, and τ = 1. For more information, see text.
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Figure 3.8: Contour plot showing virus density after 350, 1000 and 2000 days, for
various combinations of RTI and PI treatments, and τ = 1. For more information, see
text.
Figures 3.9-3.10 depict the densities of the cancer cells and of virus for distinct com-
bination therapies and different values of τ . There is not a substantial variation on the
patterns of the cancer cells and of virus for τ > 0. For τ = 0, the coinfection is less
endemic, namely, the number of cancer cells and of HIV is small. The behaviour seen
for HIV when τ = 0 agrees with previous works on the efficacies of HAART. PI-based
treatments appear to be more effective in fighting HIV [22, 48]. Nevertheless, this was
observed in non-delay models. Since there is an eclipse phase [78, 57], the delay exists
and as can be observed from the numerical simulations, it is considerably important in
the dynamics of the cancer growth and of HIV infection.
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Figure 3.9: Contour plot showing cancer cells after 350 days for distinct values of τ (Top
left - τ = 0, Top right - τ = 1, Bottom left - τ = 5, Bottom right - τ = 10). For more
information, see text.
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Figure 3.10: Contour plot showing virus after 350 days for distinct values of the τ (Top
left - τ = 0, Top right - τ = 1, Bottom left - τ = 5, Bottom right - τ = 10). For more
information, see text.
Figure 3.11 depicts the time series of the variables of model (3.17) for different values of
the delay, τ , and in the presence of HAART. It can be seen that the model bifurcates from
a disease-free state to an endemic state as the delay, τ , increases from 0. Moreover,
the severity of the endemic state reduces with τ . In particular, for τ = 10, the number of
infected T cells and of virus is significantly smaller on the transient, than for τ = 1, 5,
though the asymptotic value is the same. With respect to cancer cells, there is a slight
decrease for τ = 10, in comparison to τ = 1, 5. It is worth noting that higher values of
HIV peaks induce lower immune responses and heavier and difficult to treat HIV-related
illnesses and co-morbidities.
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Figure 3.11: Time series of the variables of system (3.17) for different values of τ .
Parameter values and initial conditions are given in the text, except ǫRT = ǫP = 0.8.
Figure 3.12 shows the reduction curves representing the cancer cells after time t =
350, 1000, 2000 days, for various values of HAART efficacy, ǫRT = ǫP . This figure
suggests that early HAART initiation is preferred, since a decline of the cancer cells’
number is achieved for higher values of the treatment efficacy.
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Figure 3.12: Variation of the number of the cancer cells after time t = 350, 1000, 2000
days, for ǫRT = ǫP ∈ [0, 1] and τ = 1 (Left) and τ = 10 (Right). Parameter values and
initial conditions are given in the text.
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Figure 3.13 shows the time series of the variables of model (3.17) for distinct values of
ǫRT = ǫP . As the efficacy increases, the concentration of cancer cells, infected cells
and virus decrease. On the other hand, the concentration of healthy cells increases. In
Figure 3.14, a similar analysis is done for ǫRT + ǫP = 0.9. Results reveal that if one
of the drugs (ǫRT or ǫP ) is high enough then lower number of cancer cells and higher
CD4+ T cells concentrations are obtained, despite higher viral loads. Designing of new
chemotherapies and HAART in HIV-infected patients with AIDS-related cancers, may
also take into account this valuable information. A compromise between cancer cells’
declining and smaller viral loads must be achieved.
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Figure 3.13: Dynamics of the variables of system (3.17) for different values of ǫRT = ǫP .
Parameter values and initial conditions are given in the text, except τ = 1.
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Figure 3.14: Dynamics of the variables of system (3.17) for different values of ǫRT+ǫP =
0.9. Parameter values and initial conditions are given in the text, except τ = 1.
Figure 3.15 clearly suggests that in the presence of smaller HIV infection rates, HAART
reduces cancer growth, even when HAART efficacy is only 50%. Whereas for higher
HIV infection rates, higher values of ǫRT and ǫP are needed to prevent cancer develop-
ment. Nowadays, HAART efficacies are high. In particular, the efficacy of an integrase
inhibitor, named Raltegravir, was estimated to 0.94, when combined with emtricitabine
and tenofovir disoproxil fumarate, and 0.997 during monotherapy [31]. Thus, HIV-
infected patients with AIDS-related cancers surely benefit from full adherence to HAART
treatment protocol.
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Figure 3.15: Dynamics of the cancer cells of system (3.17) for two values of the HIV
infection rate, (Left - k2 = 2.4 × 10
−8, Right - k2 = 2.4 × 10
−5) . Two cases were
considered: HAART with two efficacies ǫRT = ǫP = 0.5 (Top) and ǫRT = ǫP = 0.95
(Bottom), and without HAART (ǫRT = ǫP = 0). Parameter values and initial conditions
are given in the text, except τ = 1.
Figure 3.16 shows several plots of the function g(C) as a function of C, for distinct
values of the cancer killing rate, k1. Each trajectory represents different values of k1,
which increase from top to bottom trajectory/line. The values considered were in the
range 1×10−9 to 2×10−8 and the step size was 1×10−9, for the two cases considered:
with and without HAART. HAART is a key factor in cancer growth control, as can be
seen by the magnitude of the values of C that zeroes the function g(C). Smaller C⋆
are obtained when treatment is considered, thus lowering the values of V ⋆ (3.36) and
I⋆ (3.37).
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Figure 3.16: Plot of the function g(C) for different values of k1, the rate of cancer cells
loss, without HAART (Left - ǫRT = ǫP = 0) and with HAART (Right - ǫRT = ǫP = 0.8).
Parameter values and initial conditions are given in the text, except τ = 1.)
Results with chemotherapeutic drug
The results of the simulations of model (3.18) are discussed. Figures 3.17 show the
chemotherapeutic drug administration pattern, for distinct values of dD.
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Figure 3.17: Chemotherapeutic drug dose concentration for τ = 1 and different values
of dD, the drug elimination rate (Top left - dD = 0.9, Top right - dD = 0.5, Bottom -
dD = 0.1). Parameter values are given in the text, except ǫRT = ǫP = 0.8. The initial
conditions are set to C(0) = 105 mL−1, T (0) = 3 × 105 mL−1, I(0) = 103 mL−1 and
V (0) = 4× 103 mL−1.
The concentration of the cancer cells for various values of dD is given in Fig. 3.18. The
chemotherapy effectiveness is highly dependable on the values of the drug decay rates.
The simulations of the model suggest that the administration of the same therapeutic
dosage is followed by distinct outcomes, with respect to cancer growth, when various
decay rates are considered. Smaller decay rates promote higher elimination of cancer
cells. Future chemotherapeutic protocols should take this into consideration.
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Figure 3.18: Variation of the cancer cells for τ = 1 and distinct values of the dD (Top
left - dD = 0.9, Top right - dD = 0.5, Bottom - dD = 0.1). Parameter values are given
in the text, except ǫRT = ǫP = 0.8. Initial conditions are set to C(0) = 10
5 mL−1,
T (0) = 3× 105 mL−1, I(0) = 103 mL−1 and V (0) = 4× 103 mL−1.
3.2.4 Conclusions
Model II proposes a simple delay mathematical model for the dynamics of AIDS-related
cancer in the presence of HAART and chemotherapy. The equilibria of the model
are computed. The model is simulated for relevant parameters and its behaviour is
scrutinized in the presence and absence of HAART and chemotherapy. Results show
that HAART may benefit HIV-infected patients not only by reducing HIV viral load but
by controlling cancer cell growth. Moreover, the chemotherapy effectiveness is highly
dependable on the values of the drug decay rates. Smaller decay rates promote higher
elimination of cancer cells. The delay is also a principal actor in cancer cells growth,
influencing the immune response to cancer development. Similarly to every mathemati-
cal model, the current one could be a simplified version of a much more complex model
of the biological mechanisms, behind AIDS-related cancers growth. Relevant factors to
include in such a model would be, for e.g., the contribution of the spatial dynamics of
the tumour in growth control.
Chapter 4
Models for coinfection of HIV and HCV
4.1 Model III
A.R.M. Carvalho and C.M.A. Pinto, A coinfection model for HIV and HCV, BioSystems
124, 46–60, 2014.
A mathematical model for the dynamics of HIV and HCV coinfection is proposed. This
model intends to study the effect of the treatment for both diseases and vertical transmis-
sion from mother to child, in the case of HIV. HIV and HCV share several transmission
routes, nevertheless, here only it is considered sexual transmission for HIV and HCV and
vertical transmission for HIV. The reproduction numbers and the local and global stability
of the disease free equilibrium are computed. Bifurcation diagrams are presented
that reveal the dynamical behavior of the model for variation of relevant parameters.
Simulation results of the full model are presented.
4.1.1 Description of the model
The population of the model includes nine classes, namely, the susceptible individuals,
S, the individuals infected with HIV, Ia, the individuals showing symptoms of AIDS, Aa,
the individuals infected with HCV, Ic, the individuals infected with chronic HCV, Cc,
the individuals coinfected with HIV and HCV, IaIc, the individuals coinfected with HIV
and with chronic HCV, IaCc, the individuals showing symptoms of AIDS and coinfected
with HCV, AaIc, and the individuals showing symptoms of AIDS and with chronic HCV
coinfection, AaCc.
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In Figure 4.1 it is presented the flow chart of the model. It represents schematically the
epidemiology of HIV and HCV coinfection. The different disease stages are reproduced
by the different compartments (rectangles) and the arrows indicate the way individuals
progress from one stage to the other.
Figure 4.1: Flow chart of the model.
At time t, the population of size N(t), has constant inflow of susceptible individuals, S,
at a rate Λ. For all classes, the natural mortality rate is µ. Susceptible individuals, S,
exposed to HIV, move to class Ia, at a rate λH , given by:
λH =
cbh(Ia + Aa + σ3(IaIc + IaCC))
N
Parameter bh is the effective sexual contact rate for HIV infection to occur, and c is the
average number of sexual partners per unit of time. On the other hand, when in contact
with HCV patients, susceptible individuals, S, move to class Ic, at a rate:
λC =
cbc(Ic + Cc + η1IaIc + η2IaCc)
N
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where parameter bc is the effective contact rate for HCV infection to occur. Parameters
η1, η2, σ3 > 1model the fact that dually infected individuals are more infectious than their
corresponding counterparts.
A fraction of newborns are infected with HIV during birth and hence are directly recruited
into the infectious class, Ia, at a rate (1 − ǫ)θ. Other children die at birth (0 ≤ ǫ ≤ 1),
where ǫ is the fraction of newborns infected with HIV that die immediately after birth, and
θ is the rate of newborns infected with HIV. The individuals infected with HIV, Ia, move
at a rate ρ to the AIDS class, Aa. Individuals showing symptoms of AIDS are treated at
a rate υ1, and die because of AIDS at a rate da.
The individuals infected with HCV, Ic move to the susceptible class, S, after treatment
at a rate r1. They can progress to a chronic stage, Cc, at a rate ρ1σC , where ρ1 is the
proportion of infected individuals who are chronic carriers and 1
σC
is the average time
that an individual infected with HCV remains in a state of acute infection. The individuals
with chronic HCV infection, Cc, die because of HCV at a rate dc.
Now the dynamics of the coinfection are defined. The individuals infected with HIV, Ia,
are infected with HCV at a rate σλC and move to class IaIc. Modification parameter
σ > 1 accounts for the fact that there is an increased risk of getting HCV for someone
already infected with HIV, due to the vulnerability of the immune system. Reciprocally,
the individuals infected with HCV, Ic are infected with HIV at a rate δλH and move to the
class IaIc. Parameter δ > 1 accounts for the increased susceptibility to HIV infection
for HCV infected people, since HCV accelerates the decline of the immune function.
Dually infected individuals, IaIc, recover from HCV infection at a rate r2 and move to
class Ia. On the other hand, they can progress to AIDS at a rate ρ and move to class
AaIc. Moreover, IaIc individuals may become HCV chronic carriers, at a rate ρ2σC , and
move to class IaCc. Parameter ρ2 is the proportion of dually infected individuals who are
chronic carriers. Dually HIV and chronic HCV infected individuals, IaCc, may progress
to AIDS at a rate ρ and move to class AaCc.
Individuals showing symptoms of AIDS, Aa, are infected with HCV at a rate σλC and
move to class AaIc. The individuals in class AaIc are treated and recover from HCV
infection at a rate r3 and move to class Aa or are treated and recover from AIDS stage
at a rate υ2 and move to class IaIc. The individuals in class AaIc become HCV chronic
carriers at a rate ρ3σC and move to class AaCc. Parameter ρ3 is the proportion of
individuals in AaIc class who are chronic carriers. Individuals showing symptoms of
AIDS and with chronic HCV coinfection, AaCc, are treated for HIV at a rate υ3, and
move to IaCc.
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The following nonlinear system of ordinary differential equations summarizes the de-
scription of the model:
dS
dt
= Λ− λHS − λCS + r1Ic − µS
dIa
dt
= λHS − (ρ+ σλC + µ)Ia + (1− ǫ)θIa + r2IaIc + υ1Aa
dAa
dt
= ρIa − (υ1 + da + µ)Aa + r3AaIc − σλCAa
dIc
dt
= λCS − (r1 + δλH + ρ1σC + µ)Ic
dCc
dt
= ρ1σCIc − (δλH + µ+ dc)Cc
dIaIc
dt
= δλHIc + σλCIa + υ2AaIc − (r2 + ρ+ ρ2σC + µ)IaIc
dIaCc
dt
= ρ2σCIaIc + δλHCc + υ3AaCc − (ρ+ µ+ dc)IaCc
dAaIc
dt
= σλCAa + ρIaIc − (r3 + υ2 + ρ3σC + µ+ da)AaIc
dAaCc
dt
= ρ3σCAaIc + ρIaCc − (υ3 + µ+ da + dc)AaCc
(4.1)
The dynamics of the total population N(t) = S(t) + Ia(t) + Aa(t) + Ic(t) + Cc(t) +
IaIc(t) + IaCc(t) + AaIc(t) + AaCc(t) is given by:
dN
dt
= Λ+ (1− ǫ)θIa − µN − da(Aa + AaIc + AaCc)− dc(Cc + IaCc + AaCc)
In Table 4.1, it summarizes the parameters and the variables of model (4.1).
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Variable/Parameter Description
S Susceptible individuals
Ia Individuals infected with HIV
Aa Individuals showing symptoms of AIDS
Ic Individuals infected with HCV
Cc Individuals infected with chronic HCV
IaIc Individuals coinfected with HIV and HCV
IaCc Individuals coinfected with HIV and chronic HCV
AaIc Individuals showing symptoms of AIDS and with HCV coinfection
AaCc Individuals showing symptoms of AIDS and
with chronic HCV coinfection
Λ Recruitment rate
µ Natural mortality rate
c Average number of sexual partners
bh Effective sexual contact rate for HIV transmission to occur
bc Effective sexual contact rate for HCV transmission to occur
σ3 Modification parameter
ηi, = 1, 2 Modification parameter
ri i = 1, 2, 3 HCV treatment rates
ρi, i = 1, 2, 3 Proportion of infected individuals who are chronic carries
dc Mortality due to HCV
ǫ Fraction of newborns infected with HIV
that die immediately after birth
θ Rate of newborns infected with HIV
ρ Rate of progression to AIDS
υi, i = 1, 2, 3 HIV treatment rate
da Mortality due to HIV
σ Modification parameter
δ Modification parameter
1
σC
Average time that an individual infected with HCV
remains in a state of acute infection
Table 4.1: Description of the variables and the parameters of model (4.1).
4.1.2 Reproduction numbers and stability of disease-free equilibria
In this subsection, the reproduction number of model (4.1), R0, is calculated. The basic
reproduction number is defined as the number of secondary infections due to a single
infection in a completely susceptible population [150].
Initially two sub-models of model (4.1) are considered. Model (4.2) is obtained from
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model (4.1) by setting the variables concerning HCV dynamics (Ic, Cc, IaIc, IaCc, AaIc
and AaCc) to zero, and model (4.4) follows from model (4.1) by setting the variables
concerning HIV dynamics (Ia, Aa, IaIc, IaCc, AaIc and AaCc) to zero.
It starts by computing the reproduction number of the system (4.2), RHIV . The next
generation method [150] is used.
dS
dt
= Λ− λHS − µS
dIa
dt
= λHS − (ρ+ µ)Ia + (1− ǫ)θIa + υ1Aa
dAa
dt
= ρIa − (υ1 + da + µ)Aa
(4.2)
where λH =
cbh(Ia+Aa)
N
The disease free equilibrium of model (4.2) is given by:
P 10 =
(
S10 , Ia
1
0, Aa
1
0,
)
=
(
Λ
µ
, 0, 0
)
Using the notation in [150] on system (4.2), matrices for the new infection terms, F , and
the other terms, V , are given by:
F =

cbh cbh
0 0


V =

ρ+ µ− (1− ǫ)θ −υ1
−ρ υ1 + da + µ


The associative basic reproduction number is given by:
RHIV = ρ(FV
−1) =
bhc(υ1 + da + µ+ ρ)
ρ(da + µ) + (µ− (1− ǫ)θ)(υ1 + da + µ)
(4.3)
where ρ indicates the spectral radius of FV −1. By Theorem 2 in [150], the following
lemma is obtained.
Lema 4.1.1 The disease free equilibrium P 10 is locally asymptotically stable if RHIV < 1
and unstable if RHIV > 1.
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The computation of the reproduction number of submodel (4.4) below, RHCV , follows.
dS
dt
= Λ− λCS + r1Ic − µS
dIc
dt
= λCS − (r1 + ρ1σC + µ)Ic
dCc
dt
= ρ1σCIc − (µ+ dc)Cc
(4.4)
where λC =
cbc(Ic+Cc)
N
.
The disease free equilibrium state P 20 of model (4.4) is given by:
P 20 = (S
2
0 , Ic
2
0, Cc
2
0) =
(
Λ
µ
, 0, 0
)
Using the notation in [150] on system (4.4), matrices for the new infection terms, F , and
the other terms, V , are given by:
F =

cbc cbc
0 0


V =

r1 + ρ1σC + µ 0
−ρ1σC dc + µ


The associative basic reproduction number is given by:
RHCV = ρ(FV
−1) =
cbc(dc + µ+ ρ1σC)
(dc + µ)(r1 + ρ1σC + µ)
(4.5)
where ρ indicates the spectral radius of FV −1. By Theorem 2 in [150], the following
result is obtained.
Lema 4.1.2 The disease free equilibrium P 20 is locally asymptotically stable if RHCV < 1
and unstable if RHCV > 1.
Now the calculation of the reproduction number of the full model (4.1), R0, is continued.
The disease free equilibrium state, P0, of model (4.1) is given by:
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P0 = (S
0, I0a , A
0
a, I
0
c , C
0
c , IaI
0
c , IaC
0
c , AaI
0
c , AaC
0
c )
=
(
Λ
µ
, 0, 0, 0, 0, 0, 0, 0, 0
) (4.6)
Using the notation in [150] on system (4.1), matrices for the new infection terms, F , and
the other terms, V , are given by:
F =


cbh cbh 0 0 cbhσ3 cbhσ3 0 0
0 0 0 0 0 0 0 0
0 0 cbc cbc cbcη1 cbcη2 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0


V =


ρ+ µ− (1− ǫ)θ −υ1 0 0 −r2 0 0 0
−ρ υ1 + da + µ 0 0 0 0 −r3 0
0 0 r1 + ρ1σC + µ 0 0 0 0 0
0 0 −ρ1σC dc + µ 0 0 0 0
0 0 0 0 r2 + ρ+ ρ2σC + µ 0 −υ2 0
0 0 0 0 −ρ2σC ρ+ dc + µ 0 −υ3
0 0 0 0 −ρ 0 r3 + υ2 + ρ3σC + da + µ 0
0 0 0 0 0 −ρ −ρ3σC υ3 + µ+ da + dc


The associative basic reproduction number of the full model is computed to be:
R0 = ρ(FV
−1) = max{RHIV , RHCV } (4.7)
where ρ indicates the spectral radius of FV −1. By Theorem 2 [150], the following lemma
is derived.
Lema 4.1.3 The disease free equilibrium P0 is locally asymptotically stable if R0 < 1
and unstable if R0 > 1.
4.1.3 Global stability of the disease-free equilibria
In this subsection, the global stability of the disease free equilibrium of the full model (4.1)
is calculated. The stability of the disease free equilibria of the two submodels (4.2)
and (4.4) is ptoven.
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Lema 4.1.4 For model (4.2), the disease free equilibrium P 10 is globally asymptotically
stable if RHIV < 1.
Proof The comparison theorem is used to prove the global stability of the disease free
equilibrium of submodel (4.2). The rate of change of the variables (Ia, Aa) of system
(4.2) can be rewritten as follows.

 I˙a
A˙a

 = (F − V )

 Ia
Aa

− (1− S
N
)
F

 Ia
Aa

 (4.8)
where F and V are as defined above for system (4.2). Since S ≤ N for all t ≥ 0, then:

 I˙a
A˙a

 ≤ (F − V )

 Ia
Aa

 (4.9)
If RHIV < 1, then ρ(FV
−1) < 1, which is equivalent to say that the matrix F − V
has all eigenvalues in the left-half plane [150]. It follows that the linear system given
by equality (4.9) is stable whenever RHIV < 1, and hence (Ia(t), Aa(t)) → (0, 0) as
t → ∞ for this linear ordinary differential equation (ODE) system. Consequently, after
using a standard comparison theorem [63, 133], one obtains (Ia(t), Aa(t))→ (0, 0), for
the nonlinear system given by the last two equations of system (4.2). Returning now to
the first equation of model (4.2) and substituting Ia = Aa = 0, one gets a linear system
with S(t) → Λ
µ
. Thus, (S(t), Ia(t), Aa(t)) → (
Λ
µ
, 0, 0) as t → ∞ for RHIV < 1, so that
P 10 is globally asymptotically stable if RHIV < 1.

Now it’s repeated the same procedure for the computation of the global stability of the
disease free equilibrium of submodel (4.4).
Lema 4.1.5 For the submodel (4.4), the disease free equilibrium P 20 is globally asymp-
totically stable if RHCV < 1.
Proof The comparison theorem is used to prove the global stability of the disease
free equilibrium of submodel (4.4). The rate of change of the variables (Ic, Cc) of
system (4.4) can be rewritten as:
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
 I˙c
C˙c

 = (F − V )

 Ic
Cc

− (1− S
N
)
F

 Ic
Cc

 (4.10)
where F and V are as defined above for system (4.4). Since S ≤ N for all t ≥ 0, then:

 I˙c
C˙c

 ≤ (F − V )

 Ic
Cc

 (4.11)
If RHCV < 1, then ρ(FV
−1) < 1, which is equivalent to say that the matrix F − V has
all eigenvalues in the left-half plane [150]. It follows that the linear system given by the
equality (4.11) is stable whenever RHCV < 1, and hence (Ic(t), Cc(t)) → (0, 0) as t →
∞ for this linear ODE system. Consequently, a standard comparison theorem [63, 133]
is used, to obtain (Ic(t), Cc(t)) → (0, 0) for the nonlinear system, given by the last two
equations of (4.4). Returning now to the first equation of submodel (4.4) and substituting
Ic = Cc = 0 gives a linear system with S(t) →
Λ
µ
. Thus, (S(t), Ic(t), Cc(t)) → (
Λ
µ
, 0, 0)
as t→∞ for RHCV < 1, so that P
2
0 is globally asymptotically stable if RHCV < 1.

The global stability of the disease free equilibrium of model (4.1), can only be achieved
in very specific conditions, namely, when new coinfection cases are prevented from
occurring. Patients infected with HIV or HCV could not become coinfected in such
conditions. As this condition is somewhat unrealistic it is not included here. New
techniques will be applied in future work in order to try to prove the global stability of
the disease free equilibrium.
4.1.4 Bifurcation analysis of the model
In this section, XPPAUT [40] is used to draw schematic bifurcation diagrams for six
relevant parameters of the model (4.1). Changing colors indicates a change in the
stability of the equilibria.
Figure 4.2 is a sketch of the bifurcation diagram of model (4.1) for the variation of
parameter bh, the effective sexual contact rate for a HIV infection to occur. It starts
from a disease-free equilibrium at bh = 0. At bh = 0.0456, there is a bifurcation point (1),
at which the model bifurcates to the stable HIV endemic equilibrium. The color green
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means that the disease-free equilibrium is stable and the color red means that it has lost
stability, and now is the HIV endemic equilibrium that it is stable. Thus, increasing the
effective sexual contact rate for HIV infection to occur will translate in new cases of HIV
infections.
Figure 4.2: Sketch of the bifurcation diagram of model (4.1), for different values of bh, the
effective sexual contact rate for a HIV infection to occur. Remaining parameter values
are given in Table 4.2. Green - stable disease-free equilibrium, red - stable HIV endemic
equilibrium. For more information, see text.
Figure 4.3 depicts the sketch of the bifurcation diagram of model (4.1), for different
values of bc, the effective contact rate for HCV infection to occur. It starts from a stable
disease-free equilibrium at bc = 0. At bc = 0.2758, there is a bifurcation point (1), where
the model bifurcates to the stable HCV endemic equilibrium. This means that increasing
the effective contact rate for HCV infection to occur will promote the appearance of new
cases of HCV.
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Figure 4.3: Schematic bifurcation diagram of model (4.1), for different values of bc, the
effective contact rate for HCV infection to occur. Remaining parameter values are given
in Table 4.2. Green - stable disease-free equilibrium, orange - stable HCV endemic
equilibrium. For more information, see text.
In Figure 4.4 a sketch of the bifurcation diagram of model (4.1) is drawn, for variation
of parameter c, the average number of sexual partners. It starts from a disease-free
equilibrium at c = 0. At c = 1.267, there is a bifurcation point (1), at which the
model bifurcates to the stable HIV endemic equilibrium. This means that increasing
the average number of sexual partners of susceptible individuals will, as expected,
translate in new cases of HIV infections. Increasing further c, a secondary bifurcation
occurs at c = 8.651 (2), at which the model changes the dynamical behavior to a stable
full endemic equilibrium. Biologically this implies that increasing the average number
of sexual partners will burst coinfection cases. Note that as both diseases, HIV and
HCV share the same transmission route, in this case, by sexual contact, increasing the
average number of sexual partners affects both diseases. Moreover, as HCV is more
difficult to be transmitted through sexual intercourse, it is reasonable that for HCV to
occur a larger number of sexual partners is needed.
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Figure 4.4: Sketch of the bifurcation diagram of model (4.1), for different values of c, the
average number of sexual partners. Remaining parameter values are given in Table 4.2.
Green - stable disease-free equilibrium, red - stable HIV endemic equilibrium, black -
stable full endemic equilibrium. For more information, see text.
In Figure 4.5, a schematic bifurcation diagram of model (4.1) is described, for different
values of θ, the fraction of newborns infected with HIV during birth. It starts from a stable
HIV endemic equilibrium at θ = 0.1. At θ = 0.0084 there is a bifurcation point (1), at
which the model bifurcates to the stable disease-free equilibrium. The model predicts,
in this case, that decreasing the number of infected newborns will decrease the number
of HIV infected individuals.
Figure 4.5: Sketch of the bifurcation diagram of model (4.1), for different values of θ, the
fraction of newborns infected with HIV during birth. Remaining parameter values are
given in Table 4.2. Red - stable HIV endemic equilibrium, green - stable disease-free
equilibrium. For more information, see text.
Figure 4.6 shows the sketch of the bifurcation diagram for different values of r1, the
treatment rate for individuals solely infected with HCV. It starts from a stable HCV
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endemic equilibrium at r1 = 0. At r1 = 0.5277, there is a bifurcation point (1), at
which the model bifurcates to the disease-free equilibrium. This means that increasing
the treatment rate for individuals solely infected with HCV is a successful strategy, since
patients recover from HCV infection.
Figure 4.6: Bifurcation diagram of model (4.1), for different values of r1, the treatment
rate for individuals solely infected with HCV. Remaining parameter values are given in
Table 4.2, except for bc = 0.5. Orange - stable HCV endemic equilibrium, green - stable
disease-free equilibrium. For more information, see text.
In Figure 4.7 a schematic bifurcation diagram of model (4.1) is drawn, for different values
of r2, the treatment rate for HCV, of individuals dually infected with HIV and HCV. It starts
from a stable two disease endemic equilibrium. At r2 = 0.4203 there is a bifurcation point
(1), at which the model bifurcates to the stable HIV endemic equilibrium. Biologically,
this means that increasing the treatment rate for HCV of individuals dually infected with
HIV and HCV leads to a recovery from the HCV infection. The individual returns to the
stage of HIV solely infection.
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Figure 4.7: Sketch of the bifurcation diagram of model (4.1), for different values of r2,
the treatment rate for HCV of individuals dually infected with HIV and HCV. Remaining
parameter values are given in Table 4.2, except for bh = 0.15, bc = 0.5 and σC = 0.43.
Black - stable two disease endemic equilibrium, red - stable HIV endemic equilibrium.
For more information, see text.
In the next section, numerical simulations are presented where bifurcation between
distinct equilibria can be observed, for variation of the parameters considered above.
4.1.5 Numerical results
The numerical simulations of model (4.1) are presented. The parameter values used in
the simulations can be found in Table 4.2 and the following initial conditions S(0) = 500,
Ia(0) = 10 = IaIc(0), Aa(0) = 5, Cc(0) = 5, Ic(0) = 15, IaCc(0) = 10, AaIc(0) = 3,
AaCc(0) = 1 are used.
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Parameter Value Reference
c 1 Estimated
bh 0.036 [54]
σ3 1.0002 Estimated
bc 0.05 [149]
η1 1.0002 [16]
η2 1.002 Estimated
Λ 12 Estimated
µ 0.02 [16]
r1 0.25 [16]
r2 0.2 Estimated
r3 0.15 Estimated
ρ 0.1908 [85]
σ 1.001 [16]
ǫ 0.2 [157]
θ 0.1 Estimated
υ1 0.2 [16]
υ2 0.2 Estimated
υ3 0.15 Estimated
da 0.33 [16]
dc 0.2801 [16]
δ 1.001 [16]
ρ1 0.43 [123]
ρ2 0.45 Estimated
ρ3 0.47 Estimated
σC 0.1667 [123]
Table 4.2: Parameters used in the numerical simulations of model (4.1). Where
appropriate the units are yr−1.
In Figure 4.8, the dynamics of the relevant variables of system (4.1) are plotted. It is ob-
served that, for the given parameter values and initial conditions, the model approaches
asymptotically the stable disease-free equilibrium.
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Figure 4.8: Disease-free equilibrium of system (4.1) for parameter values given in
Table 4.2 and initial conditions (RHIV = 0.1813, RHCV = 0.7895, R0 = 0.7895).
Remaining variables tend asymptotically to zero.
In Figure 4.9, it is observed that the model approaches asymptotically the stable en-
demic HIV equilibrium.
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Figure 4.9: Stable endemic HIV equilibrium of system (4.1) for given parameter values
in Table 4.2, except bh = 0.1, and initial conditions (RHIV = 2.1930, RHCV = 0.1813,
R0 = 2.1930). Remaining variables go asymptotically to zero.
Figure 4.10 shows the stable endemic HCV equilibrium for system (4.1).
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Figure 4.10: Stable HCV endemic equilibrium of system (4.1) for parameter values given
in Table 4.2, except bc = 0.5, and initial conditions (RHIV = 0.7895, RHCV = 1.8129,
R0 = 1.8129). Remaining variables tend asymptotically to zero.
Figure 4.11 describes the dynamics of the variables of system (4.1). It is observed that,
for the given parameter values and initial conditions, the model approaches asymptoti-
cally the stable two disease endemic equilibrium.
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Figure 4.11: Stable two disease endemic equilibrium of system (4.1) for given parameter
values in Table 4.2, except for bh = 0.15, σC = 0.43 and bc = 0.5, and initial conditions
(RHIV = 3.2895, RHCV = 1.7764, R0 = 3.2895).
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Figure 4.12 shows the dynamics of the variables of system (4.1) for different values of
bh, the effective contact rate for HIV infection to occur. It is observed that as bh increases
the system (4.1) bifurcates from the stable disease-free equilibrium to the stable HIV en-
demic equilibrium. Realistically, augmenting the sexual contact rate between individuals
is followed by a burst of HIV infection.
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Figure 4.12: Dynamics of the relevant variables of system (4.1) for different values of
bh, the effective sexual contact rate for HIV transmission to occur, for given parameter
values in Table 4.2 and initial conditions. For more information, see text.
In Figure 4.13, it is shown the dynamics of the variables of system (4.1) for different
values of bc, the effective contact rate for HCV infection to occur. It is observed that as
bc increases the system (4.1) bifurcates from the stable disease-free equilibrium to the
stable HCV endemic equilibrium. This behavior translates, biologically, in new cases of
HCV for higher values of bc.
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Figure 4.13: Dynamics of the relevant variables of system (4.1) for different values of bc,
the effective contact rate for HCV infection to occur. Parameter values are in Table 4.2
and initial conditions in the text. For more information, see text.
Figure 4.14 depicts the behavior of system (4.1) for different values of c, the average
number of sexual partners per unit of time. It is observed that as c increases the sys-
tem (4.1) bifurcates from the stable disease-free equilibrium to the stable HIV endemic
equilibrium and then, increasing further the value of c, there is another bifurcation to the
full endemic equilibrium. Biologically, this means that augmenting the average number
of sexual partners fuels the appearance of new cases of HIV infection, and, after some
value, it even promotes the appearance of coinfection cases.
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Figure 4.14: Dynamics of the relevant variables of system (4.1) for different values of c,
the average number of sexual partners per unit of time, for given parameter values in
Table 4.2 and initial conditions. For more information, see text.
In Figure 4.15 are depicted the dynamics of the variables of system (4.1) for different
values of θ, the fraction of newborns infected with HIV during birth. It is observed that as
θ increases the system (4.1) bifurcates from the stable disease-free equilibrium to the
stable HIV endemic equilibrium.
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Figure 4.15: Dynamics of the relevant variables of system (4.1) for different values of
θ, the fraction of newborns infected with HIV during birth, for given parameter values in
Table 4.2, except for bh = 0.1, and initial conditions. For more information, see text.
In Figure 4.16 the behavior of system (4.1) is drawn for different values of r1, the
treatment rate for individuals solely infected with HCV. It is observed that as r1 increases
the stable HCV endemic state gives rise to the stable disease-free equilibrium. This
means that the treatment was successful and patients recovered from HCV.
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Figure 4.16: Dynamics of the relevant variables of system (4.1) for different values of r1,
the treatment rate for individuals solely infected with HCV, for given parameter values in
Table 4.2, except for bc = 0.5, and initial conditions. For more information, see text.
In Figure 4.17, the effects on the dynamics of model (4.1) are observed, for variation of
r2, the treatment rate for individuals dually infected with HIV and HCV. As r2 increases
the system (4.1) bifurcates from the stable full endemic equilibrium to the stable HIV
endemic equilibrium. Thus, patients recover from HCV infection.
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Figure 4.17: Dynamics of the relevant variables of system (4.1) for different values of
r2, the treatment rate for HCV in individuals dually infected with HIV and HCV, for given
parameter values in Table 4.2, except for bh = 0.15, bc = 0.5, and σC = 0.43, and initial
conditions. For more information, see text.
4.1.6 Conclusions
Model III includes treatment for both diseases, and vertical transmission in the case of
HIV. The local stability of the disease-free equilibria for the full model and the global
stability of the disease-free equilibria for the two submodels (HCV only and HIV only
submodels) are studied. XPPAUT is used to sketch bifurcation diagrams, for relevant
parameters, e.g., the mean number of sexual partners, the sexual contact rates, and the
treatment rates. Numerical results illustrate the change on the dynamical behavior of the
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model for these parameters. The outcomes suggest that specific measures should be
considered, by the policy makers, in order to reduce HIV infection, such as: distributing
more condoms to individuals; develop campaigns in order to warn individuals about the
consequences of having many sexual partners; continuing treatment for AIDS and pur-
suing the investigation of new and better drugs to combat HIV, treat newborns infected
with HIV and advise pregnant women for the benefits of HIV treatment. Considering
HCV infection, treatment is highly recommended as well as other measures (e.g., more
informational campaigns about the disease, its transmission routes, amongst others) in
order to decrease the number of infectious and of chronic carriers. Future work will focus
on the study of regular screening for HIV and of condom use, of the effects of needle
sharing, as well as an application/validation of the model to real portuguese data, with
corresponding estimation of parameter values.
4.2 Model IV
C.M.A. Pinto and A.R.M. Carvalho, Effects of treatment, awareness and condom use
in a coinfection model for HIV and HCV in MSM, Journal of Biological Systems 23(2),
165–193, 2015.
A HIV and HCV coinfection model is described, with the objective of studying the effectc
of treatment for both diseases, screening, unawareness and awareness of HIV infection,
and the use of condom. The reproduction numbers of the full model, and of the two
submodels (HIV only and HCV only models) are computed. The local stability of the
disease-free equilibria is studied. The sensitivity indices of the reproduction number to
relevant parameters of the model are computed. Bifurcation diagrams are presented,
built with the help of XPPAUT, to better understand the dynamics of the proposed model.
Finally, simulation results of the full model are presented.
4.2.1 Description of the model
The total population, N(t) is divided in the following sixteen classes: the unscreened
susceptible individuals, Ss˜(t), the screened susceptible individuals, Ss(t), the HIV un-
aware infected individuals, Ia˜(t), the HIV aware infected individuals, Ia(t), the unaware
individuals showing symptoms of AIDS, Aa˜(t), the aware individuals that developed
AIDS, Aa(t), the HCV infected individuals screened for HIV, Ic(t), the HCV infected
individuals unscreened for HIV, Ic˜(t), the chronic HCV infected individuals unscreened
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for HIV, Cs˜(t), the chronic HCV infected individuals screened for HIV, Cs(t), the HCV
and HIV unaware coinfected individuals, IcIa˜(t), the HCV and HIV aware coinfected
individuals, IcIa(t), the chronic HCV and HIV unaware coinfected individuals, CIa˜(t),
the chronic HCV and HIV aware coinfected individuals, CIa(t), the HCV and AIDS
dually infected individuals, IcA(t), and the chronic HCV and AIDS coinfected individuals,
CA(t).
The schematic diagram of the model is given in Figure 4.18.
Figure 4.18: Flow chart of the model.
The population of size N(t), at time t, has constant inflow of susceptibles Ss˜(t) and
Ss(t), Λ = Λ1+Λ2. The natural mortality rate is µ in all classes. Susceptible unscreened
individuals, Ss˜(t), get infected with HIV at a rate λh, where:
λh = c(1− θ)bh
Ia(t) + Ia˜(t) + η1(IcIa˜(t) + IcIa(t))
N(t)
Parameter bh is the probability that a contact will result in an HIV infection and c is the
mean number sexual parterns that a susceptible individual acquires, annually. To model
4.2. MODEL IV 95
the impact of condom use as a primary prevention tool, it is assumed that the level of
protection by condoms is given by θ ∈ [0, 1]. If θ = 0 then condoms do not offer any
protection, whereas θ = 1 implies perfect protection [84]. Parameter η1 > 1 models
the fact that dually infected individuals are more infectious than their corresponding
counterparts [19, 34, 16]. Unscreened individuals are screened at a rate k and move to
the class of screened susceptible individuals, Ss(t).
Screened susceptible individuals, Ss(t) are infected with HIV at a rate (1− ψ)λh, where
0 ≤ ψ ≤ 1 measures the efficacy of screening in reducing disease transmission. If
ψ = 0, then the screening has no effect on the behavior of individuals, on the contrary, if
ψ = 1 then screening is 100% effective in preventing HIV transmission. It is considered
that screened susceptible individuals can be infected. Routine testing serves only one
individual knowing his or her HIV status and accessing care if he or she needs it. A
proportion p of screened individuals enter the infected class of individuals who are
aware of their condition, Ia(t). A proportion (1 − p) of infected individuals that are
not routinely screened go to the class Ia˜(t) and are unaware of their infectious state.
These unscreened individuals are screened after some time at a rate k and move to
class Ia(t). Individuals at class Ia(t) receive HAART treatment, nevertheless there are
some that develop AIDS at a rate ρ2. Individuals in class Ia˜(t) may also develop AIDS at
a rate ρ1. It is assumed ρ1 ≥ ρ2, since individuals at class Ia˜(t) do not receive HAART
treatment, due to their unawareness of the disease condition. AIDS induced death rate
is δ2.
Considering now HCV infection, susceptible unscreened individuals, Ss˜(t) are infected
with HCV at a rate λc, and move to class Ic˜, where:
λc = c(1− θ)bc
Ic(t) + Ic˜(t) + η2(IcIa˜(t) + IcIa(t))
N(t)
Parameter bc is the probability that a contact will result in an HCV infection, η2 > 1 mod-
els the fact that dually infected individuals are more infectious than their corresponding
counterparts [19, 34, 16]. The HCV, unscreened for HIV, infected individuals, Ic˜(t),
recover spontaneously (or from treatment), at a rate υ, and return to class Ss˜(t). They
can also progress to a chronic stage, Cs˜(t), at a rate σ1. Or they can be screened at
a rate k and move to class Ic(t). These individuals are infected with HIV at a rate δλh,
where δ accounts for the susceptibility to HIV infection for HCV infected people [16, 114].
The screened susceptible individuals, Ss(t) are infected with HCV at a rate λc and move
to class Ic(t). The screened HCV infected individuals are infected with HIV at a rate
(1 − ψ)λhδ, recover at a rate υ and move back to class Ss(t), or progress to a chronic
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phase at a rate σ1 and move to class Cs(t).
The chronic HCV infected individuals, unscreened for HIV, Cs˜(t), are infected with HIV
at a rate δλh and move to the class CIa˜(t), and are screened at a rate k and move to
class Cs(t). The chronic HCV infected individuals, screened for HIV, Cs(t), are infected
with HIV at a rate (1− ψ)δλh.
The HIV unaware infected individuals, Ia˜(t), are infected with HCV at a rate σλc, and
move to class IcIa˜(t), where σ > 1 is the modification parameter modeling the increased
risk of being infected with HCV when a person is already infected with HIV [149, 34, 16].
Reciprocally, the HCV infected indiviuals, screened for HIV, Ic(t), are infected with HIV
at a rate (1 − p)(1 − ψ)δλh and also move to class IcIa˜(t). Individuals in class IcIa˜(t)
spontaneously recover from HCV infection, at a rate υ1, and move to class Ia˜(t), or
progress to AIDS at a rate ρ2 and move to class IcA(t). They can also be screened for
HIV and move to class IcIa(t). Finally individuals in class IcIa˜(t) can become chronic
carriers at a rate σ2 and move to class CIa˜(t).
The HIV aware infected individuals, Ia(t), are infected with HCV at a rate σλc, and move
to class IcIa(t). Reciprocally, the HCV infected individuals, Ic(t), are infected with HIV at
a rate δ(1−ψ)λh. Individuals in class IcIa(t) spontaneously recover from HCV infection
at a rate υ1 and move to the class Ia(t). They progress to AIDS at a rate ρ2, and move
to class IcA(t). Or they may become HCV chronic carriers, at a rate σ2, and move to
class CIa(t).
The individuals with chronic HCV infection, and unscreened for HIV, Cs˜(t), are infected
with HIV at a rate δλh and move to class CIa˜(t). Individuals in this class are screened
at a rate k and move to class CIa or progress to AIDS at a rate ρ2. HCV induced death
is δ1 in all HCV classes.
The HCV infected individuals at chronic phase, screened for HIV, Cs(t), are infected
with HIV at a rate (1− ψ)δλh. The chronic HCV carriers and HIV aware dually infected
individuals, CIa(t) progress to AIDS at a rate ρ2 and move to class CA(t).
AIDS aware individuals, As(t), are infected with HCV at a rate σλc and move to class
IcA(t). The individuals in class IcA(t) are treated for HCV infection at a rate υ2 and
move to class As. The individuals in class IcA(t) become HCV chronic carriers at a rate
σ2 and move to class CA(t).
The parameters and variables of the model are summarized in Table 4.3.
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Variable/Parameter Description
Ss(t) susceptible screened individuals
Ss˜(t) susceptible unscreened individuals
Ia(t) HIV infected aware individuals
Ia˜(t) HIV infected unaware individuals
Aa(t) aware individuals showing symptoms of AIDS
Aa˜(t) unaware individuals showing symptoms of AIDS
Ic(t) screened for HIV, HCV infected individuals
Ic˜(t) unscreened for HIV, HCV infected individuals
Cs(t) screened for HIV, chronic HCV infected individuals
Cs˜(t) unscreened for HIV, chronic HCV infected individuals
IcIa(t) HCV and HIV aware coinfected individuals
IcIa˜(t) HCV and HIV unaware coinfected individuals
CIa(t) HIV aware and chronic HCV dually infected individuals
CIa˜(t) HIV unaware and chronic HCV coinfected individuals
IcA(t) HCV and AIDS coinfected individuals
CA(t) chronic HCV and AIDS coinfected individuals
Λ1 recruitment rate of unscreened individuals
Λ2 recruitment rate of screened individuals
µ natural mortality rate
bh probability that a contact will result in an HIV infection
bc probability that a contact will result in an HCV infection
c mean number sexual parterns a susceptible individual acquires
θ level of protection by condoms
p proportion of screened individuals aware of their HIV status
ψ efficacy of screening in reducing HIV transmission
υ, υi, i = 1, 2 recovery rate of treated for HCV
σi, i = 1, 2 rate of progression to chronic phase of HCV
δ1 mortality due to HCV
ρi, i = 1, 2 rate of progression to AIDS
k awareness of unscreened HIV infected individuals after being
screened
δ2 mortality due to HIV
ηi, i =, 1, 2 modification parameter
σ modification parameter
δ modification parameter
Table 4.3: Definition of parameters and variables of model (4.12).
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The system of nonlinear ordinary differential equations for the proposed model is given
by:
dSs˜
dt
= Λ1 + υIc˜ − λhSs˜ − λcSs˜ − kSs˜ − µSs˜
dSs
dt
= Λ2 + kSs˜ − (1− ψ)λhSs − λcSs + υIc − µSs
dIa˜
dt
= (1− p)(1− ψ)λhSs + λhSs˜ + υ1IcIa˜ − (k + ρ1 + σλc + µ)Ia˜
dIa
dt
= p(1− ψ)λhSs + kIa˜ + υ1IcIa − (σλc + ρ2 + µ)Ia
dAa˜
dt
= ρ1Ia˜ − (µ+ δ2)Aa˜
dAa
dt
= ρ2Ia + υ2IcA− (σλc + µ+ δ2)Aa
dIc˜
dt
= λcSs˜ − (k + υ + σ1 + δλh + µ+ δ1)Ic˜
dIc
dt
= λcSs + kIc˜ − (υ + σ1 + (1− ψ)δλh + µ+ δ1)Ic
dCs˜
dt
= σ1Ic˜ − (k + δλh + µ+ δ1)Cs˜
dCs
dt
= σ1Ic + kCs˜ − ((1− ψ)δλh + µ+ δ1)Cs
dIcIa˜
dt
= (1− p)(1− ψ)δλhIc + δλhIc˜ + σλcIa˜−
−(k + σ2 + ρ2 + υ1 + µ+ δ1)IcIa˜
dIcIa
dt
= p(1− ψ)δλhIc + σλcIa + kIcIa˜ − (υ1 + ρ2 + σ2 + µ+ δ1)IcIa
dCIa˜
dt
= (1− p)(1− ψ)λhδCs + δλhCs˜ + σ2IcIa˜ − (k + ρ2 + µ+ δ1)CIa˜
dCIa
dt
= p(1− ψ)δλhCs + σ2IcIa + kCIa˜ − (ρ2 + µ+ δ1)CIa
dIcA
dt
= σλcAa + ρ2IcIa˜ + ρ2IcIa − (υ2 + σ2 + µ+ δ1 + δ2)IcA
dCA
dt
= ρ2CIa˜ + ρ2CIa + σ2IcA− (µ+ δ1 + δ2)CA
(4.12)
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with non-negative initial conditions given by:
Ss(0) = Ss0, Ss˜ = Ss˜0, Ia˜(0) = Ia˜0, Ia = Ia0, Aa(0) = Aa0, Aa˜ = Aa˜0,
Ic(0) = Ic0, Ic˜ = Ic˜0, Cs(0) = Cs0, Cs˜ = Cs˜0IcIa˜ = IcIa˜0,
IcIa(0) = IcIa0, CIa˜(0) = CIa˜0, CIa(0) = CIa0, IcA(0) = IcA0,
CA(0) = CA0
(4.13)
Model (4.12) will be analyzed in the domain Ω ⊂ R16+0, given by:
Ω = {(Ss, Ss˜, Ia, Ia˜, Aa, Aa˜,
Ic, Ic˜, Cs, Cs˜m, IcIa, CIa, IcIa˜, CIa, CIa˜, IcA,CA) ∈ R
16
+ : 0 ≤ N ≤
Λ1+Λ2
µ
}
Theorem 4.2.1 The solutions of system (4.12) with initial conditions (4.13) satisfy Ss˜(t) ≥
0, Ss(t) ≥ 0, Ia˜(t) ≥ 0, Ia(t) ≥ 0, Aa˜(t) ≥ 0, Aa(t) ≥ 0, Ic˜(t) ≥ 0, Ic(t) ≥ 0, Cs˜(t) ≥ 0,
Cs(t) ≥ 0, IcIa˜(t) ≥ 0, IcIa(t) ≥ 0, CIa˜(t) ≥ 0, CIa(t) ≥ 0, IcA(t) ≥ 0, CA(t) ≥ 0
for all t > 0. The region Ω ∈ R16+0 is positively invariant and attracting with respect to
system (4.12).
Proof From the first equation of model (4.12) has:
S˙s˜ ≥ − [λh + λc + k + µ]S
thus:
Ss˜(t) ≥ Ss˜(0)e
[
−
∫ t
0
[λh(s)+λc(s)+k+µ]ds
]
> 0
Similarly for the second equation of system (4.12):
Ss ≥ Ss(0)e
[
−
∫ t
0
((1−ψ)+λc+µ)
]
> 0
In an analogous fashion, this can easily be shown Ia(t), Ia˜, Aa(t), Aa˜, Ic(t), Ic˜, Cs(t),
Cs˜, IcIa˜(t), IcIa(t), CIa˜(t), CIa(t), IcA(t), and CA(t) are all positive for all t > 0.
It is now shown that all feasible solutions are uniformly bounded in Ω. Adding all
equations of system (4.12) gets:
N˙ = Λ1 + Λ2 − µN − δ2(Aa + Aa˜ + IcA+ CA)− δ1(Ic + Ic˜ + Cs + Cs˜ + IcIa˜ + IcIa + CIa˜ + CIa),
N˙ ≤ Λ1 + Λ2 − µN
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This differential equation is solved by observing that:
0 ≤ N ≤
Λ
µ
+N(0)e−µt
where Λ = Λ1 + Λ2, N(0) represents the initial value of the model’s variables. Then
0 ≤ N ≤ Λ
µ
, as t → ∞. Therefore, Λ
µ
is an upper bound of N provided that N(0) ≤ Λ
µ
.
If N(0) > Λ
µ
, then N(t) will decrease to this level. Thus, all feasible solutions of the
system enter or remain in the region Ω. Hence, the region of biological interest Ω is
positively invariant under the flow induced by system (4.12).

4.2.2 Reproduction numbers and stability of disease-free equilibria
In this subsection, the reproduction number,R0, of model (4.12) is calculated. The basic
reproduction number is defined as the number of secondary infections due to a single
infection in a completely susceptible population.
The following two sub-models of model (4.12) are considered. Model (4.14) is derived
from model (4.12) by setting the variables concerning HIV dynamics (Ia˜, Ia, As˜, As,
IcIa˜, IcIa, CIa˜, CIa, IcA and CA) to zero, and model (4.16) follows from model (4.12)
by setting the variables concerning HCV dynamics (Ic˜, Ic, Cs˜, Cs, IcIa˜, IcIa, CIa˜, CIa,
IcA and CA) to zero.
The reproduction number, RHCV , of system (4.14) is calculated. The next generation
method [150] is used.
dSs˜
dt
= Λ1 + υIc˜ − λcSs˜ − kSs˜ − µSs˜
dS
dt
= Λ2 + kSs˜ − λcSs + υIc − µSs
dIc˜
dt
= λcSs˜ − (k + υ + σ1 + µ+ δ1)Ic˜
dIc
dt
= λcSs − (υ + σ1 + µ+ δ1)Ic
dCs˜
dt
= σ1Ic˜ − (k + µ+ δ1)Cs˜
dCs
dt
= σ1Ic + kCs˜ − (µ+ δ1)Cs
(4.14)
where λc = c(1− θ)bc
Ic+Ic˜
N
.
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The disease-free equilibrium of model (4.14) is given by:
P 10 =
(
Λ1
k + µ
,
Λ2
µ
+
kΛ1
µ(k + µ)
, 0, 0, 0, 0
)
Using the notation of [150], matrices for the new infection terms, F , and the other terms,
V , are given by:
F =


c(1− θ)bc
Λ1µ
Λ1(µ+1)+Λ2(k+µ)
c(1− θ)bc
Λ1µ
Λ1(µ+1)+Λ2(k+µ)
0 0
c(1− θ)bc
Λ1µ+Λ2(k+µ)
Λ1(µ+1)+Λ2(k+µ)
c(1− θ)bc
Λ1µ+Λ2(k+µ)
Λ1(µ+1)+Λ2(k+µ)
0 0
0 0 0 0
0 0 0 0


V =


k + υ + σ1 + µ+ δ1 0 0 0
−k υ + σ1 + µ+ δ1 0 0
−σ1 0 k + µ+ δ1 0
0 −σ1 −k µ+ δ1


The associative basic reproduction number is thus:
RHCV = ρ(FV
−1) =
c(1− θ)bc
υ + σ1 + µ+ δ1
(4.15)
where ρ indicates the spectral radius of FV −1. By Theorem 2 [150], the following lemma
is obtained.
Lema 4.2.2 The disease-free equilibrium P 10 is locally asymptotically stable ifRHCV < 1
and unstable if RHCV > 1.
This is followed by the calculation of the reproduction number, RHIV , of model (4.16).
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dSs˜
dt
= Λ1 − λhSs˜ − kSs˜ − µSs˜
dSs
dt
= Λ2 + kSs˜ − (1− ψ)λhSs − µSs
dIa˜
dt
= (1− p)(1− ψ)λhSs + λhSs˜ − (k + ρ1 + µ)Ia˜
dIa
dt
= p(1− ψ)λhSs + kIa˜ − (ρ2 + µ)Ik
dAs˜
dt
= ρ1Ia˜ − (µ+ δ2)Aa˜
dA
dt
= ρ2Ia − (µ+ δ2)A
(4.16)
where λh = c(1− θ)bh
Ia˜+Ia
N
.
The disease-free equilibrium state P 20 of model (4.16) is given by:
P 20 =
(
Λ1
k + µ
,
Λ2
µ
+
kΛ1
µ(k + µ)
, 0, 0, 0, 0
)
Using the notation of [150], matrices for the new infection terms, F , and the other terms,
V , are the following:
F =


c(1−θ)bh
(Λ1+Λ2)(µ+k)
[(1− p)(1− ψ)(kΛ1 + Λ2(k + µ)) + Λ1µ]
c(1−θ)bh
(Λ1+Λ2)(µ+k)
[(1− p)(1− ψ)(kΛ1 + Λ2(k + µ)) + Λ1µ] 0 0
p(1− ψ)c(1− θ)bh
kΛ1+Λ2(k+µ)
(Λ1+Λ2)(µ+k)
p(1− ψ)c(1− θ)bh
kΛ1+Λ2(k+µ)
(Λ1+Λ2)(µ+k)
0 0
0 0 0 0
0 0 0 0


V =


k + ρ1 + µ 0 0 0
−k ρ2 + µ 0 0
−ρ1 0 µ+ δ2 0
0 −ρ2 0 µ+ δ2


The associative basic reproduction number is given by:
RHIV = ρ(FV
−1)
= c(1−θ)bh
(k+µ+ρ1)(ρ2+µ)(Λ1+Λ2)(µ+k)
[(1− ψ)(kΛ1 + Λ2(k + µ))(k + µ+ ρ2 + p(ρ1 − ρ2)) + Λ1µ(k + µ+ ρ2)]
(4.17)
where ρ indicates the spectral radius of FV −1. By Theorem 2 [150], the following lemma
is obtained.
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Lema 4.2.3 The disease-free equilibrium P 20 is locally asymptotically stable if RHIV < 1 and unstable if RHIV > 1.
The calculation of the reproduction number, R0, of the full model (4.12) follows. The disease-free equilibrium state P0 of model
(4.12) is given by:
P0 =
(
Λ1
k + µ
,
Λ2
µ
+
kΛ1
µ(k + µ)
, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0
)
Using the notation in [150] on system (4.12), the matrices for the new infection terms, F , and the other terms, V , and the matrix
FV −1 are calculated. Then, the reproduction number is the spectral radius of FV −1.
F =


c(1−θ)bh
(Λ1+Λ2)(µ+k)
[(1− p)(1− ψ)(kΛ1 + Λ2(k + µ)) + Λ1µ]
c(1−θ)bh
(Λ1+Λ2)(µ+k)
[(1− p)(1− ψ)(kΛ1 + Λ2(k + µ)) + Λ1µ] 0 0 0 0 0 0
c(1−θ)bh
(Λ1+Λ2)(µ+k)
[(1− p)(1− ψ)(kΛ1 + Λ2(k + µ)) + Λ1µ]
c(1−θ)bh
(Λ1+Λ2)(µ+k)
[(1− p)(1− ψ)(kΛ1 + Λ2(k + µ)) + Λ1µ] 0 0 0 0
p(1− ψ)c(1− θ)bh
kΛ1+Λ2(k+µ)
(Λ1+Λ2)(µ+k)
p(1− ψ)c(1− θ)bh
kΛ1+Λ2(k+µ)
(Λ1+Λ2)(µ+k)
0 0 0 0 0 0 p(1− ψ)c(1− θ)bh
kΛ1+Λ2(k+µ)
(Λ1+Λ2)(µ+k)
p(1− ψ)c(1− θ)bh
kΛ1+Λ2(k+µ)
(Λ1+Λ2)(µ+k)
0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 c(1− θ)bc
Λ1µ
(Λ1+Λ2)(µ+k)
c(1− θ)bc
Λ1µ
(Λ1+Λ2)(µ+k)
0 0 c(1− θ)bc
Λ1µ
(Λ1+Λ2)(µ+k)
c(1− θ)bc
Λ1µ
(Λ1+Λ2)(µ+k)
0 0 0 0
0 0 0 0 c(1− θ)bc
kΛ1+Λ2(k+µ)
(Λ1+Λ2)(µ+k)
c(1− θ)bc
kΛ1+Λ2(k+µ)
(Λ1+Λ2)(µ+k)
0 0 c(1− θ)bc
kΛ1+Λ2(k+µ)
(Λ1+Λ2)(µ+k)
c(1− θ)bc
kΛ1+Λ2(k+µ)
(Λ1+Λ2)(µ+k)
0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0


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V =


k + ρ1 + µ 0 0 0 0 0 0 0 −υ1 0 0 0 0 0
−k ρ2 + µ 0 0 0 0 0 0 0 −υ1 0 0 0 0
−ρ1 0 µ+ δ2 0 0 0 0 0 0 0 0 0 0 0
0 −ρ2 0 µ+ δ2 0 0 0 0 0 0 0 0 −υ2 0
0 0 0 0 k + υ + σ1µ+ δ1 0 0 0 0 0 0 0 0 0
0 0 0 0 −k υ + σ1 + µ+ δ1 0 0 0 0 0 0 0 0
0 0 0 0 −σ1 0 k + µ+ δ1 0 0 0 0 0 0 0
0 0 0 0 0 −σ1 −k µ+ δ1 0 0 0 0 0 0
0 0 0 0 0 0 0 0 k + σ2 + rho2 + υ1 + µ+ δ1 0 0 0 0 0
0 0 0 0 0 0 0 0 −k υ1 + ρ2 + µ+ δ1 0 0 0 0
0 0 0 0 0 0 0 0 −σ2 0 k + ρ2 + µ+ δ1 0 0 0
0 0 0 0 0 0 0 0 0 −σ2 −k ρ2 + µ+ δ1 0 0
0 0 0 0 0 0 0 0 −ρ2 −ρ2 0 0 υ2 + σ2 + µ+ δ1 + δ2 0
0 0 0 0 0 0 0 0 0 0 −ρ2 −ρ2 −σ2 µ+ δ1 + δ2


FV −1 =


A
k+µ+ρ1
+ Ak
(k+µ+ρ1)(µ+ρ2)
A
µ+ρ2
0 0 0 0 0 0 ⋆ ⋆ 0 0 0 0
B
k+µ+ρ1
+ Bk
(k+µ+ρ1)(µ+ρ2)
B
µ+ρ2
0 0 0 0 0 0 ⋆ ⋆ 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 C
δ1+k+µ+σ1+υ
+ Ck
(δ1+µ+σ1+υ)(δ1+k+µ+σ1+υ)
C
(δ1+µ+σ1+υ)
0 0 ⋆ ⋆ 0 0 0 0
0 0 0 0 D
δ1+k+µ+σ1+υ
+ Dk
(δ1+µ+σ1+υ)(δ1+k+µ+σ1+υ)
D
(δ1+µ+σ1+υ)
0 0 ⋆ ⋆ 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0


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where A = c(1−θ)bh
(Λ1+Λ2)(µ+k)
[(1− p)(1− ψ)(kΛ1 + Λ2(k + µ)) + Λ1µ], B = p(1 − ψ)c(1 −
θ)bh
kΛ1+Λ2(k+µ)
(Λ1+Λ2)(µ+k)
, C = c(1 − θ)bc
Λ1µ
(Λ1+Λ2)(µ+k)
, and D = c(1 − θ)bc
kΛ1+Λ2(k+µ)
(Λ1+Λ2)(µ+k)
. The
formulas represented by ⋆ are irrelevant to compute the eigenvalues, so, for the sake of
simplicity, it was decided not to include those here.
In order to compute R0, the basic reproduction number for the whole model (4.12), it
is necessary to compute the eigenvalues of the matrix FV −1, since R0 is the spectral
radius of FV −1, i.e., it is the dominant eigenvalue of this matrix.
Let’s now proceed with the computation of the eigenvalues by calculating the determi-
nant below:
FV −1 =


A
k+µ+ρ1
+ Ak
(k+µ+ρ1)(µ+ρ2)
− λ A
µ+ρ2
0 0
B
k+µ+ρ1
+ Bk
(k+µ+ρ1)(µ+ρ2)
B
µ+ρ2
− λ 0 0
0 0 C
δ1+k+µ+σ1+υ
+ Ck
(δ1+µ+σ1+υ)(δ1+k+µ+σ1+υ)
− λ C
(δ1+µ+σ1+υ)
0 0 D
δ1+k+µ+σ1+υ
+ Dk
(δ1+µ+σ1+υ)(δ1+k+µ+σ1+υ)
D
(δ1+µ+σ1+υ)
− λ


As FV −1 is a matrix of the form:

 U1 0
0 U2

, then its eigenvalues are the ones of
matrices U and V , where:
U1 =

 Ak+µ+ρ1 + Ak(k+µ+ρ1)(µ+ρ2) − λ Aµ+ρ2
B
k+µ+ρ1
+ Bk
(k+µ+ρ1)(µ+ρ2)
B
µ+ρ2
− λ

 ;
U2 =

 Cδ1+k+µ+σ1+υ + Ck(δ1+µ+σ1+υ)(δ1+k+µ+σ1+υ) − λ C(δ1+µ+σ1+υ)
D
δ1+k+µ+σ1+υ
+ Dk
(δ1+µ+σ1+υ)(δ1+k+µ+σ1+υ)
D
(δ1+µ+σ1+υ)
− λ


After some algebra manipulation R0 is given by:
R0 = ρ(FV
−1) = max{RHIV , RHCV } (4.18)
By Theorem 2 [150], the following lemma is obtained.
Lema 4.2.4 The disease-free equilibrium P0 is locally asymptotically stable if R0 < 1
and unstable if R0 > 1.
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4.2.3 Bifurcation analysis
In this section, XPPAUT [40] is used to build bifurcation diagrams for distinct parameters
of model (4.12).
Figure 4.19 shows the sketch of the bifurcation diagram for different values of βc, the
probability that a contact will result in an HCV infection. Increasing βc, at βc = 0.2031,
there is a bifurcation point (1), at which the model bifurcates from a stable disease-
free equilibrium to a stable HCV endemic equilibrium. This means that increasing the
probability that a contact will result in an HCV infection originates new cases of HCV
infections. This is a realistic prediction.
Figure 4.19: Sketch of the bifurcation diagram for different values of βc, the probability
that a contact will result in HCV transmission. Remaining parameter values are given
in Table 4.5, except for βh = 0.032. At the bifurcation point (1) βc ≃ 0.2031. Orange
dashed line - stable disease-free equilibrium, green filled line - stable HCV endemic
equilibrium. For more information, see text.
Figure 4.20 depicts the bifurcation diagram for different values of βh, the probability that
a contact will result in an HIV infection. Beginning from a disease-free equilibrium and
increasing βh, at βh = 0.034, there is a bifurcation point (1), at which the model bifur-
cates to the stable HIV endemic equilibrium. This means that increasing the probability
that a contact will result in an HIV infection promotes the appearance of new cases of
HIV infections, as biologically expected.
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Figure 4.20: Drawing of the bifurcation diagram for different values of βh, the probability
that a contact will result in HIV transmission. Remaining parameter values are given in
Table 4.5. At the bifurcation point (1) βh ≃ 0.034. Orange dashed line - stable disease-
free equilibrium, red filled line - stable HIV endemic equilibrium. For more information,
see text.
Figure 4.21 depicts the bifurcation diagram for different values of βc, the probability that
a contact will result in an HCV infection. Beginning from an HIV endemic equilibrium
and increasing βc, at βc = 0.2503, there is a bifurcation point (1), at which the model
bifurcates to the stable two endemic equilibrium. This means that in a population already
infected with HIV, with lowered defense mechanisms, increasing the probability of a
contact resulting in HCV infection will set off new coinfection cases.
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Figure 4.21: Sketch of the bifurcation diagram for different values of βc, the probability
that a contact will result in an HCV infection. Remaining parameter values are given in
Table 4.5. At the bifurcation point (1) βc = 0.2503. Red filled line - stable HIV endemic
equilibrium, black filled line - stable two endemic equilibrium. For more information, see
text.
Figure 4.22 depicts the bifurcation diagram for different values of βh, the probability that
a contact will result in an HIV infection. Beginning from an HCV endemic equilibrium
and increasing βh, at βh = 0.0503, there is a bifurcation point (1), at which the model
bifurcates to the stable two endemic equilibrium. This means that in a population
with impaired immune system due to infection with HCV, increasing the probability of
a contact resulting in HIV infection will trigger new coinfection cases.
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Figure 4.22: Sketch of the bifurcation diagram for different values of βh, the probability
that a contact will result in an HIV infection. Remaining parameter values are given in
Table 4.5. At the bifurcation point (1) βh = 0.0503. Green filled line - stable HCV endemic
equilibrium, black filled line - stable two endemic equilibrium. For more information, see
text.
4.2.4 Sensitivity analysis
In this section, the sensitivity indices of the reproduction number, R0, to relevant pa-
rameters of model (4.12) are performed. The procedure developed in [27] follows. The
sensitivity analysis is used to measure the relative change in a state variable when a
given parameter is varied. Measuring the R0 sensitivity indices is extremely important
since the value of R0 determines the spread or the eradication of the disease.
The sensitivity index of R0 = max{RHIV , RHCV } with respect to parameter βc = c(1−
θ)bc is given by:
∂R0
∂βc
×
βc
R0
= 1
The sensitivity index of R0 with respect to parameter βh = c(1− θ)bh is given by:
∂R0
∂βh
×
βh
R0
= 1
These values for this sensitivity index mean that the probability of HCV or HIV transmis-
sion has strong influence in HCV and HIV control and management. Similar expressions
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may be obtained for the other parameters of R0. Nevertheless, most of the expres-
sions for the sensitivity indices are complex with little obvious structure. Therefore, the
corresponding values for the parameter values given in Table 4.5 are computed. The
signs of the sensitivity indices may be found in Table 4.4. A positive sign implies that
increases in the corresponding parameter values translate in an increase in the value
of R0. Inversely for a negative sign, a negative index means than an increase in the
parameter value implies a decrease in the value of R0. For example, an increase of
5% in the values of βh or βc augments 5% the value of R0. Similar inferences may be
performed for the other indices.
Parameter Sensitivity index sign
βc +
βh +
θ -
ν -
σ1 -
σ2 -
p +
k +
ρ2 -
ρ1 -
Table 4.4: Sensitivity indexes for relevant parameters of model (4.12).
4.2.5 Numerical results
In this section, the numerical simulations of model (4.12) are presented. The param-
eter values used in the simulations can be found in Table 4.5 and the following initial
conditions: Ss˜(0) = 500, Ss(t) = 0 (assume that no individuals were screened initially),
Ia˜(0) = 80, Ia(0) = 0, Aa(t) = 0, Aa˜ = 15, Ic(t) = 0, Ic˜ = 20, Cs(0) = 0, Cs˜ = 5,
IcIa(0) = IcIa˜ = CIa = CIa˜ = IcA = CA = 0 are used.
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Parameter Value Reference
Λ1 8 Assume
Λ2 4 Assume
c 8 Assume
θ 0.20 [2]
bh 0.036 [54]
bc 0.05 [149]
η1 1.0002 [16]
η2 1.0002 [16]
υ 0.25 [149]
υ1 0.27 Assume
υ2 0.25 Assume
µ 0.020 [16]
p 0.0367 [85]
ψ 0.0288 [85]
k 0.00388 [85]
ρ1 0.1908 [85]
ρ2 0.1511 [85]
δ1 0.2801 Assume
δ2 0.2801 [85]
δ 1.0001 [16]
σ 1.001 [16]
σ1 0.75 [87]
σ2 0.75 [87]
Table 4.5: Parameters used in the numerical simulations of model (4.12), where
appropriate units are yr−1.
In Figures 4.23, it is observed that the model approaches asymptotically the stable HIV
endemic equilibrium.
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Figure 4.23: Stable HIV endemic equilibrium of system (4.12) for given parameter values
in Table 4.5, and given initial conditions (RHIV = 1.0875, RHCV = 0.2461, R0 = 1.0875).
The remaining variables go asymptotically to 0. For more information, see text.
Figure 4.24 shows the stable HCV endemic equilibrium for system (4.12).
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Figure 4.24: Stable HCV endemic equilibrium of system (4.12) for parameter values
given in Table 4.5, except βc = 0.25 and βh = 0.032, and given initial conditions (RHIV =
0.9667, RHCV = 1.2307, R0 = 1.2307). The remaining variables go asymptotically to 0.
For more information, see text.
In Figure 4.25, the dynamics of the variables of system (4.12)is drawn. It is observed
that, for the given parameters values and initial conditions, the model approaches asymp-
totically the stable two disease endemic equilibrium.
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Figure 4.25: Stable two disease endemic equilibrium of system (4.12) for given
parameter values in Table 4.5, except for bh = 0.054, bc = 0.25, and given initial
conditions (RHIV = 1.6313, RHCV = 1.2307, R0 = 1.6313) (relevant variables). For
more information, see text.
In Figure 4.26, it plots the dynamics of the relevant variables of system (4.12) for
different values of θ, the level of protection against HIV and HCV by condom use. It
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is observed that as θ decreases the system (4.12) bifurcates from the stable disease-
free equilibrium to the stable HIV endemic equilibrium. This suggests that individuals
should, as expected, use condom, to prevent being infected with HIV.
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Figure 4.26: Dynamics of the relevant variables of the system (4.12) for different values
of θ, the level of protection against HIV and HCV by condom use. Parameter values
are given in Table 4.5 and initial conditions are in the text. The remaining variables go
asymptotically to zero. For more information, see text.
Figure 4.27 shows the dynamics of the relevant variables of system (4.12) for diferent
values of βh, the probability that a contact will result in an HIV infection. It is observed
that increasing the system (4.12) has a bifurcation point as βh increases from 0.030
till 0.1. The system bifurcates from a stable disease-free equilibrium to a stable HIV
endemic equilibrium. This was a predictable outcome and suggests that measures that
reduce this probability βh should be taken under consideration in order to reduce HIV
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transmission.
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Figure 4.27: Dynamics of the relevant variables of the system (4.12) for diferent values
βh, the probability that a contact will result in an HIV infection. Parameter values are
given in Table 4.5 and initial conditions are in the text. The remaining variables go
asymptotically to zero. For more information see text.
In Figure 4.28, the dynamics of the relevant variables of system (4.12) are plotted for
different values of βc, the probability that a contact will result in an HCV infection. It
is observed that as βc increases from 0.05 to 0.25 there is a bifurcation from a state
without disease to a state with HCV infection that persists with the continuous increase
of βc. The number of chronic carriers also increases. Biologically this is a reasonable
outcome, one would expect an augment in the number of new disease cases as the
probability of transmission increases.
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Figure 4.28: Dynamics of the relevant variables of the system (4.12) for different values
of βc, the probability that a contact will result in an HCV infection. Parameter values
are given in Table 4.5, except bh = 0.032 and initial conditions are in the text. For more
information, see text.
In Figure 4.29, the dynamics of the relevant variables of system (4.12) are plotted
for different values of ψ, the parameter that measures the efficacy of screening in
reducing HIV transmission. It is observed that as ψ increases the number of individuals
infected with HIV and suffering from AIDS decreases, in fact, the system (4.12) is initially
at a stable HIV endemic equilibrium and changes its qualitative behavior to a stable
disease-free equilibrium. In real life, this means that individuals that are screened should
change their behavior in order to prevent transmission of the disease. In fact, there are
some studies that show that screened HIV infectives tend to change their behavior and
those whose test is negative don’t [160]. Nevertheless, the tests are meant to promote
118 CHAPTER 4. MODELS FOR COINFECTION OF HIV AND HCV
behavior change and to access to health care for all screened individuals.
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Figure 4.29: Dynamics of the relevant variables of the system (4.12) for different
values of ψ, the parameter that measures the efficacy of screening in reducing HIV
transmission. Parameter values are given in Table 4.5 and initial conditions are in the
text. Remaining variables go asymptotically to zero. For more information, see text.
4.2.6 Conclusions
Model IV is a coinfection model for HCV and HIV infections, that includes treatment
for both diseases, unawareness and awareness if HIV infection, and the use of condom.
The local stability of the disease-free equilibria for the full model and for the two submod-
els (HCV only and HIV only submodels) are studied. Bifurcation diagrams are sketched
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for relevant parameters, such as the probabilities that a contact will result in a HIV or an
HCV infection. Numerical examples are used to illustrate the change of the dynamical
behavior of certain relevant parameters. The results obtained suggest that specific
measures should be considered in order to reduce HIV infection, such as: distributing
more condoms to individuals and try to forward the message that condom should be
used during anal intercourse (though this might not be well accepted in MSM population
due to unprotected sex negotiation); develop campaigns in order to warn individuals
about the consequences of having many sexual partners; continuing treatment for AIDS
and pursuing the investigation of new and better drugs to combat the virus; regular
screening. Considering HCV infection, treatment is also highly recommended as well
as other measures (e.g., more informational campaigns about the disease) in order to
decrease the number of infectious and of chronic carriers. MSM population is at risk
of HCV reinfection following successful treatment and documented clearance of HCV,
they should be warned about this important risk. Future work will consider the effect of
needle sharing in the case of HIV and HCV transmission rates, and an application of the
model to real Portuguese data, with corresponding estimation of parameter values.
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Chapter 5
Models for coinfection of HIV and TB
C.M.A. Pinto and A.R.M. Carvalho, The HIV/TB coinfection severity in the presence of
TB multi-drug resistant strains, Ecological Complexity 32, 1–20, 2017.
Based on the previously mentioned research, it is considered a non-integer order model
for HIV and TB coinfection, with the objective of studying the presence of drug resistant
TB strains and treatment for both diseases. The novelty of this model is the inclusion of
the derivation of a fractional order model for the dynamics of the coinfection of HIV
and TB in the presence of TB resistant strains. The model is introduced, and the
reproduction number and stability of the disease-free equilibrium are studied. It follows
the proofs for the global stability of the disease-free equilibria of the two submodels and
of the full model. The sensitivity analysis is done. Numerical simulations of the model
for distinct values of the order of the fractional derivative and relevant parameters, and
discussion of the results, are done.
5.1 Description of the model
The model is composed of 13 classes. In Fig. 5.1, it is depicted the flow chart of the
model. It represents schematically the epidemiology of HIV and TB coinfection. The
different disease stages are reproduced by the different compartments (rectangles) and
the arrows indicate the way individuals progress from one stage to the other.
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Figure 5.1: Flow chart of the model.
The individuals in the susceptible class, S, are recruited at a rate Λα. They are infected
by individuals infected with HIV and active TB at rates:
λH =
βαH(IH + ET IH +RIH + ηH(ITH + TRIH))
N
and
λT =
βαT (IT + ηTTR + ηTH(ITH + TRIH))
N
respectively. Parameters βαH and β
α
T are the effective contact rates for HIV and TB infec-
tion, respectively. The modification parameters ηH and ηTH account for the increased
infectiousness of individuals coinfected with HIV and TB, when compared to individuals
solely infected with either HIV or TB, respectively. The modification parameter ηT rep-
resents the increased infectiousness of the MRD-TB drug-resistant infected individuals
when compared to the individuals infected with non-resistant TB strains. It is considered,
for simplification, that people showing symptoms of AIDS do not infect others.
The individuals exposed to TB, ET , develop active TB at rate ǫ
α and move to the class
of infected individuals, IT . The exposed, ET , may also be infected with HIV at a rate
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λH and move to the class of individuals exposed to TB and infected with HIV, ET IH .
Individuals IT may recover from TB at rate γ
α and move to the recovered class, R.
They become resistant to the first line of TB treatment at rate σαT , and move to the
MDR-TB drug-resistant individuals’ class, TR. IT individuals are infected with HIV at
rate ψ3λH , where ψ3 > 1 captures the fact that individuals infected with TB are more
infectious than the ones only exposed to TB, and move to the dually infected class,
ITH . The individuals infected with the MDR-TB strains, TR, recover from TB at rate a
α.
The recovered individuals, R, become susceptible to TB at rate ρα, since there is no
permanent TB immunity.
The individuals infected with HIV, IH , develop AIDS at a rate σ
α
H moving to the class
of patients showing symptoms of AIDS, A. They are also infected with TB at rate
ψ1λT , where ψ1 is a modification parameter, and move to class ET IH . The individuals
with AIDS, A, are treated at rate τα2 , and move to class IH . They are infected with
TB at rate ψ2λT , where ψ2 > ψ1 is modification parameter, and move to the class
of individuals exposed to TB and showing symptoms of AIDS, ETA. The inequality
ψ2 > ψ1 represents the fact that the individuals with AIDS are more infectious than
those only infected with HIV. The individuals in class ET IH , and in class ETA, develop
active TB at rates η1ǫ
α and η2ǫ
α, and move to classes ITH and ITA, respectively. The
class ITA are the dually infected individuals with active TB and AIDS. It is noted that
η2 > η1, since patients with AIDS develop active TB faster than individuals infected only
with HIV. The patients in class ET IH and in class ITH proceed to AIDS at rates θ1σ
α
H and
θ2σ
α
H , respectively, where θ2 > θ1. The later translates the fact that individuals infected
with TB proceed faster to AIDS than the ones exposed to TB. The individuals in class
ITH are treated for TB at rate γ
α
1 and move to class RIH (patients recovered from TB
and infected with HIV). Moreover, patients in class ITH may develop MDR-TB strains
at rate σαT1 and move to class TRIH (individuals dually infected with HIV and MDR-TB
strains). The later recover from TB at rate aα1 . The TB recovered individuals, RIH move
to the HIV solely infected class (IH) at rate ρ
α. The individuals in class ITA are treated
for HIV and move to class ITH at rate τ
α
3 . All individuals die from natural causes at rate
µα. Depending on the state of infection, individuals die from HIV, or TB, or HIV and TB
coinfection, at rates δαi , i = 1, · · · , 9.
The nonlinear system of fractional-order differential equations describing the dynamics
of the model is:
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dαS
dtα
= Λα − λTS − λHS + ρ
αR− µαS
dαET
dtα
= λTS − (λH + ǫ
α + µα)ET
dαIT
dtα
= ǫαET − (ψ3λH + γ
α + σαT + µ
α + δα1 )IT
dαR
dtα
= γαIT + a
αTR − (ρ
α + µα)R
dαTR
dtα
= σαT IT − (a
α + µα + δα2 )TR
dαIH
dtα
= λHS + τ
α
2 A+ ρ
αRIH − (ψ1λT + σ
α
H + µ
α + δα3 )IH
dαA
dtα
= σαHIH − (ψ2λT + τ
α
2 + µ
α + δα4 )A
dαET IH
dtα
= λHET + ψ1λT IH + τ
α
2 ETA− (η1ǫ
α + θ1σ
α
H + µ
α + δα5 )ET IH
dαETA
dtα
= θ1σ
α
HET IH + ψ2λTA− (η2ǫ
α + τα2 + µ
α + δα6 )ETA
dαITH
dtα
= η1ǫ
αET IH + ψ3λHIT + τ
α
3 ITA− (γ
α
1 + σ
α
T1 + θ2σ
α
H + µ
α + δα7 )ITH
dαITA
dtα
= θ2σ
α
HITH + η2ǫ
αETA− (τ
α
3 + µ
α + δα8 )ITA
dαRIH
dtα
= γα1 ITH + a
α
1TRIH − (ρ
α + µα + δα3 )RIH
dαTRIH
dtα
= σαT1ITH − (a
α
1 + µ
α + δα9 )TRIH
(5.1)
where α ∈ (0, 1] is the order of the fractional derivative. When α = 1, then the model is
the integer order counterpart. The fractional derivative of the proposed model is used in
the Caputo sense, i.e.:
dαy(t)
dtα
= Ip−αy(p)(t), t > 0
where p = ⌈α⌉ is the value of α rounded up to the nearest integer, y(p) is the p-th
derivative of y(r), Ip1 is the Riemann-Liouville fractional integral given by:
Ip1z(t) =
1
Γ(p1)
∫ t
0
(
t− t
′
)p1−1
z(t
′
)dt
′
The main advantage using Caputo’s fractional derivative is that the classical initial con-
ditions can be used without encountering any problem during solvability.
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5.1.1 Non-negative solutions
Denote R13+ = {x ∈ R
13 | x ≥ 0} and let
x(t) = (S(t), ET (t), IT (t), R(t), TR(t), IH(t), A(t), ET IH(t), ETA(t), ITH(t), ITA(t), RIH(t), TRIH(t))
T
(5.2)
To prove the main theorem, the following Generalized Mean Value Theorem [86] and
corollary are needed.
Lema 5.1.1 [86] Suppose that f(x) ∈ C[a, b] and Dαa f(x) ∈ C(a, b], for 0 < α ≤ 1,
then
f(x) = f(a) +
1
Γ(α)
(Dαa f)(ξ)(x− a)
α
with a ≤ ξ ≤ x, ∀x ∈ (a, b] and Γ(·) is the gamma function.
Corollary 5.1.2 Suppose that f(x) ∈ C[a, b] and Dαa f(x) ∈ C(a, b], for 0 < α ≤ 1. If
Dαa f(x) ≥ 0, ∀x ∈ (a, b), then f(x) is non-decreasing for each x ∈ [a, b]. If D
α
a ≤ 0,
∀x ∈ (a, b), then f(x) is non-increasing for each x ∈ [a, b].
Now the main theorem is proved.
Theorem 5.1.3 There is a unique solution
x(t) = (S(t), ET (t), IT (t), R(t), TR(t), IH(t), A(t), ET IH(t), ETA(t), ITH(t), ITA(t), RIH(t), TRIH(t))
T
(5.3)
of the model (5.1) on t ≥ 0 and the solution will remain in R13+ .
Proof From Theorem 3.1 and Remark 3.2 of [67], the solution is known in (0,+∞) of
the initial value problem exists and is unique. It is now proven that the non-negative
orthant R13+ is a positively invariant region. To do this, it is necessary to show that on
each hyperplane bounding the non-negative orthant, the vector field points to R13+ . From
model (5.1):
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DαS |S=0= Λ
α + ραR ≥ 0 DαET |ET=0= λTS ≥ 0 D
αIT |IT=0= ǫ
αET ≥ 0
DαR |R=0= γ
αIT + a
αTR ≥ 0 D
αTR |TR=0= σ
α
T IT ≥ 0
DαIH |IH=0= λHS + τ
α
2 A+ ρ
αRIH ≥ 0 D
αA |A=0= σ
α
HIH ≥ 0
DαET IH |ET IH=0= λHET + ψ1λT IH + τ2ETA ≥ 0
DαETA |ETA=0= θ1σ
α
HET IH + ψ2λTA ≥ 0
DαITH |ITH=0= η1ǫ
αET IH + ψ3λHIT ≥ 0 D
αITA |ITA=0= θ2σ
α
HITH + η2ǫ
αETA ≥ 0
DαRIH |RIH=0= γ
α
1 ITH + a
α
1TRIH ≥ 0 D
αTRIH |TRIH=0= σ
α
T1ITH ≥ 0
Then, by Corollary 2, the solution will remain in R13+ .

5.2 Reproduction number
In this section, the reproduction number of model (5.1), R0, is calculated. The basic
reproduction number is defined as the number of secondary infections due to a single
infection in a completely susceptible population.
Are considered two sub-models of model (5.1). Model (5.4) arises from model (5.1)
by setting the variables concerning HIV/AIDS dynamics (IH , A, ET IH , ETA, ITH , ITA,
RIH and TRIH) to zero, and model (5.8) follows from model (5.1) by setting the variables
concerning TB (ET , IT , R, TR, ET IH , ETA, ITH , ITA, RIH and TRIH) to zero.
One starts with the computation of the reproduction number of system (5.4), RT . The
next generation method is used to compute RT [150].
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dαS
dtα
= Λα − λTS + ρ
αR− µαS
dαET
dtα
= λTS − (ǫ
α + µα)ET
dαIT
dtα
= ǫαET − (γ
α + σαT + µ
α + δα1 )IT
dαR
dtα
= γαIT + a
αTR − (ρ
α + µα)R
dαTR
dtα
= σαT IT − (a
α + µα + δα2 )TR
(5.4)
where λT =
βαT (IT+ηT TR)
N
. The disease-free equilibrium of model (5.4) is given by:
P 10 = (S0, ET0, IT0, RT0, TR0) =
(
Λα
µα
, 0, 0, 0, 0
)
(5.5)
Using the notation in [150] on system (5.4), matrices for the new infection terms, FT ,
and the other terms, VT , are given by:
FT =


0 βαT β
α
TηT
0 0 0
0 0 0


VT =


ǫα + µα 0 0
−ǫα γα + σαT + µ
α + δα1 0
0 −σαT a
α + µα + δα2


The associative basic reproduction number is given by:
RT = ρ(FTV
−1
T ) =
ǫαβαT (ηTσ
α
T + a
α + δα2 + µ
α)
(ǫα + µα)(γα + σαT + µ
α + δα1 )(a
α + µα + δα2 )
(5.6)
where ρ indicates the spectral radius of FTV
−1
T .
The linearisation matrix of model (5.4) around the disease-free equilibrium, P 10 , is:
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M1 =


−µα 0 −βαT ρ
α −βαT ηT
0 −(ǫα + µα) βαT 0 β
α
TηT
0 ǫα −(γα + σαT + µ
α + δα1 ) 0 0
0 0 γα −(ρα + µα) aα
0 0 σαT 0 −(a
α + µα + δα2 )


The stability of P 10 can be determined using the following lemma:
Lema 5.2.1 (Theorem 2, [141])
Let α
(
= p
q
)
where p, q ∈ Z+ and gdc(p, q) = 1. Define M = q, then the disease-free
equilibrium P 10 of the system (5.4) is asymptotically stable if |arg(λ)| >
π
2M
for all roots
λ of the following equation
det
(
diag
[
λMαλMαλMαλMαλMα
]
−M1
)
= 0
Lema 5.2.2 The disease-free equilibrium P 10 of the system (5.4) is unstable if RT > 1.
Proof Expanding, det
(
diag
[
λMαλMαλMαλMαλMα
]
−M1
)
= 0, the following equation
in terms of λ is obtained:
(
λMα + µα
) (
λMα + (ρα + µα)
) [
λ3Mα + (aα + δα2 + ǫ
α + γα + σαT + δ
α
1 + 3µ
α)λ2Mα
+ [(aα + µα + δα2 )(ǫ
α + γα + σαT + δ
α
1 + 2µ
α) + (ǫα + µα)(γα + σαT + µ
α + δα1 )(
1−
RT (a
α+µα+δα1 )
ηT σ
α
T+a
α+µα+δα1
)]
λMα + (ǫα + µα)(γα + σαT + µ
α + δα1 )(a
α + µα + δα2 ) (1−RT )
]
= 0
(5.7)
Now, the arguments of the roots of the equation, λMα + µα = 0, are given by:
arg(λk) =
π
Mα
+ k
2π
Mα
>
π
M
>
π
2M
where k = 0, 1, .., (Mα− 1).
Similarly, the arguments of the roots of the equation, λMα+(ρα+µα) = 0 are all greater
than π
2M
. Thus, using Lemma 5.2.1, it is shown that disease-free equilibrium P 10 of the
system (5.4) is unstable if there exists at least one root of the polynomial,
λ3Mα + (aα + δα2 + ǫ
α + γα + σαT + δ
α
1 + 3µ
α)λ2Mα + [(aα + µα + δα2 )(ǫ
α + γα + σαT + δ
α
1 + 2µ
α)
+(ǫα + µα)(γα + σαT + µ
α + δα1 )
(
1−
RT (a
α+µα+δα1 )
ηT σ
α
T
+aα+µα+δα1
)]
λMα
+(ǫα + µα)(γα + σαT + µ
α + δα1 )(a
α + µα + δα2 ) (1− RT ) = 0
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having argument less than π
2M
, for RT > 1.
Using Descartes’ rule of signs, there is exactly one sign change of the equation:
λ3Mα + (aα + δα2 + ǫ
α + γα + σαT + δ
α
1 + 3µ
α)λ2Mα + [(aα + µα + δα2 )(ǫ
α + γα + σαT + δ
α
1 + 2µ
α)
+(ǫα + µα)(γα + σαT + µ
α + δα1 )
(
1−
RT (a
α+µα+δα1 )
ηT σαT+a
α+µα+δα1
)]
λMα
+(ǫα + µα)(γα + σαT + µ
α + δα1 )(a
α + µα + δα2 ) (1− RT ) = 0
for RT > 1, thus there is exactly one positive real root of the aforesaid equation, for
which the argument is less than π
2M
. Thus, if RT > 1, the disease-free equilibrium, P
1
0 ,
of the system (5.4) is unstable.

The computation of the reproduction number of model (5.8) below, RH , follows.
dαS
dtα
= Λα − λHS − µ
αS
dαIH
dtα
= λHS + τ
α
2 A− (σ
α
H + µ
α + δα3 )IH
dαA
dtα
= σαHIH − (τ
α
2 + µ
α + δα4 )A
(5.8)
where λH =
βαHIH
N
. The disease-free equilibrium state P 20 of model (5.8) is given by:
P 20 = (S
2
0 , I
2
H0, A
2
0) =
(
S10 , 0, 0
)
Using the notation in [150] on system (5.8), matrices for the new infection terms, FH ,
and the other terms, VH , are given by:
FH =

 βαH 0
0 0


VH =

 σαH + µα + δα3 −τα2
−σαH τ
α
2 + µ
α + δα4


The associative basic reproduction number is computed to be:
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RH = ρ(FHV
−1
H ) =
βαH(τ
α
2 + µ
α + δα4 )
(µα + δα3 )(µ
α + δα4 + τ
α
2 ) + σ
α
H(µ
α + δα4 )
(5.9)
where ρ indicates the spectral radius of FHV
−1
H .
The linearisation matrix of model (5.8) around the disease-free equilibrium, P 20 , is:
M2 =


−µα −βαH 0
0 βαH − (σ
α
H + µ
α + δα3 ) τ
α
2
0 σαH −(τ
α
2 + µ
α + δα4 )


The stability of P 20 is derived using the following lemma:
Lema 5.2.3 (Theorem 2, [141])
Let α
(
= p
q
)
where p, q ∈ Z+ and gdc(p, q) = 1. Define M = q, then the disease-free
equilibrium P 20 of the system (5.8) is asymptotically stable if |arg(λ)| >
π
2M
for all roots
λ of the following equation
det
(
diag
[
λMαλMαλMα
]
−M2
)
= 0
The next lemma is:
Lema 5.2.4 The disease-free equilibrium P 20 of the system (5.8) is unstable if RH > 1.
Proof Expanding, det
(
diag
[
λMαλMαλMα
]
−M2
)
= 0, there is the following equation
in terms of λ:
(
λMα + µα
) [
λ2Mα +
[
(µα + δα3 )(1−RH) + σ
α
H +
1
τα2 +µ
α+δα4
((τα2 + µ
α + δα4 )
2 − RHσ
α
H(µ
α + δα4 ))
]
λMα
+(µα + δα3 )(µ
α + δα4 + τ
α
2 )(1− RH) + (µ
α + δα4 )σ
α
H(1− RH)] = 0
(5.10)
The arguments of the roots of the equation, λMα + µα = 0, are given by:
arg(λk) =
π
Mα
+ k
2π
Mα
>
π
M
>
π
2M
where k = 0, 1, .., (Mα− 1).
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Thus, using Lemma 5.2.3, it is shown that the disease-free equilibrium, P 20 , of system
(5.8) is unstable if there exists at least one root of the polynomial:
λ2Mα +
[
(µα + δα3 )(1−RH) + σ
α
H +
1
τα2 +µ
α+δα4
((τα2 + µ
α + δα4 )
2 − RHσ
α
H(µ
α + δα4 ))
]
λMα
+(µα + δα3 )(µ
α + δα4 + τ
α
2 )(1− RH) + (µ
α + δα4 )σ
α
H(1−RH) = 0
which has argument less than π
2M
, for RH > 1. Using Descartes’ rule of signs, there is
exactly one sign change of the equation:
λ2Mα +
[
(µα + δα3 )(1− RH) + σ
α
H +
1
τα2 +µ
α+δα4
((τα2 + µ
α + δα4 )
2 −RHσ
α
H(µ
α + δα4 ))
]
λMα
+(µα + δα3 )(µ
α + δα4 + τ
α
2 )(1− RH) + (µ
α + δα4 )σ
α
H(1−RH) = 0
for RH > 1, thus there is exactly one positive real root of the last equation for which the
argument is less than π
2M
. Thus, for RH > 1, the disease-free equilibrium P
2
0 of system
(5.8) is unstable.

The reproduction number of the full model (5.1), R0, is calculated. The disease-free
equilibrium state, P0, of model (5.1) is given by:
P0 = (S
0, E0T , I
0
T , R
0, T 0R, I
0
H , A
0, ET I
0
H , ETA
0, I0TH , ITA
0, RI0H , TRI
0
H)
=
(
Λ
µ
, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0
)
Using the notation in [150] on system (5.1), matrices for the new infection terms, F , and
the other terms, V , are given by:
1
3
2
C
H
A
P
T
E
R
5
.
M
O
D
E
L
S
F
O
R
C
O
IN
F
E
C
T
IO
N
O
F
H
IV
A
N
D
T
B
F =


0 βαT 0 β
α
TηT 0 0 0 0 β
α
T ηTH 0 0 β
α
TηTH
0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 βαH 0 β
α
H 0 β
α
HηH 0 β
α
H β
α
HηH
0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0


V =


ǫα + µα 0 0 0 0 0 0 0 0 0 0 0
−ǫα γα + σαT + µ
α + δα1 0 0 0 0 0 0 0 0 0 0
0 −γα ρα + µα −aα 0 0 0 0 0 0 0 0
0 −σαT 0 a
α + µα + δα2 0 0 0 0 0 0 0 0
0 0 0 0 σαH + µ
α + δα3 −τ
α
2 0 0 0 0 −ρ
α 0
0 0 0 0 −σαH τ
α
2 + µ
α + δα4 0 0 0 0 0 0
0 0 0 0 0 0 η1ǫ
α + θ1σ
α
H + µ
α + δα5 −τ
α
2 0 0 0 0
0 0 0 0 0 0 −θ1σ
α
H η2ǫ
α + τα2 + µ
α + δα6 0 0 0 0
0 0 0 0 0 0 −η1ǫ
α 0 γα1 + σ
α
T1 + θ2σ
α
H + µ
α + δα7 −τ
α
3 0 0
0 0 0 0 0 0 0 −η2ǫ
α −θ2σ
α
H τ
α
3 + µ
α + δα8 0 0
0 0 0 0 0 0 0 0 −γα1 0 ρ
α + µα + δα3 −a
α
1
0 0 0 0 0 0 0 0 −σαT1 0 0 a
α
1 + µ
α + δα9


The associative basic reproduction number is computed to be:
R0 = ρ(FV
−1) = max{RT , RH} (5.11)
where ρ indicates the spectral radius of FV −1.
5
.2
.
R
E
P
R
O
D
U
C
T
IO
N
N
U
M
B
E
R
1
3
3
The matrix of the linearisation of model (5.1) around the disease-free equilibrium, P0, is:
M3 =


−µα 0 −βαT ρ
α −βαT ηT −β
α
H 0 −β
α
H 0 −β
α
HηH − β
α
TηTH 0 −β
α
H −β
α
HηH − β
α
TηTH
0 −(ǫα + µα) βαT 0 β
α
TηT 0 0 0 0 β
α
TηT 0 0 β
α
TηT
0 ǫα −(γα + σαT + µ
α + δα1 ) 0 0 0 0 0 0 0 0 0 0
0 0 γα −(ρα + µα) aα 0 0 0 0 0 0 0 0
0 0 σαT 0 −(a
α + µα + δα2 ) 0 0 0 0 0 0 0 0
0 0 0 0 0 βαH − (σ
α
H + µ
α + δα3 ) τ
α
2 β
α
H 0 β
α
HηH 0 β
α
H + ρ
α βαHηH
0 0 0 0 0 σαH −(τ
α
2 + µ
α + δα4 ) 0 0 0 0 0 0
0 0 0 0 0 0 0 −(η1ǫ
α + θ1σ
α
H + µ
α + δα5 ) τ
α
2 0 0 0 0
0 0 0 0 0 0 0 θ1σ
α
H −(η2ǫ
α + τα2 + µ
α + δα6 ) 0 0 0 0
0 0 0 0 0 0 0 η1ǫ
α 0 −(γα1 + σ
α
T1 + θ2σ
α
H + µ
α + δα7 ) τ
α
3 0 0
0 0 0 0 0 0 0 0 η2ǫ
α θ2σ
α
H −(τ
α
3 + µ
α + δα8 ) 0 0
0 0 0 0 0 0 0 0 0 γα1 0 −(ρ
α + µα + δα3 ) a
α
1
0 0 0 0 0 0 0 0 0 σαT1 0 0 −(a
α
1 + µ
α + δα9 )


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The stability of P0 is determined by the next lemma:
Lema 5.2.5 (Theorem 2, [141])
Let α
(
= p
q
)
where p, q ∈ Z+ and gdc(p, q) = 1. Define M = q, then the disease-free
equilibrium P0 of the system (5.1) is asymptotically stable if |arg(λ)| >
π
2M
for all roots λ
of the following equation
det
(
diag
[
λMαλMαλMαλMαλMαλMαλMαλMαλMαλMαλMαλMαλMα
]
−M3
)
= 0
There is the following lemma:
Lema 5.2.6 The disease-free equilibrium P0 of the system (5.1) is unstable if R0 > 1.
Proof Expanding
det
(
diag
[
λMαλMαλMαλMαλMαλMαλMαλMαλMαλMαλMαλMαλMα
]
−M3
)
= 0
the next equations are obtained in terms of λ:
(
λMα + µα
) (
λMα + (ρα + µα)
) (
λMα + (ρα + µα + δα3 )
) (
λMα + (aα1 + µ
α + δα9 )
) [
λ2Mα+
+ (γα1 + σ
α
T1 + θ2σ
α
H + µ
α + δα7 + τ
α
3 + µ
α + δα8 ))λ
Mα + (γα1 + σ
α
T1 + θ2σ
α
H + µ
α + δα7 )(µ
α + δα8 ) + τ
α
3 (γ
α
1 + σ
α
T1 + µ
α + δα7 )
]
[
λ2Mα + (η1ǫ
α + θ1σ
α
H + µ
α + δα5 + η2ǫ
α + τα2 + µ
α + δα6 )λ
Mα + (η1ǫ
α + µα + δα5 )(η2ǫ
α + τα2 + µ
α + δα6 ) + θ1σ
α
H(η2ǫ
α + µα + δα6 )
]
[
λ3Mα + (aα + δα2 + ǫ
α + γα + σαT + δ
α
1 + 3µ
α)λ2Mα + [(aα + µα + δα2 )(ǫ
α + γα + σαT + δ
α
1 + 2µ
α)
+(ǫα + µα)(γα + σαT + µ
α + δα1 )
(
1−
RT (a
α+µα+δα1 )
ηT σ
α
T
+aα+µα+δα1
)]
λMα + (ǫα + µα)(γα + σαT + µ
α + δα1 )(a
α + µα + δα2 ) (1− RT )
]
[
λ2Mα +
[
(µα + δα3 )(1− RH) + σ
α
H +
1
τα2 +µ
α+δα4
((τα2 + µ
α + δα4 )
2 −RHσ
α
H(µ
α + δα4 ))
]
λMα
+(µα + δα3 )(µ
α + δα4 + τ
α
2 )(1−RH) + (µ
α + δα4 )σ
α
H(1− RH)] = 0
(5.12)
Now arguments of the roots of the equation, λMα + µα = 0, are given by: arg(λk) =
π
Mα
+ k 2π
Mα
> π
M
> π
2M
, where k = 0, 1, .., (Mα − 1). Similarly, it is proved that the
arguments of the next six terms obey arg(λk) >
π
2M
. By Lemma 5.2.5, it is shown that
disease-free equilibrium P0 of system (5.1) is unstable if there exists at least one root of
the polynomials:
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λ3Mα + (aα + δα2 + ǫ
α + γα + σαT + δ
α
1 + 3µ
α)λ2Mα + [(aα + µα + δα2 )(ǫ
α + γα + σαT + δ
α
1 + 2µ
α)
+(ǫα + µα)(γα + σαT + µ
α + δα1 )
(
1−
RT (a
α+µα+δα1 )
ηT σ
α
T
+aα+µα+δα1
)]
λMα + (ǫα + µα)(γα + σαT + µ
α + δα1 )
(aα + µα + δα2 ) (1− RT ) = 0
or
λ2Mα +
[
(µα + δα3 )(1− RH) + σ
α
H +
1
τα2 +µ
α+δα4
((τα2 + µ
α + δα4 )
2 −RHσ
α
H(µ
α + δα4 ))
]
λMα
+(µα + δα3 )(µ
α + δα4 + τ
α
2 )(1− RH) + (µ
α + δα4 )σ
α
H(1−RH) = 0
with arguments less than π
2M
, for RT > 1 or RH > 1, respectively.
As shown previously, there is exactly one sign change for each polynomial when RT > 1
and RH > 1, respectively. Since R0 = max{RT , RH}, then the disease-free equilibrium
P0 of the system (5.1) is unstable for RT > 1 and RH > 1.

5.3 Global stability of the disease-free equilibria
In this section, the global stability of the disease-free equilibrium of the two submod-
els (5.4) and (5.8) and of the full model (5.1) are calculated.
The proof begins by proving the conditions that guarantee the global stability of the
disease-free state for the TB submodel (5.4). The submodel (5.4) is rewritten as:
dαXTB
dtα
= FTB(XTB, ZTB)
dαZTB
dtα
= GTB(XTB, ZTB), GTB(XTB, 0) = 0
(5.13)
where XTB = (S,R) and ZTB = (ET , IT , TR), with XTB ∈ R
2
+ denoting the number
of uninfected individuals and ZTB ∈ R
3
+ denoting the number of infected individuals
(including the latent, the infectious and the drug-resistant).
The disease-free equilibrium is denoted by UTB = (X
⋆
TB, 0), where X
⋆
TB =
(
λα
µα
, 0
)
.
The conditions (H11) and (H21)must be met to guarantee the global asymptotic stability
of the disease-free equilibrium of the TB submodel (5.4):
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(H11) : For
dαXTB
dtα
= FTB(XTB, 0), X
⋆
TB is globally asymptotically stable
(H21) : GTB(XTB, ZTB) = ATBZTB − GˆTB(XTB, ZTB), GˆTB ≥ 0, for (XTB, ZTB) ∈ Υ1
(5.14)
where ATB = DZGTB(X
⋆
TB, 0) is a M-matrix (the off-diagonal elements of ATB are
non-negative) and Υ1 is the region where the model makes biological sense. If the
system (5.13) satisfies the condition in (5.14) the following theorem holds.
Theorem 5.3.1 The fixed point UTB = (X
⋆
TB, 0) is a globally asymptotically stable
equilibrium of the system (5.13) provided that RT < 1 and that the assumptions in
(5.14) are satisfied.
Proof Let
FTB(XTB, 0) =

λα − µαS
0

 (5.15)
and
ATB =


−(ǫα + µα) βαT β
α
TηT
ǫα −(γα + σαT + µ
α + δα1 ) 0
0 σαT −(a
α + µα + δα2 )

 (5.16)
and
GˆTB(XTB, ZTB) =


Gˆ1(XTB, ZTB)
Gˆ2(XTB, ZTB)
Gˆ3(XTB, ZTB)

 =


λTN
(
1− S
N
)
0
0

 (5.17)
Thus Gˆ1(XTB, ZTB) ≥ 0 and Gˆ2(XTB, ZTB) = Gˆ3(XTB, ZTB) = 0 ⇒ GˆTB(X,Z) ≥ 0.
Conditions in (5.14) are satisfied, thus the disease-free equilibrium of the TB sub-
model (5.4) is globally asymptotically stable for RT < 1.

Now the same procedure is repeated for the computation of the global stability of the
disease-free equilibrium of the HIV submodel (5.8). The later is rewritten as:
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dαXA
dtα
= FA(XA, ZA)
dαZA
dtα
= GA(XA, ZA), GA(XA, 0) = 0
(5.18)
where XA = (S) and ZA = (IH , A), XA ∈ R
1
+ denoting the number of uninfected
individuals and ZA ∈ R
2
+ denoting the number of infected individuals.
The disease-free equilibrium is given by UA = (X
⋆
A, 0), where X
⋆
A =
(
λα
µα
, 0
)
.
The conditions (H12) and (H22)must be met to guarantee the global asymptotic stability
of the disease-free equilibrium of the HIV submodel (5.8):
(H12) : For
dαXA
dtα
= FA(XA, 0), X
⋆
A is globally asymptotic stable
(H22) : GA(XA, ZA) = AAZA − GˆA(XA, ZA), GˆA ≥ 0, for (XA, ZA) ∈ Υ2
(5.19)
where AA = DZGA(X
⋆
A, 0) is a M-matrix (the off-diagonal elements of A are non-
negative) and Υ2 is the region where the model makes biological sense. If the sys-
tem (5.18) satisfies the conditions in (5.19) the the next theorem follows.
Theorem 5.3.2 The fixed point UA = (X
⋆
A, 0) is a globally asymptotically stable equilib-
rium of the system (5.18) provided that RH < 1 and that the assumptions in (5.19) are
satisfied.
Proof Let
FA(XA, 0) = [λ
α − µαS] (5.20)
AA =

 βαH − (σαH + µα + δα3 ) τα2
σαH −(τ
α
2 + µ
α + δα4 )

 (5.21)
and
GˆA(XA, ZA) =

Gˆ11(XA, ZA)
Gˆ22(XA, ZA)

 =

λTN
(
1− S
N
)
0

 (5.22)
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Thus Gˆ11(XA, ZA) ≥ 0 and Gˆ22(XA, ZA) = 0 ⇒ GˆA(XA, ZA) ≥ 0. Conditions in
(5.19) are satisfied, thus the disease-free equilibrium of the submodel (5.8) is globally
asymptotically stable for RH < 1.

The procedure is now applied to find the global asymptotic stability of the disease-free
equilibrium of the full model. Again, the model (5.1) is rewritten as:
dαX
dtα
= F (X,Z)
dαZ
dtα
= G(X,Z), G(X, 0) = 0
(5.23)
when X = (S,R) and Z = (ET , IT , TR, IH , A, ET IH , ETA, ITH , ITA,RIH , TRIH), with
X ∈ R2+ denoting the number of uninfected individuals and Z ∈ R
11
+ denoting the
number of infected individuals.
The disease-free equilibrium is denoted by U0 = (X
⋆, 0), where X⋆ =
(
λα
µα
, 0
)
.
The conditions H1 and H2 must be met to guarantee global asymptotic stability of the
disease-free equilibrium of the model (5.1):
(H1) : For
dαX
dtα
= F (X, 0), X⋆ is globally asymptotic stable
(H2) : G(X,Z) = AZ − Gˆ(X,Z), Gˆ ≥ 0, for (X,Z) ∈ Υ
(5.24)
where A = DZG(X
⋆, 0) is a M-matrix (the off-diagonal elements of A are non-negative)
and Υ is the region where the model makes biological sense. If the system (5.23)
satisfies the conditions in (5.24), the following theorem is valid.
Theorem 5.3.3 The fixed point U0 = (X
⋆, 0) is a globally asymptotically stable equilib-
rium of the system (5.23) provided that R0 < 1 and that the assumptions in (5.24) are
satisfied.
Proof Let
5
.3
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F (X, 0) =

 λα − µαS
−(ρα + µα)R

 (5.25)
A =


−(ǫα + µα) βαT 0 0 0 0 0 β
α
TηTH 0 0 β
α
TηTH
ǫα −(γα + σαT + µ
α + δα1 ) 0 0 0 0 0 0 0 0 0
0 σαT −(a
α + µα + δα2 ) 0 0 0 0 0 0 0 0
0 0 0 βαH − (σ
α
H + µ
α + δα3 ) τ
α
2 β
α
H 0 β
α
HηH 0 β
α
H + ρ
α βαHηH
0 0 0 σαH −(τ
α
2 + µ
α + δα4 ) 0 0 0 0 0 0
0 0 0 0 0 −(η1ǫ
α + θ1σ
α
H + µ
α + δα5 ) τ
α
2 0 0 0 0
0 0 0 0 0 θ1σ
α
H −(η2ǫ
α + τα2 + µ
α + δα6 ) 0 0 0 0
0 0 0 0 0 η1ǫ
α 0 −(γα1 + σ
α
T1 + θ2σ
α
H + µ
α + δα7 ) τ
α
3 0 0
0 0 0 0 0 0 η2ǫ
α θ2σ
α
H −(τ
α
3 + µ
α + δα8 ) 0 0
0 0 0 0 0 0 0 γα1 0 −(ρ
α + µα + δα3 ) a
α
1
0 0 0 0 0 0 0 σαT1 0 0 −(a
α
1 + µ
α + δα9 )


(5.26)
and
Gˆ(X,Z) =


Gˆ1(X,Z)
Gˆ2(X,Z)
Gˆ3(X,Z)
Gˆ4(X,Z)
Gˆ5(X,Z)
Gˆ6(X,Z)
Gˆ7(X,Z)
Gˆ8(X,Z)
Gˆ9(X,Z)
Gˆ10(X,Z)
Gˆ11(X,Z)


=


λTN
(
1− S
N
)
+ λHET
ψ3λHIT
0
λHN
(
1− S
N
)
+ ψ1λT IH
ψ2λTA
−λHET − ψ1λT IH
−ψ2λTA
−ψ3λHIT
0
0
0


(5.27)
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Condition H2 in (5.24) is not satisfied since Gˆ6 < 0, Gˆ7 < 0 and Gˆ8 < 0. Consequently,
U0 may not globally asymptotically stable. Thus, in this case, a backward bifurcation
seems to occur at R0 = 1 and the double endemic equilibria exists for R0 < 1. Note that
the negative terms are associated with the coinfection.

5.4 Sensitivity analysis
In this section sensitivity analysis of the reproduction number,R0, to relevant parameters
of model (5.1) is performed. This analysis measures the relative change in a variable
subjected to the variation of a given parameter. Following is the procedure developed
in [27]. Since R0 is the threshold for the existence of disease, it becomes imperative to
compute the sensitivity indices for R0.
The calculations are done for the parameter values given in Table 5.2. The signs of the
sensitivity indices may be found in Table 5.1. A positive sign indicates an increase in
the value of R0 as the parameter is increased. Inversely a negative sign of the index
means that R0 decreases as the parameter is increased. For example, increasing the
effective contact rates for HIV or TB, βαH and β
α
T , respectively, will increase the number
of infectious individuals in the population, leading to a boost of the epidemics.
Parameter Sensitivity index sign
βαT +
ηT +
σαT +
aα -
δα2 -
µα -
ǫα +
γα -
δα1 -
βαH +
τα2 +
δα4 -
δα3 -
σαH -
Table 5.1: Sensitivity indexes for relevant parameters of model (5.1).
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5.5 Numerical results
Simulations of the model (5.1) for different values of the order of the fractional derivative,
α ∈]0, 1], and for biologically relevant parameters are done. The predictor-corrector
PECE method of Adams-Bashford-Moulton type [38] is applied. The parameters used in
the simulations are given in Table 5.2 and the initial conditions are set to: S(0) = 5×105,
ET (0) = 4 × 10
3, IT (0) = R(0) = TR(0) = IH(0) = A(0) = ET IH(0) = ETA(0) =
ITH(0) = ITA(0) = RIH(0) = TRIH(0) = 1000.
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Parameter Value Reference
Λ 50000 [125]
βT 0.75 [4]
ηT 1.02 [15]
ηTH 1.02 [15]
βH 0.45 [4]
ηH 1.05 [15]
ρ 0.05 [118]
µ 0.02 [125]
ψ3 1.03 [15]
ǫ 0.25 [118]
γ 0.2 [15]
σT 0.003 [115]
δ1 0.01 [125]
a 0.11 [118]
δ2 0.02 [125]
τ2 0.33 [131]
ψ1 1.1 Estimated
ψ2 1.2 [15]
σH 0.1 [4]
δ3 0.01 [125]
δ4 0.02 [125]
η1 1.5 [15]
θ1 1.02 [15]
δ5 0.03 [125]
η2 1.8 [15]
δ6 0.03 [125]
γ1 0.13 Estimated
σT1 0.003 Estimated
τ3 0.33 Estimated
a1 0.10 Estimated
θ2 2.5 [15]
δ7 0.03 [125]
δ8 0.03 [125]
δ9 0.03 [125]
Table 5.2: Parameters used in the numerical simulations of models (5.1), where
appropriate the units are yr−1.
In Figures 5.2-5.4, it is shown the dynamics of relevant variables of system (5.1) for dif-
ferent values of ηT , the increased infectiousness of the MRD-TB drug-resistant infected
individuals, when compared to individuals infected with non-resistant TB strains, and for
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three values of α. It is observed that an increase in ηT boosts the number of individuals
infected with TB, suggesting that the increased infectiousness of the MRD-TB strains
influences negatively the recovery of TB infection. Similar patterns are present for all
values of the order of the fractional derivative, α. To avoid an excessive number of
figures in the paper and some redundancy in terms of results, only the figures for three
values of α are left here.
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Figure 5.2: Dynamics of the relevant variables of system (5.1) for different values of
ηT , the increased infectiousness of the MRD-TB infected individuals when compared
to individuals infected with non-resistant TB strains, and α = 1. Parameter values and
initial conditions are in the text. (ηT = 1.02 - RT = 3.0412, RH = 11.0265, R0 = 11.0265,
ηT = 1.1 - RT = 3.0460, RH = 11.0265, R0 = 11.0265 and ηT = 2 - RT = 3.0997,
RH = 11.0265, R0 = 11.0265)
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Figure 5.3: Dynamics of the relevant variables of system (5.1) for different values of
ηT , the increased infectiousness of the MRD-TB infected individuals when compared to
individuals infected with non-resistant TB strains, and α = 0.7. Parameter values and
initial conditions are in the text. (ηT = 1.02 - RT = 1.6467, RH = 3.8568, R0 = 3.8568,
ηT = 1.1 - RT = 1.6530, RH = 3.8568, R0 = 3.8568 and ηT = 2 - RT = 1.7235,
RH = 3.8568, R0 = 3.8568)
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Figure 5.4: Dynamics of the relevant variables of system (5.1) for different values of
ηT , the increased infectiousness of the MRD-TB infected individuals when compared to
individuals infected with non-resistant TB strains, and α = 0.5. Parameter values and
initial conditions are in the text. (ηT = 1.02 - RT = 0.9907, RH = 1.9402, R0 = 1.9402,
ηT = 1.1 - RT = 0.9971, RH = 1.9402, R0 = 1.9402 and ηT = 2 - RT = 1.07,
RH = 1.9402, R0 = 1.9402)
In Figures 5.5-5.7, are seen the dynamics of the variables of system (5.1) for different
values of ηTH , the increased infectiousness of individuals coinfected with HIV and TB,
when compared to individuals solely infected with TB, and for three values of α. The
figures show that as ηTH increases, there is an overall increase in the numbers of
individuals infected with TB and coinfected with HIV and TB, showing or not symptoms
of AIDS. Thus, the coinfection adds severity to the epidemics. The behaviour is similar
for all values of α.
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Figure 5.5: Dynamics of the relevant variables of system (5.1) for different values of ηTH ,
the increased infectiousness of individuals coinfected with HIV and TB, when compared
to individuals solely infected with TB, and α = 1. Parameter values and initial conditions
are in the text. (RT = 3.0412, RH = 11.0265, R0 = 11.0265)
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Figure 5.6: Dynamics of the relevant variables of system (5.1) for different values of
ηTH , the increased infectiousness of individuals coinfected with HIV and TB, when
compared to individuals solely infected with TB, and α = 0.7. Parameter values and
initial conditions are in the text. (RT = 1.6467, RH = 3.8568, R0 = 3.8568)
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Figure 5.7: Dynamics of the relevant variables of system (5.1) for different values of
ηTH , the increased infectiousness of individuals coinfected with HIV and TB, when
compared to individuals solely infected with TB, and α = 0.5. Parameter values and
initial conditions are in the text. (RT = 0.9907, RH = 1.9402, R0 = 1.9402)
Figures 5.8-5.10, depict the dynamics of the variables of system (5.1) for different values
of ηH , the increased infectiousness of individuals coinfected with HIV and TB, when
compared to individuals solely infected with HIV, and three values of α. Larger values
of ηH promote higher numbers of individuals infected solely with HIV and of individuals
coinfected with HIV and TB, showing or not symptoms of AIDS. Again, the coinfection
seems to accelerate the epidemics. This occurs for all values of α.
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Figure 5.8: Dynamics of the relevant variables of system (5.1) for different values of ηH ,
the increased infectiousness of individuals coinfected with HIV and TB, when compared
to individuals solely infected with HIV, and α = 1. Parameter values and initial conditions
are in the text. (RT = 3.0412, RH = 11.0265, R0 = 11.0265)
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Figure 5.9: Dynamics of the relevant variables of system (5.1) for different values of ηH ,
the increased infectiousness of individuals coinfected with HIV and TB, when compared
to individuals solely infected with HIV, and α = 0.7. Parameter values and initial
conditions are in the text. (RT = 1.6467, RH = 3.8568, R0 = 3.8568)
5.5. NUMERICAL RESULTS 149
0 2 4 6 8 10
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
x 104
Time (years)
I H
α=0.5
 
 
ηH=1.05
ηH=1.1
ηH=2
0 2 4 6 8 10
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
5500
Time (years)
A
α=0.5
 
 
ηH=1.05
ηH=1.1
ηH=2
0 2 4 6 8 10
0
100
200
300
400
500
600
700
800
900
1000
Time (years)
I T
H
α=0.5
 
 
ηH=1.05
ηH=1.1
ηH=2
0 2 4 6 8 10
0
200
400
600
800
1000
1200
Time (years)
I T
A
α=0.5
 
 
ηH=1.05
ηH=1.1
ηH=2
Figure 5.10: Dynamics of the relevant variables of system (5.1) for different values
of ηH , the increased infectiousness of individuals coinfected with HIV and TB, when
compared to individuals solely infected with HIV, and α = 0.5. Parameter values and
initial conditions are in the text. (RT = 0.9907, RH = 1.9402, R0 = 1.9402)
Figures 5.11-5.13, show the dynamics of the variables of system (5.1) for different values
of σT , the rate of TB infected individuals that become resistant to the first line of TB
treatment, and three values of α. From the observation of the figures, one concludes that
an increase in the resistance to treatment, due, for e.g., to lack of adherence, induces
higher numbers of the MDR-TB infected individuals, and of TB exposed individuals.
More exposed individuals, with drug-resistant strains, imply, on the long run, a TB
transmission dominated by the MDR-TB strains, which could impair TB control and final
elimination in the future. This behaviour is repeated for all values of α.
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Figure 5.11: Dynamics of the relevant variables of system (5.1) for different values of
σT , the rate of the TB infected individuals that become resistant to the first line of TB
treatment, and α = 1.0. Parameter values and initial conditions are in the text, except
σT1 = σT . (σT = 0.005 - RT = 3.0556, RH = 11.0265, R0 = 11.0265, σT = 0.05 -
RT = 3.3234,RH = 11.0265, R0 = 11.0265 and σT = 0.1 - RT = 3.5354, RH = 11.0265,
R0 = 11.0265)
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Figure 5.12: Dynamics of the relevant variables of system (5.1) for different values of
σT , the rate of the TB infected individuals that become resistant to the first line of TB
treatment, and α = 0.7. Parameter values and initial conditions are in the text, except
σT1 = σT . (σT = 0.005 - RT = 1.6538, RH = 3.8568, R0 = 3.8568, σT = 0.05 -
RT = 1.7296, RH = 3.8568, R0 = 3.8568 and σT = 0.1 - RT = 1.7723, RH = 3.8568,
R0 = 3.8568)
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Figure 5.13: Dynamics of the relevant variables of system (5.1) for different values of
σT , the rate of the TB infected individuals that become resistant to the first line of TB
treatment, and α = 0.5. Parameter values and initial conditions are in the text, except
σT1 = σT . (σT = 0.005 - RT = 0.9934, RH = 1.9402, R0 = 1.9402, σT = 0.05 -
RT = 1.0147, RH = 1.9402, R0 = 1.9402 and σT = 0.1 - RT = 1.0245, RH = 1.9402,
R0 = 1.9402)
In Figures 5.14-5.16 show the dynamics of the variables of system (5.1) for different
values of τ2 the rate of individuals infected with AIDS are treated for HIV, respectively,
and three values of α. It is observed that as τ2 increases there is a decrease in the
number of TB infected individuals and a decrease in the number of individuals showing
symptoms of AIDS. ART enhances the immunity, which translates in an improvement of
patients’ health status. This is seen for all values of α.
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Figure 5.14: Dynamics of the relevant variables of system (5.1) for different values of τ2,
the rate of individuals infected with AIDS are treated for HIV, respectively, and α = 1.0.
Parameter values and initial conditions are in the text, except τ3 = τ2. (τ2 = 0.33 -
RT = 3.0412, RH = 11.0265, R0 = 11.0265, τ2 = 0.5 - RT = 3.0412, RH = 12.0297,
R0 = 12.0297 and τ2 = 0.99 - RT = 3.0412, RH = 13.2808, R0 = 13.2808)
0 2 4 6 8 10
0
1
2
3
4
5
6
7
x 104
Time (years)
I H
α=0.7
 
 
τ2=0.33
τ2=0.5
τ2=0.99
0 2 4 6 8 10
0
2000
4000
6000
8000
10000
12000
Time (years)
A
α=0.7
 
 
τ2=0.33
τ2=0.5
τ2=0.99
0 2 4 6 8 10
0
500
1000
1500
2000
2500
Time (years)
I T
H
α=0.7
 
 
τ2=0.33
τ2=0.5
τ2=0.99
0 2 4 6 8 10
0
200
400
600
800
1000
1200
1400
1600
Time (years)
I T
A
α=0.7
 
 
τ2=0.33
τ2=0.5
τ2=0.99
Figure 5.15: Dynamics of the relevant variables of system (5.1) for different values of τ2,
the rate of individuals infected with AIDS are treated for HIV, respectively, and α = 0.7.
Parameter values and initial conditions are in the text, except τ3 = τ2. (τ2 = 0.33 -
RT = 1.6467, RH = 3.8568, R0 = 3.8568, τ2 = 0.5 - RT = 1.6467, RH = 4.1099,
R0 = 4.1099 and τ2 = 0.99 - RT = 1.6467, RH = 4.4855, R0 = 4.4855)
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Figure 5.16: Dynamics of the relevant variables of system (5.1) for different values of τ2,
the rate of individuals infected with AIDS are treated for HIV, respectively, and α = 0.5.
Parameter values and initial conditions are in the text, except τ3 = τ2. (τ2 = 0.33 -
RT = 0.9907, RH = 1.9402, R0 = 1.9402, τ2 = 0.5 - RT = 0.9907, RH = 2.0219,
R0 = 2.0219 and τ2 = 0.99 - RT = 0.9907, RH = 2.1541, R0 = 2.1541)
The results of the simulations of our model support evidence that HIV and TB coinfection
poses a significant threat to the public health care system. Coinfection is responsible for
more infectious individuals, who are more prone to spread the epidemics. Moreover, the
MDR-TB strains transmission in the population, together with HIV infection, constitutes
a major challenge with respect to treatment, which requires anti-tuberculosis and ART
to be administered unitedly. The later raises important issues, namely pill burden,
patient compliance, drug interactions and toxic effects, as well as immune reconstitution
inflammatory syndrome. All together, the coinfection burden increases concerns of an
extreme difficulty in TB control and elimination worldwide, as well as jeopardizes the
ending of AIDS epidemic. Note that the 90-90-90 ambitious treatment target to help end
the AIDS epidemics relies on three premisses by 2020: 90% of all people living with HIV
will know their HIV status; 90% of all people with diagnosed HIV infection will receive
sustained ART; and 90% of all people receiving ART will have viral suppression [92].
The fractional order derivative brings additional information on the epidemics, which
may be associated with individuals’ specificities of the immune system (for e.g., on HIV
progression one can distinguish the rapid progressors, the long-term non progressors
and the elite controllers), existence of other comorbidities, access to medical care, and
the issues related to treatment (adherence, toxicity, etc).
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5.6 Conclusions
A FO model is proposed for the coinfection of HIV and TB, in the presence of MDR-
TB strains and treatment for both diseases. The model’s behaviour is analyzed for
distinct values of the order of the fractional derivative, α, and for biologically relevant
parameters, namely the ones related with the coinfection and treatment. It is observed
that the coinfection burden increases the severity of the disease and poses a significant
threat to the public health care system. Coinfection is responsible for more infectious
individuals, who are more prone to spread the epidemics. Moreover, the MDR-TB strains
transmission in the population, together with HIV infection, constitutes a major challenge
with respect to treatment, which requires anti-tuberculosis and ART to be administered
unitedly. All together, the coinfection burden increases concerns of an extreme difficulty
in TB control and elimination worldwide, as well as jeopardizes the ending of AIDS
epidemic. The order of the fractional derivative, α, may be associated with differences
in individuals’ immune system, age, treatment compliance, treatment toxicities, other
comorbidities, amongst others.
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Chapter 6
Conclusions
For those who work in compartmental models, mathematical models are the equivalent
of a laboratory. Models are mathematical representations of biological processes that
allow transparency and precision in relation to the epidemiological assumptions. They
allow to test the understanding of the epidemiology of the disease, comparing the results
of the model and the observed patterns. These methods provide the tools to bridge the
micro and macro gap in the study of HIV population dynamics. As models become
more sophisticated and more capable of capturing the heterogeneities observed in the
data, one begins to think of the changes induced by the model in spread of the disease.
Mathematical models and computational simulations are thus useful experimental tools
for constructing and testing theories, evaluating quantitative conjectures, answering
specific questions, determining sensitivities to changes in parameter values and the key
to estimating model parameters. Model analysis and predictions provide crucial data
that can be used in treatment strategies and prevention. Moreover, they are the tools
needed to demonstrate the impact of a social or behavioral intervention in a population.
On the other hand, an important role of modeling is that it can alert us to deficiencies
in our current understanding of the epidemiology of various infectious diseases and
suggest crucial questions for research and data that need to be collected.
In this work, mathematical models for HIV/AIDS virus transmission and relevant coin-
fections are studied. The major limitation of studies of this type is the lack of real
data that would allow one to compare the results of the theoretical models with the
real data. For this reason, most of the parameter values used in the simulations of
the proposed models are based on the HIV/AIDS literature. Future work will focus on
studying models of HIV/AIDS and fitting the simulations of the models to real data.
Permissions to ethical commissions of Portuguese hospitals have already been asked
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with some positive replies. The data from real HIV infected Portuguese patients is being
collected to be further analyzed.
6.1 Thesis results
The present thesis originated results presentation to the scientific community in the form
of articles. The following are the results:
• C.M.A. Pinto and A.R.M. Carvalho, New findings on the dynamics of HIV and TB
coinfection models, Applied Mathematics and Computation 242, 36–46, 2014.
Abstract: In this paper we study a model for HIV and TB coinfection. We consider the integer order and the fractional
order versions of the model. Let α ∈ [0.78; 1.0] be the order of the fractional derivative, then the integer order model is
obtained for α = 1.0. The model includes vertical transmission for HIV and treatment for both diseases. We compute the
reproduction number of the integer order model and HIV and TB submodels, and the stability of the disease free equilibrium.
We sketch the bifurcation diagrams of the integer order model, for variation of the average number of sexual partners per
person and per unit time, and the tuberculosis transmission rate. We analyze numerical results of the fractional order model
for different values of α, including α = 1. The results show distinct types of transients, for variation of α. Moreover, we
speculate, from observation of the numerical results, that the order of the fractional derivative may behave as a bifurcation
parameter for the model. We conclude that the dynamics of the integer and the fractional order versions of the model are
very rich and that together these versions may provide a better understanding of the dynamics of HIV and TB coinfection.
• A.R.M. Carvalho and C.M.A. Pinto, A coinfection model for HIV and HCV, BioSys-
tems 124, 46–60, 2014.
Abstract: We study a mathematical model for the human immunodeficiency virus (HIV) and hepatites C virus (HCV)
coinfection. The model predicts four distinct equilibria: the disease free, the HIV endemic, the HCV endemic, and the full
endemic equilibria. The local and global stability of the disease free equilibrium was calculated for the full model and the HIV
and HCV submodels. We present numerical simulations of the full model where the distinct equilibria can be observed. We
show simulations of the qualitative changes of the dynamical behavior of the full model for variation of relevant parameters.
From the results of the model, we infer possible measures that could be implemented in order to reduce the number of
infected individuals.
• C.M.A. Pinto and A.R.M. Carvalho, Effects of treatment, awareness and condom
use in a coinfection model for HIV and HCV in MSM, Journal of Biological Systems
23(2), 165–193, 2015.
Abstract: We develop a new a coinfection model for hepatitis C virus (HCV) and the human immunodeficiency virus
(HIV). We consider treatment for both diseases, screening, unawareness and awareness of HIV infection, and the use of
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condoms. We study the local stability of the disease-free equilibria for the full model and for the two submodels (HCV only
and HIV only submodels). We sketch bifurcation diagrams for different parameters, such as the probabilities that a contact
will result in a HIV or an HCV infection. We present numerical simulations of the full model where the HIV, HCV and double
endemic equilibria can be observed. We also show numerically the qualitative changes of the dynamical behavior of the
full model for variation of relevant parameters. We extrapolate the results from the model for actual measures that could be
implemented in order to reduce the number of infected individuals.
• C.M.A. Pinto and A.R.M. Carvalho, Fractional Modeling of Typical Stages in HIV
Epidemics with Drug-Resistance, Progress in Fractional Differentiation and Appli-
cations 1(2), 111–122, 2015.
Abstract: In this paper it is studied a fractional order model for the three stages of HIV epidemics with drug-resistance. The
model includes CD4+ T cells, CTLs, macrophages, and the virus populations. We simulate the model for different values
of the fractional derivative α ∈ [0.5, 1.0]. The fractional order system untangles generous dynamical characteristics, such
as faster transients and slower evolutions as time increases. These traits are not seen in integer-order models, since they
are customary of memory-preserving systems.
• A.R.M. Carvalho and C.M.A. Pinto, Emergence of drug-resistance in HIV dynam-
ics under distinct HAART regimes, Communications in Nonlinear Science and
Numerical Simulation 30, 207–226, 2016.
Abstract: In this paper we propose a model for the dynamics of HIV epidemics under distinct HAART regimes, and study
the emergence of drug-resistance. Themodel predicts HIV dynamics of untreated HIV patients for all stages of the infection.
We compute the local and the global stability of the disease-free equilibrium of the model. We simulate the model for two
distinct HIV patients, the rapid progressors and the long-term non-progressors. We study the effects of equal RTI and PI
efficacies, as well as distinct drug efficacies, namely RTI-based and PI-based therapeutics. Treatment is initiated when the
CD4+ T cells count is less than 350 cells mm−3. The PI-based drugs seem to produce better outcomes, with respect to
disease progression, than RTI-based regimes.
• C.M.A. Pinto and A.R.M. Carvalho, Fractional complex-order model for HIV infec-
tion with drug resistance during therapy, Journal of Vibration and Control 22(9),
2222–2239, 2016.
Abstract: We propose a fractional complex-order model for drug-resistance in HIV infection. We consider three distinct
growth rates for the CD4+ T helper cells. We simulate the model for different values of the fractional derivative of complex
order Dα±β , where α, β ∈ R+, and for the distinct growth rates. The fractional derivative of complex order is a
generalization of the integer order derivative where α = 1 and β = 0. The fractional complex-order system reveals
rich dynamics and variation of the value of the complex-order derivative sheds new light on the modeling of the intracellular
delay. Additionally, fractional patterns are characterized by time responses with faster transients and slower evolutions
towards the steady-state.
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• C.M.A. Pinto and A.R.M. Carvalho, A latency fractional order model for HIV dy-
namics, Journal of Computational and Applied Mathematics 31, 240–256, 2017.
Abstract: We study a fractional order model for HIV infection where latent T helper cells are included. We compute the
reproduction number of the model and study the stability of the disease free equilibrium. We observe that the reproduction
number varies with the order of the fractional derivative α. In terms of epidemics, this suggests that varying α induces a
change in the patients’ epidemic status. Moreover, we simulate the variation of relevant parameters, such as the fraction of
uninfected CD4+ T cells that become latently infected, and the CTLs proliferation rate due to infected CD4+ T cells. The
model produces biologically reasonable results.
• A.R.M. Carvalho and C.M.A. Pinto, Within-host and synaptic transmissions: con-
tributions to the spread of HIV infection, Mathematical Methods in the Applied
Sciences 40(4), 1231–1264, 2017.
Abstract: We study the contributions of within-host (virus-to-cell) and synaptic (cell-to-cell) transmissions in a mathematical
model for human immunodeficiency virus epidemics. The model also includes drug resistance. We prove the local and
global stability of the disease-free equilibrium and the local stability of the endemic equilibrium. We analyse the effect of
the cell-to-cell transmission rate on the value of the reproduction number, R0. Moreover, we show evidence of a qualitative
change in the models’ dynamics, subjected to the value of the drug efficacy. In the end, important inferences are drawn.
• C.M.A. Pinto and A.R.M. Carvalho, The role of synaptic transmission in a HIV
model with memory, Applied Mathematics and Computation 292, 76–95, 2017.
Abstract: We propose a mathematical model with memory for the dynamics of HIV epidemics, where two transmission
modes, cell-to-cell and virus-to-cell, and drug resistance are considered. Systems with memory, or fractional order systems,
have largely been applied to the modeling of several real life phenomena. Here, we consider a fractional model where the
order of the non-integer derivative takes values in the interval [0.5, 1.0]. We prove the local and global stability of the
disease-free equilibrium. We study the role of the cell-to-cell transmission probability on the dynamics of the model, and
on the value of the reproduction number, R0, for distinct values of the fractional order derivative, α. Moreover, we show
evidence of an improvement of HIV infected patients quality of life, due to the increase of the drug efficacy. In the end,
important inferences are drawn.
• C.M.A. Pinto and A.R.M. Carvalho, The HIV/TB coinfection severity in the pres-
ence of TB multi-drug resistant strains, Ecological Complexity 32, 1–20, 2017.
Abstract:We introduce a novel fractional-order model for the coinfection of HIV and tuberculosis (TB), in the presence of
multi-drug resistant TB strains (MDR-TB) and treatment for both diseases. We compute the reproduction number of the
HIV and TB submodels and of the full model and the local and global stabilities of the disease-free equilibria. Numerical
simulations show the different dynamics of the model for variation of biologically relevant parameters, and for the order of
the fractional derivative α ∈]0, 1]. The results obtained highlight the importance of treatment for HIV and TB and the role of
the MDR-TB strains in the severity of the coinfection. Moreover, the order of the fractional derivative is a significant player
in the epidemics theatre.
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• Ana R.M. Carvalho and Carla M.A. Pinto, New developments on AIDS-related
cancers: the role of the delay and treatment options, Mathematical Methods in the
Applied Sciences, 1–14, DOI: 10.1002/mma.4657, 2017.
Abstract: We propose a simple delay mathematical model for the dynamics of AIDS-related cancers with treatment for HIV
and chemotherapy. The main goals are to study the effects of the delay and of treatment (HAART and chemotherapy) in
cancer cells growth. The model was simulated for several biologically reasonable values of the delay, of HAART efficacies
and of chemotherapeutic drugs decay rates. The results of the simulations reveal an epidemiologically well-defined model.
Important inferences are drawn for designing future treatment protocols.
• C.M.A. Pinto and A.R.M. Carvalho, Fractional dynamics of a HIV infection model
with time-varying drug exposure, Journal of Computational and Nonlinear Dynam-
ics, 2017, DOI: 10.1115/1.4038643.
Abstract: We introduce a fractional order model for the human immunodeficiency virus dynamics, where time-varying
drug-exposure and drug-resistance are assumed. We derive conditions for the local and global asymptotic stability of
the disease-free equilibrium. We find periodic stable endemic states for certain parameter values, for sinusoidal drug
efficacies and when considering a density dependent decay rate for the T cells. Other classes of periodic drug-efficacies
are considered and the effect of the phases of these functions on the dynamics of the model are also studied. The order of
the fractional derivative plays an important role in the severity of the epidemics.
• C.M.A. Pinto and A.R.M. Carvalho, The impact of pre-exposure prophylaxis (PrEP)
and screening on the dynamics of HIV, Journal of Computational and Applied
Mathematics, 2017, https://doi.org/10.1016/j.cam.2017.10.019.
Abstract: We analyse the impact of pre-exposure prophylaxis (PrEP) and screening effects on HIV dynamics in infected
patients. Our model incorporates condom use, the number of sexual partners, and treatment for HIV. Numerical simulations
are performed and the model is fitted to data on the cumulative HIV and AIDS cases in Portugal. Moreover, critical
epidemiological parameters are also varied. Inferences are made concerning the epidemiological consequences of the
model’s predictions on public HIV/AIDS planning. The order of the fractional derivative is suggested to have a powerful role
in the drama of HIV epidemics.
• A.R.M. Carvalho, C.M.A. Pinto and D. Baleanu, HIV/HCV coinfection model: a
fractional order perspective for the effect of the HIV viral load, Advances in Differ-
ence Equations 2018(2): 1–22, 2018.
Abstract: We study the burden of the HIV viremia and of treatment efficacy in the severity of the patterns of the HIV/HCV
coinfection. For this, we derive a simple non-integer order (fractional order) model for the coinfection patterns. The basic
reproduction number and the stability of the disease-free equilibrium are computed. The numerical results suggest that
the HIV viral load impacts impressively the severity of the HCV infection. The treatment efficacy is also found to influence
the natural progression of HCV on the HIV/HCV coinfection. The later repeats for all values of the order of the fractional
derivative.
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• Ana R.M. Carvalho and Carla M.A. Pinto, Non-integer order analysis of the impact
of diabetes and resistant strains in a model for TB infection, Communications in
Nonlinear Science and Numerical Simulation, Accept, January 2018.
Abstract:We study the impact of diabetes and multi-drug resistant strains in a model for tuberculosis (TB) infection in a
community. We compute the reproduction number, R0, of the model and analyse its behaviour numerically for variation of
epidemiologically relevant parameters. Namely, the increased susceptibility to TB due to diabetes, the diabetes recruitment
rate, and the increased progression of non-diabetics TB infectious to diabetic TB infectious individuals, due to their active
TB status. Moreover, we have also performed numerical simulations of the model for the mentioned parameters and the
results confirm the dynamics predicted by the value of R0. The sensitivity indices of R0 were also determined. The order
of the fractional derivative adds more information on the dynamics of the model and may help distinguishing dynamical
traits in distinct patients.
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